COMPOUNDS FOR OPTICALLY ACTIVE DEVICES

20230084690 · 2023-03-16

Assignee

Inventors

Cpc classification

International classification

Abstract

The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive unit, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalmic devices.

Claims

1. An ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formula (I) ##STR01081## wherein A is the same or different at each instance and is CH.sub.2, CHR.sub.0 or C(R.sub.0).sub.2; m is 0, 1, 2 or 3; Y is independently of each other O, S, SO.sub.2, or a bond; n is 0 or 1; m1 is 0 or 1; n+m1 is 1; n1 is 0, 1, 2, 3 or 4; R.sub.0 is at each occurrence independently selected from the group consisting of F, a linear or branched alkyl group having 1 to 4 C atoms and a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms; R′ is at each occurrence independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms; R.sub.1 is a trialkoxysilyl group or a dialkoxyalkylsilyl group where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or a silyl group of formula (1), (2) or (3) or a polymerizable group of formula (4), ##STR01082## where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk “*” denotes at each occurrence independently of each other a linkage to the linker [—R.sub.2—Y].sub.n or [Y—R.sub.2—].sub.m1; and wherein X.sub.11 is selected from the group consisting of O, S, O—SO.sub.2, SO.sub.2—O, C(═O), OC(═O), C(═O)O, S(C═O) and (C═O)S, R.sub.10, R.sub.11, R.sub.12 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms and aryl with 6 to 14 C atoms and c is 0 or 1; —R.sub.2— is —(C(R).sub.2).sub.o—, or —(C(R).sub.2).sub.p—X.sub.8—(C(R).sub.2).sub.q—(X.sub.9).sub.s—(C(R).sub.2).sub.r—(X.sub.10).sub.t—(C(R).sub.2).sub.u—; R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms; o is selected from the group consisting of 0 to 20, X.sub.8, X.sub.9, X.sub.10 are at each occurrence independently O, S, SO.sub.2, or NR.sub.0, s, t is 0 or 1, p, q are at each occurrence independently selected from the group consisting of 1 to 10, r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for —(C(R).sub.2).sub.p—X.sub.8—(C(R).sub.2).sub.q—(X.sub.9).sub.s—(C(R).sub.2).sub.r—(X.sub.10)—(C(R).sub.2).sub.u— is up to 20 atoms, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 are at each occurrence independently selected from the group consisting of H, F, Cl, Br, CN, SO.sub.2CF.sub.3, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated and partially or completely halogenated thioalkyl group having 1 to 20 C atoms; R.sub.9 is H or R′ in case m1 is 0 and R.sub.9 is R.sub.1 in case m1 is 1.

2. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 wherein in polymerized compounds of formula (I) n is 1 and m1 is 0 said compounds being of formula (I′) ##STR01083## wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, A, m, R′, and n1 have a meaning as indicated for formula (I).

3. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 wherein in polymerized compounds of formula (I) n is 0 and m1 is 1 said compounds being of formula (I″) ##STR01084## wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, A, m, R′ and n1 have a meaning as indicated for formula (I).

4. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 comprising an oligomer, polymer or copolymer comprising a constitutional unit M.sup.0 based on formulae (I), (I′) or (I″) where R.sub.1 on each occurrence is polymerized, R.sub.1 thus forms the regioregular, alternated, regiorandom, statistical, block or random oligomer or polymer backbone or is part of the copolymer backbone.

5. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 where said polymerized group R.sub.1 is of formulae (1-p), (2-p), (3-p) or (4-p) ##STR01085## where the asterisk “*” within formulae (1-p) to (4-p) denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group, the asterisk “**” within formulae (1-p) to (4-p) denotes the linkage to the remainder of formula (I), (I′) or (I″) and R.sub.10, R.sub.11, R.sub.12, X.sub.11 and c has a meaning according for formula (I).

6. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 wherein the constitutional unit M.sup.0 is of formulae (M.sup.0-I′-a), (M.sup.0-I′-b), (M.sup.0-I′-c), (M.sup.0-I′-d) or (M.sup.0-I″), ##STR01086## where —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, A, m, R′, n1, X.sub.11, R.sub.10, R.sub.11, R.sub.12 and c have a meaning according for formula (I) and R.sup.9 is H or R′ and where the asterisk “*” denotes at each occurrence a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group.

7. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 comprising beside of the at least one polymerized compound of formulae (I), (I′) or (I″) or the constitutional unit M.sup.0 of formulae (M.sup.0-I′-a), (M.sup.0-I′-b), (M.sup.0-I′-c), (M.sup.0-I′-d) or (M.sup.0-I″) at least one further polymerized monomer selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), methyl acrylate, n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA), 2-[3′-2′H-benzotriazol-2′-yl)-4′-hydroxyphenyl]ethyl methacrylate (BTPEM) or ehtyleneglycoldimethacrylate.

8. The ophthalmic device or the precursor article for an ophthalmic device according to claim 7 wherein the at least one further polymerized monomer is selected from methyl methacrylate, 2-hydroxyethyl methacrylate, 2-phenoxyethyl acrylate, ethoxyethoxy ethylacrylate, 8-methylnonyl methacrylate, n-butyl methacrylate, 2-ethyl hexylmethacrylate or a mixture thereof.

9. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 wherein —R.sub.2— is at each occurrence independently —(C(R).sub.2).sub.o— and R and o have a meaning as indicated for formula (I).

10. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 wherein A is independently at each occurrence CH.sub.2.

11. The ophthalmic device or the precursor article for an ophthalmic device according to claim 1 wherein polymerized R.sub.1 is at each occurrence independently derived from an acryl or methacryl radical.

12. The precursor article for an ophthalmic device according to claim 1 wherein said precursor article is a blank which may be transformed into an eye implant, preferably an intraocular lens.

13. Process of forming an ophthalmic device or a precursor article for an ophthalmic device according to claim 1, said process comprising the steps of providing a composition comprising at least one compound of formula (I) and/or an oligomer or polymer comprising a constitutional M.sup.0 based on formulae (i) where R.sub.1 on each occurrence is polymerized, R.sub.1 thus forms the regioregular, alternated, regiorandom, statistical, block or random oligomer or polymer backbone or is part of the copolymer backbone, but having at least one reactive group left for polymerization and optionally further monomers different from compounds of formula (I) and/or crosslinking agents and/or UV absorbers and/or radical initiators; subsequently forming the ophthalmic device or precursor article of said composition.

14. Process of changing the optical properties of an ophthalmic device or a precursor article for an ophthalmic device according to claim 1, said process comprising the steps of providing an ophthalmic device or a precursor article, and subsequently exposing said ophthalmic device or precursor article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.

15. Oligomer, polymer or copolymer comprising at least one polymerized compound of formula (I) as described in claim 1 where oligomers, polymers and copolymers of 2-(4-vinylphenyl)indene and 2-[4-(2-propen-1-yl)phenyl-1H-indene are excluded.

16. Polymer according to claim 15 comprising beside of the polymerized compounds of formula (I) at least one further polymerized monomer selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), methyl acrylate, n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA), 2-[3′-2′H-benzotriazol-2′-yl)-4′-hydroxyphenyl]ethyl methacrylate (BTPEM) or ehtyleneglycoldimethacrylate.

17. Composition for polymerization comprising at least one compound of formula (I) as described in claim 1 and/or an oligomer or polymer comprising a constitutional unit M.sup.0 based on formulae (I) where R.sub.1 on each occurrence is polymerized, R.sub.1 thus forms the regioregular, alternated, regiorandom, statistical, block or random oligomer or polymer backbone or is part of the copolymer back bone, but having at least one reactive group left for polymerization excluding 2-(vinylphenyl)indene, 2-[4-(2-propen-1-yl)phenyl-1H-indene and any oligomer, polymer or copolymer derived from 2-(vinylphenyl)indene and 2-[4-(2-propen-1-yl)phenyl-1H-indene and/or a crosslinking agent and/or a UV absorber and/or a radical initiator and optionally further monomers different from compounds of formula (I).

18. Compounds of formula (I) ##STR01087## wherein A is the same or different at each instance and is CH.sub.2, CHR.sub.0 or C(R.sub.0).sub.2; m is 0, 1, 2 or 3; Y is independently of each other O, S, SO.sub.2, or a bond; n is 0 or 1; m1 is 0 or 1; n+m1 is 1; n1 is 0, 1, 2, 3 or 4; R.sub.0 is at each occurrence independently selected from the group consisting of F, a linear or branched alkyl group having 1 to 4 C atoms and a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms; R′ is at each occurrence independently selected from the group consisting of F, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated, partially or completely halogenated thioalkyl group having 1 to 20 C atoms; R.sub.1 is a trialkoxysilyl group or a dialkoxyalkylsilyl group where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or a silyl group of formula (1), (2) or (3) or a polymerizable group of formula (4), ##STR01088## where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk “*” denotes at each occurrence independently of each other a linkage to the linker [—R.sub.2—Y].sub.n or [Y—R.sub.2—].sub.m1; and wherein X.sub.11 is selected from the group consisting of O, S, O—SO.sub.2, SO.sub.2—O, C(═O), OC(═O), C(═O)O, S(C═O) and (C═O)S, R.sub.10, R.sub.11, R.sub.12 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms and aryl with 6 to 14 C atoms and c is 0 or 1; —R.sub.2— is —(C(R).sub.2).sub.o—, or —(C(R).sub.2).sub.p—X.sub.8—(C(R).sub.2).sub.q—(X.sub.9).sub.s—(C(R).sub.2).sub.r—(X.sub.10).sub.t—(C(R).sub.2).sub.u—; R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms; o is selected from the group consisting of 0 to 20; X.sub.8, X.sub.9, X.sub.10 are at each occurrence independently O, S, SO.sub.2, or NR.sub.0; s, t is 0 or 1; p, q are at each occurrence independently selected from the group consisting of 1 to 10; r, u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for —(C(R).sub.2).sub.p—X.sub.8—(C(R).sub.2).sub.q—(X.sub.9).sub.s—(C(R).sub.2).sub.r—(X.sub.10).sub.t(C(R).sub.2).sub.u is up to 20 atoms; R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 are at each occurrence independently selected from the group consisting of H, F, Cl, Br, CN, SO.sub.2CF.sub.3, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated and partially or completely halogenated thioalkyl group having 1 to 20 C atoms; R.sub.9 is H or R′ in case m1 is 0 and R.sub.9 is R.sub.1 in case m1 is 1, provided that in case of m is 0, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20, and provided that in case of m is 0 and m1 is 1, two substituents from the group of R.sub.3, R.sub.4 and R.sub.5 are not simultaneously F, and provided that in case of m is 0, m1 is 1 and Y is a bond or 0, R′ is on each occurrence not F; and provided that in case of m is 0, R.sub.6 and R.sub.7 are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and provided that in case of m is 1, n is 1 and Y is a bond, o is selected from 1 to 20; and provided that in case of m is 2, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and provided that in case of m is 2, m1 is 1 and Y is 0, o is selected from the group consisting of 1 to 20; and provided that in case of m is 2, n is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and provided that in case of m is 2, n is 1 and Y is 0, o is selected from the group consisting of 1 to 20.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0101] Compounds of formula (I) as described before or preferably described below can be preferably used as monomers for the preparation of a precursor article such as a blank which may be transformed to an ophthalmic device such as an eye-implant or specifically an intraocular lens or can be preferably used for the preparation of the ophthalmic device as such as described before or preferably described below.

[0102] The compounds of formula (I) and all preferred embodiments of compounds of formula (I) including any monomeric units according to the present invention include all stereoisomers or racemic mixtures.

[0103] The compounds of formula (I) provide several advantages over prior art materials for the preparation of ophthalmic devices or precursor articles for an ophthalmic device [0104] the number of C atoms of the linker —R.sub.2— is reduced compared to the 1-benzopyran-2-one, 1-benzopyran-2-thione, thiochromene-2-one, thiochromene-2-thione, quinolin-2-one or quinolin-2-thione ring systems of the state of the art but still their melting points or glass transition temperatures allow for foldable or bendable ophthalmic devices or precursor articles for an ophthalmic device comprising polymerized compounds of formula (I), [0105] due to the low melting points and/or liquid monomers of formula (I) at room temperature, the handling of the materials is much easier and their use enable a higher flexibility in the choice of initiators for a thermally activated polymerization within the process of manufacturing the ophthalmic device or precursor article for an ophthalmic device according to the invention.

[0106] Polymers that are foldable at room temperature generally exhibit glass transition temperatures (T.sub.g) lower than room temperature (ca. 21° C.). They are easily deformable at this temperature without causing physical damage to the polymer, for example by inducing creep, stress or fissures. For polymers in intraocular lenses, T.sub.gs of less than or equal to 15° C. are preferred.

[0107] Polymers used in ophthalmic device manufacturing, preferably in intraocular lens manufacturing, have preferably relatively high refractive indices, which enable the fabrication of thinner ophthalmic devices such as intraocular lenses. Preferably, the polymer used in an ophthalmic device, preferably an intraocular lens, will have a refractive index greater than about 1.5 and presently most preferably greater than about 1.55.

[0108] In case an asterisk (“*”) is used within the description of the present invention, it denotes a linkage to an adjacent unit or group or, in case of a polymer, to an adjacent repeating unit or any other group whenever it is not specifically defined.

[0109] A linear or branched alkyl group having 1 to 10 C atoms denotes an alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, for example methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, tert-butyl, n-pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, n-heptyl, n-octyl, ethylhexyl, n-nonyl or n-decyl. A linear or branched alkyl group having 1 to 20 C atoms include all examples for a linear or branched alkyl group having 1 to 10 C atoms including any alkyl group having 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 C atoms such as n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl and n-eicosyl.

[0110] The term partially halogenated alkyl group denotes that at least one H atom of the alkyl group is replaced by F, Cl, Br or I. Preferably, the alkyl group is partially fluorinated meaning that at least one H atom of the alkyl group is replaced by F. A preferred partially halogenated alkyl group is CH.sub.2CF.sub.3.

[0111] The term completely halogenated alkyl group denotes that all H atoms of the alkyl group are replaced by F, Cl, Br and/or I. Preferably, the alkyl group is completely fluorinated meaning that all H atoms of the alkyl group are replaced by F. A preferred completely fluorinated alkyl group is trifluoromethyl or pentafluoroethyl.

[0112] The term halogenated or preferably fluorinated corresponds additionally to other groups such as a halogenated cycloalkyl group, a halogenated alkoxy group or a halogenated thioalkyl group.

[0113] A cycloalkyl group having 3 to 6 C atoms includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl which may be partially or completely halogenated or fluorinated as explained before. Preferably, the cycloalkyl group is cyclopropyl.

[0114] A linear or branched alkoxy group having 1 to 20 C atoms denotes an O-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example methoxy, ethoxy, iso-propoxy, n-propoxy, iso-butoxy, n-butoxy, tert-butoxy, n-pentyloxy, 1-, 2- or 3-methylbutyloxy, 1,1-, 1,2- or 2,2-dimethylpropoxy, 1-ethylpropoxy, n-hexyloxy, n-heptyloxy, n-octyloxy, ethylhexyloxy, n-nonyloxy, n-decyloxy, n-undecyloxy, n-dodecyloxy, n-tridecyloxy, n-tetradecyloxy, n-pentadecyloxy, n-hexadecyloxy, n-heptadecyloxy, n-octadecyloxy, n-nonadecyloxy and n-eicosyloxy which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely fluorinated alkoxy group is trifluoromethoxy.

[0115] A linear or branched thioalkyl group having 1 to 20 C atoms denotes a S-alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 C atoms, for example thiomethyl, 1-thioethyl, 1-thio-iso-propyl, 1-thio-n-propoyl, 1-thio-iso-butyl, 1-thio-n-butyl, 1-thio-tert-butyl, 1-thio-n-pentyl, 1-thio-1-, -2- or -3-methylbutyl, 1-thio-1,1-, -1,2- or -2,2-dimethylpropyl, 1-thio-1-ethylpropyl, 1-thio-n-hexyl, 1-thio-n-heptyl, 1-thio-n-octyl, 1-thio-ethylhexyl, 1-thio-n-nonyl, 1-thio-n-decyl, 1-thio-n-undecyl, 1-thio-n-dodecyl, 1-thio-n-tridecyl, 1-thio-n-tetradecyl, 1-thio-n-pentadecyl, 1-thio-n-hexadecyl, 1-thio-n-heptadecyl, 1-thio-n-octadecyl, 1-thio-n-nonadecyl and 1-thio-n-eicosyl which may be partially or completely halogenated or preferably may be partially or completely fluorinated. A preferred completely fluorinated thioether group is trifluoromethyl thioether.

[0116] Preferred alkyl and alkoxy radicals have 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms.

[0117] An aryl group in the context of this invention contains 6 to 40 ring atoms and a heteroaryl group in the context of this invention contains 5 to 40 ring atoms comprising at least one heteroatom. The heteroatoms are preferably selected from N, O and/or S. An aryl group or heteroaryl group is understood here to mean either a simple aromatic cycle, i.e. phenyl, or a simple heteroaromatic cycle, for example pyridinyl, pyrimidinyl, thiophenyl, etc., or a fused (annelated) aryl or heteroaryl group, for example naphthyl, anthracenyl, phenanthrenyl, quinolinyl or isoquinolinyl.

[0118] An aryl group or heteroaryl group is preferably derived from benzene, naphthalene, anthracene, phenanthrene, pyrene, benzanthracene, chrysene, perylene, fluoranthene, naphthacene, pentacene, benzopyrene, biphenyl, biphenylene, terphenyl, triphenylene, fluorene, spirobifluorene, dihydrophenanthrene, dihydropyrene, tetrahydropyrene, cis- or trans-indenofluorene, cis- or trans-indenocarbazole, cis- or trans-indolocarbazole, truxene, isotruxene, spirotruxene, spiroisotruxene, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzothiophene, isobenzothiophene, dibenzothiophene, pyrrole, indole, isoindole, carbazole, pyridine, quinoline, isoquinoline, acridine, phenanthridine, benzo-5,6-quinoline, benzo-6,7-quinoline, benzo-7,8-quinoline, phenothiazine, phenoxazine, pyrazole, indazole, imidazole, benzimidazole, naphthimidazole, phenanthrimidazole, pyridimidazole, pyrazinimidazole, quinoxalinimidazole, oxazole, benzoxazole, naphthoxazole, anthroxazole, 1,2,3-triazine, tetrazole, 1,2,4,5-tetrazine, 1,2,3,4-tetrazine, 1,2,3,5-tetrazine, purine, pteridine, indolizine and benzothiadiazole.

[0119] A polymerizable group is a group which can be subject to or can undergo polymerization thus forming an oligomer or a polymer.

[0120] Polymerization is the process of taking individual monomers and chaining them together to make longer units. These longer units are called polymers. The compounds of formula (I) as described before and preferably described below are suitable monomers for the preparation of an ophthalmic device or a precursor article for an ophthalmic device.

[0121] Within the gist of the invention, the polymerizable group R.sub.1 once oligomerized or polymerized thus forms or is part of the backbone of the oligomer, polymer or copolymer comprising polymerized compounds of formula (I). Suitable polymerizable groups are defined to be a trialkoxysilyl group or a dialkoxyalkylsilyl group where the alkyl and/or alkoxy groups are each independently linear or branched having 1 to 6 C atoms, or a silyl group of formula (1), (2) or (3) or a polymerizable group of formula (4),

##STR00005##

[0122] where alkyl means at each occurrence independently of each other a linear or branched alkyl group having 1 to 6 C atoms and the asterisk “*” denotes at each occurrence independently of each other a linkage to the linker [—R.sub.2— Y].sub.n or [Y—R.sub.2—].sub.m1;

[0123] and wherein

[0124] X.sub.11 is selected from the group consisting of O, S, O—SO.sub.2, SO.sub.2—O, C(═O), OC(═O), C(═O)O, S(C═O) and (C═O)S,

[0125] R.sub.10, R.sub.11, R.sub.12 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms and aryl with 6 to 14 C atoms and

[0126] c is 0 or 1.

[0127] Particularly preferred polymerizable groups are described below.

[0128] Particularly preferred polymerized groups are described below.

[0129] Aryl with 6 to 14 C atoms is an aryl group preferably selected from the group consisting of phenyl, naphthyl or anthryl, particularly preferably phenyl.

[0130] In one preferred embodiment, the compounds of formula (I) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or as compound according to the invention contain the polymerizable group R.sub.1 attached via —R.sub.2— and Y to the photoactive ring system. This is the case for compounds of formula (I) in which n is 1 and m1 is 0 which can be described accordingly in formula (I′).

[0131] The invention is therefore additionally directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formula (I′),

##STR00006##

[0132] wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, A, m, R′, and n1 have a meaning as described before or preferably described before or below and R.sup.9 is H or R′ as described before or preferably described before.

[0133] The invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m1 is 0 which can preferably be described according to formula (I′),

##STR00007##

[0134] wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, A, m, R′, and n1 have a meaning as described before or preferably described before or below and R.sup.9 is H or R′ as described before or preferably described before,

[0135] provided that in case of m is 0, R.sub.6 and R.sub.7 are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and

[0136] provided that in case of m is 1, n is 1 and Y is a bond, o is selected from 1 to 20; and

[0137] provided that in case of m is 2, n is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

[0138] provided that in case of m is 2, n is 1 and Y is O, o is selected from the group consisting of 1 to 20.

[0139] The position of substituent R.sub.1—R.sub.2—Y in formulae (I) or (I′) is not limited. In compounds of formula (I′-a), the substituent R.sub.1—R.sub.2—Y is in position 8 of the annellated aromatic ring.

[0140] In compounds of formula (I′-b), the substituent R.sub.1—R.sub.2—Y is in position 7 of the annellated aromatic ring.

[0141] In compounds of formula (I′-c), the substituent R.sub.1—R.sub.2—Y is in position 6 of the annellated aromatic ring.

[0142] In compounds of formula (I′-d), the substituent R.sub.1—R.sub.2—Y is in position 5 of the annellated aromatic ring.

[0143] The invention is therefore additionally directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formula (I) wherein n is 1 and m1 is 0 which can preferably be described according to formulae (I′-a), (I′-b), (I′-c) and (I′-d),

##STR00008##

[0144] wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, A, m, R′, and n1 have a meaning as described before or preferably described before or below.

[0145] The invention is therefore additionally directed to compounds of formula (I) wherein n is 1 and m1 is 0 which can preferably be described according to formulae (I′-a), (I′-b), (I′-c) and (I′-d),

##STR00009##

[0146] wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, A, m, R′, and n1 have a meaning as described before or preferably described before or below,

[0147] provided that in case of m is 0, R.sub.6 and R.sub.7 are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and

[0148] provided that in case of m is 1, n is 1 and Y is a bond, o is selected from 1 to 20; and

[0149] provided that in case of m is 2, n is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

[0150] provided that in case of m is 2, n is 1 and Y is O, o is selected from the group consisting of 1 to 20.

[0151] Preferred positions of R.sub.1—R.sub.2—X are position 8 and/or 7 of the annellated aromatic ring as e.g. visualized in formulae (I′-a) and (I′-b).

[0152] In another preferred embodiment of the invention, the compounds of formula (I) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or as compound according to the invention as described before contain the polymerizable group R.sub.1 attached via —R.sub.2— and Y to the phenyl substituent of the photoactive ring system. This is the case for compounds of formula (I) in which n is 0 and m1 is 1 which can be described accordingly in formula (I″).

[0153] The invention is therefore additionally directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formula (I″),

##STR00010##

[0154] wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, A, m, R′, and n1 have a meaning as described before or preferably described before or below.

[0155] The invention is therefore additionally directed to compounds of formula (I) wherein n is 0 and m1 is 1 which can preferably be described according to formula (I″),

##STR00011##

[0156] wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, A, m, R′, and n1 have a meaning as described before or preferably described before or below,

[0157] provided that in case of m is 0, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

[0158] provided that in case of m is 0 and m1 is 1, two substituents from the group of R.sub.3, R.sub.4 and R.sub.5 are not simultaneously F; and

[0159] provided that in case of m is 0, m1 is 1 and Y is a bond or O, R′ is on each occurrence not F; and

[0160] provided that in case of m is 0, R.sub.6 and R.sub.7 are on each occurrence not a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms; and

[0161] provided that in case of m is 2, m1 is 1 and Y is a bond, o is selected from the group consisting of 3 to 20; and

[0162] provided that in case of m is 2, m1 is 1 and Y is 0, o is selected from the group consisting of 1 to 20.

[0163] As described before within the ophthalmic device, precursor article, compounds of formula (I), (I′), (I″) and any oligomers, polymers or copolymers derived therefrom according to the invention, the substituents R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are at each occurrence independently selected from the group consisting of H, F, Cl, Br, CN, SO.sub.2CF.sub.3, a linear or branched, non-halogenated, partially or completely halogenated alkyl group having 1 to 20 C atoms, a non-halogenated, partially or completely halogenated cycloalkyl group having 3 to 6 C atoms, a linear or branched, non-halogenated, partially or completely halogenated alkoxy group having 1 to 20 C atoms and a linear or branched, non-halogenated and partially or completely halogenated thioalkyl group having 1 to 20 C atoms.

[0164] R.sub.3, R.sub.4 and R.sub.5 are preferably H, F, a straight-chain alkyl group with 1 to 4 C atoms or a straight-chain alkoxy group with 1 to 4 C atoms. R.sub.3, R.sub.4 and R.sub.5 are particularly preferably H.

[0165] R.sub.5 is preferably H, F, CN, SO.sub.2CF.sub.3, CF.sub.3, CF.sub.2CF.sub.3, or CH.sub.2CF.sub.3. R.sub.5 is particularly preferably H, F, CF.sub.3. R.sub.5 is very particularly preferably H or F. R.sub.5 is very particularly preferably H.

[0166] R.sub.6 and R.sub.7 are preferably independently of each other H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms. R.sub.6 is preferably H and R.sub.7 has a meaning as described or preferably described before or below. R.sub.6 and R.sub.7 are independently of each other particularly preferably H or F. R.sub.6 and R.sub.7 are preferably identical. R.sub.6 and R.sub.7 are very particularly preferably H.

[0167] With regards to the compounds according to the invention, the described disclaimers have to be considered for the definition and preferred embodiments of R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8.

[0168] Compounds of formula (I), (I′) or (I″) wherein m is 0 are based on an indene ring system and can be described as compounds of formulae (I-1), (I′-1) or (I″-1)

##STR00012##

[0169] wherein R.sub.1, —R.sub.2—, Y, n, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, m1, n1 and R′ have a meaning as described before or preferably described before or below and act preferably as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0170] Compounds of formula (I), (I′) or (I″) wherein m is 1 are based on a 1,2-dihydronaphthalene ring system and can be described as compounds of formula (I-2), (I′-2) or (I″-2)

##STR00013##

[0171] wherein A, R.sub.1, —R.sub.2—, Y, n, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, m1, n1 and R′ have a meaning as described before or preferably described before or below and act preferably as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0172] A is the same or different at each instance and is CH.sub.2, CHR.sub.0 or C(R.sub.0).sub.2 and R.sub.0 has a meaning as described before or preferably described below. Preferably, A is the same or different at each instance and is CH.sub.2 or CHR.sub.0 and R.sub.0 has a meaning as described before or preferably described below. Particularly preferably, A is at each instance CH.sub.2.

[0173] Compounds of formula (I-2), (I′-2) and (I″-2) wherein A is CH.sub.2 correspond to formulae (I-2-H), (I′-2-H) and (I″-2-H),

##STR00014##

[0174] wherein R.sub.1, —R.sub.2—, Y, n, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, m1, n1 and R′ have a meaning as described before or preferably described before or below and act preferably as monomers of formulae (I), (I′) and (I″) for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0175] Compounds of formula (I), (I′) or (I″) wherein m is 2 are based on a 6,7-dihydro-5H-benzo[7]annulene ring system and can be described as compounds of formula (I-3), (I′-3) or (I″-3)

##STR00015##

[0176] wherein A, R.sub.1, —R.sub.2—, Y, n, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, m1, n1 and R′ have a meaning as described before or preferably described before or below and act preferably as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0177] A is the same or different at each instance and is CH.sub.2, CHR.sub.0 or C(R.sub.0).sub.2 and R.sub.0 has a meaning as described before or preferably described below. Preferably, A is the same or different at each instance and is CH.sub.2 or CHR.sub.0 and R.sub.0 has a meaning as described before or preferably described below Particularly preferably, A is at each instance CH.sub.2.

[0178] Compounds of formula (I-3), (I′-3) and (I″-3) wherein each A is CH.sub.2 correspond to formulae (I-3-H), (I′-3-H) and (I″-3-H),

##STR00016##

[0179] wherein R.sub.1, —R.sub.2—, Y, n, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, m1, n1 and R′ have a meaning as described before or preferably described before or below and act preferably as monomers of formulae (I), (I′) and (I″) for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0180] Compounds of formula (I), (I′) or (I″) wherein m is 2 are based on a (Z)-5,6,7,8-tetrahydrobenzo[8]annulene ring system and can be described as compounds of formula (I-4), (I′-4) or (I″-4)

##STR00017##

[0181] wherein A, R.sub.1, —R.sub.2—, Y, n, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, m1, n1 and R′ have a meaning as described before or preferably described before or below as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0182] A is the same or different at each instance and is CH.sub.2, CHR.sub.0 or C(R.sub.0).sub.2 and R.sub.0 has a meaning as described before or preferably described below. Preferably, A is the same or different at each instance and is CH.sub.2 or CHR.sub.0 and R.sub.0 has a meaning as described before or preferably described below Particularly preferably, A is at each instance CH.sub.2.

[0183] Compounds of formula (I-4), (I′-4) and (I″-4) wherein each A is CH.sub.2 correspond to formulae (I-4-H), (I′-4-H) and (I″-4-H),

##STR00018##

[0184] wherein R.sub.1, —R.sub.2—, Y, n, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, m1, n1 and R′ have a meaning as described before or preferably described before or below and act preferably as monomers of formulae (I), (I′) and (I″) for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0185] As described before within the ophthalmic device, precursor article, compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) and any oligomers, polymers or copolymers derived therefrom according to the invention, R.sub.0 is at each occurrence independently selected from the group consisting of F, a linear or branched alkyl group having 1 to 4 C atoms and a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms. R.sub.0 is independently at each occurrence and preferably F, Methyl, Ethyl or Trifluoromethyl. R.sub.0 is independently at each occurrence particularly preferably Methyl. R.sub.0 is independently at each occurrence particularly preferably F.

[0186] The invention furthermore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 1, 2 or 3.

[0187] The invention therefore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 1.

[0188] The invention therefore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 2.

[0189] The invention therefore relates to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 3.

[0190] The invention furthermore relates to compounds of formula (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 1, 2 or 3.

[0191] The invention therefore relates to compounds of formula (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 1.

[0192] The invention therefore relates to compounds of formula (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 2.

[0193] The invention therefore relates to compounds of formula (I), (I′), (I′-a), (I′-b), (I′-c), (I′-d) or (I″) as described before or preferably described before wherein A is independently at each occurrence CH.sub.2 and m is 3.

[0194] With regards to the compounds according to the invention, the described disclaimers have to be considered when m is 0, 1 and/or 2.

[0195] As described before, the substituent R.sub.9 corresponds to H or R′ in case m1 is 0 wherein R′ has a meaning as described before or a preferred or particularly preferred meaning as described below.

[0196] In one embodiment of the invention, R.sub.9 is preferably H in case m1 is 0.

[0197] Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) where R.sub.9 is H in case m1 is 0 and n1 and R′ have a meaning as described before or preferably described below.

[0198] Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) where R.sub.9 is H in case m1 is 0 and n1 and R′ have a meaning as described before or preferably described below.

[0199] In this embodiment, it is preferred that n1 is 0.

[0200] Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is H in case m1 is 0 and n1 is 0.

[0201] Therefore, the invention is furthermore directed to compounds of formulae (I) (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is H in case m1 is 0 and n1 is 0.

[0202] In another embodiment of the invention, R.sub.9 is preferably R′ in case m1 is 0. Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is R′ in case m1 is 0 and n1 and R′ have a meaning as described before or preferably described below.

[0203] Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is R′ in case m1 is 0 and n1 and R′ have a meaning as described before or preferably described below.

[0204] In this embodiment, it is preferred that n1 is 0, 1 or 2, preferably 0 or 1. Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is R′ in case m1 is 0 and n1 is 0, 1 or 2 and R′ has a meaning as described before or preferably described below.

[0205] Therefore, the invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device comprising at least one polymerized compound of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is R′ in case m1 is 0 and n1 is 0 or 1 and R′ has a meaning as described before or preferably described below.

[0206] Therefore, the invention is furthermore directed to compounds of formulae (I) (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is R′ in case m1 is 0 and n1 is 0, 1 or 2 and R′ has a meaning as described before or preferably described below.

[0207] Therefore, the invention is furthermore directed to compounds of formulae (I) (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) wherein R.sub.9 is R′ in case m1 is 0 and n1 is 0 or 1 and R′ has a meaning as described before or preferably described below.

[0208] According to the invention, R′ is independently of each other preferably selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms.

[0209] R′ is independently of each other particularly preferably selected from the group consisting of F, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, methoxy, ethoxy, propoxy, trifluoromethoxy, pentafluoroethoxy, thiomethyl and thioethyl.

[0210] R′ is independently of each other particularly preferably selected from the group consisting of F, ethyl, n-pentyl, trifluoromethyl, methoxy and trifluoromethoxy.

[0211] With regards to the compounds according to the invention, the described disclaimers have to be considered for the definition of R′.

[0212] In these embodiments of the invention when m1 is 0, R.sub.9 is H or R′ and n1 is 0 or 1, the substitution pattern of the substituents R′ is preferably selected from (S-1) to (S-12)

##STR00019## ##STR00020##

[0213] wherein R′ has independently of each other a meaning as described before or preferably described below. Preferred substitution patterns are (S-1), (S-7), (S-10), (S-11) and (S-12). Particularly preferred substitution patterns are (S-7) and/or (S-10) and/or (S-12). A very particularly preferred substitution pattern is (S-7). A very particularly preferred substitution pattern is (S-10). A very particularly preferred substitution pattern is (S-12).

[0214] The invention therefore relates additionally to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) as described or preferably described before wherein the substitution pattern of the R′ substituents is (S-7) or (S-10) or (S-12).

[0215] The invention therefore relates additionally to compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4) and (I′-4-H) as described or preferably described before wherein the substitution pattern of the R′ substituents is (S-7) or (S-10) or (S-12).

[0216] As described before, the substituent R.sub.9 corresponds to R.sub.1 in case m1 is 1 wherein R′ has a meaning as described before or a preferred or particularly preferred meaning as described below.

[0217] Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 and R′ have a meaning as described before or preferably described below.

[0218] Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 and R′ have a meaning as described before or preferably described below.

[0219] In this embodiment of the invention, n1 is preferably 0 or 1 and R′ has a meaning as described or preferably described before. In this embodiment where R.sub.9 is R.sub.1 and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group, such R.sub.1—R.sub.2— Y-group is preferably in ortho, meta or para position to the bond of said phenyl group linked to the rest of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H).

[0220] In this embodiment where R.sub.9 is R.sub.1 and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group, such R.sub.1—R.sub.2—Y-group is particularly preferably in ortho or para position to the bond of said phenyl group linked to the rest of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H). In this embodiment where R.sub.9 is R.sub.1 and R.sub.1 is linked via —R.sub.2— Y— to the phenyl group, such R.sub.1—R.sub.2—Y-group is very particularly preferably in para position to the bond of said phenyl group linked to the rest of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H).

[0221] Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1, n1 is 0 or 1 and R′ has a meaning as described before or preferably described below and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group and such R.sub.1—R.sub.2—Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae.

[0222] Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1, n1 is 0 or 1 and R′ has a meaning as described before or preferably described below and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group and such R.sub.1—R.sub.2—Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae.

[0223] In this embodiment, it is preferred that n1 is 0.

[0224] Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 is 0.

[0225] Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 is 0.

[0226] Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 is 0 and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group and such R.sub.1—R.sub.2—Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae.

[0227] Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 is 0 and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group and such R.sub.1—R.sub.2—Y-group is in para position to the bond of said phenyl group linked to the rest of said formulae.

[0228] Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 is 0 and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group and such R.sub.1—R.sub.2—Y-group is in ortho, meta or para position, preferably in meta or para position, particularly preferably in para position to the bond of said phenyl group linked to the rest of said formulae.

[0229] Therefore, the invention is furthermore directed to compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) wherein R.sub.9 is R.sub.1 in case m1 is 1 and n1 is 0 and R.sub.1 is linked via —R.sub.2—Y— to the phenyl group and such R.sub.1—R.sub.2—Y-group is in para position to the bond of said phenyl group linked to the rest of said formulae.

[0230] An ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formula (I) with linkers and substituents as described before or preferably described before or below are preferred when m is 1 or 2.

[0231] Compounds of formula (I) with linkers and substituents as described before or preferably described before or below are preferred when m is 1 or 2.

[0232] An ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formula (I) with linkers and substituents as described before or preferably described before or below are preferred when m is 2.

[0233] Compounds of formula (I) with linkers and substituents as described before or preferably described before or below are particularly preferred when m is 2.

[0234] The preferred position of the phenyl group in all compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) is at the C atom of the isolated double bond which is adjacent to C(R.sub.6)(R.sub.7). Correspondingly, the preferred position of R.sub.5 in all compounds of formulae (I), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) is at the C atom adjacent to the fused aromatic ring.

[0235] The following formula summarizes the preferred positions of R.sub.5 and phenyl group for compounds of formula (I) reading formula (I#),

##STR00021##

[0236] wherein R.sub.1, —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, A, m, R′, and n1 have a meaning as described before or preferably described before or below. Such compounds according to formula (I#) act preferably as monomers of formulae (I) for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention.

[0237] According to the invention, compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) with substituents as described before or preferably described before have a polymerizable group as described before or preferably described before or below and have at least one linking element Y—R.sub.2.

[0238] According to the invention, Y is independently at each occurrence O, S, O═S═O or a bond.

[0239] According to the invention, the linking element —R.sub.2— is selected from the group consisting of —(C(R).sub.2).sub.o—, or —(C(R).sub.2).sub.p—X.sub.8—(C(R).sub.2).sub.q—(X.sub.9).sub.s—(C(R).sub.2).sub.r—(X.sub.10).sub.t—C(R).sub.2).sub.u—, R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms and o is selected from the group consisting of 1 to 20, X.sub.8, X.sub.9 and X.sub.10 are at each occurrence O, S, SO.sub.2, or NR.sub.0, s and t are at each occurrence independently 0 or 1, p and q are at each occurrence independently selected from the group consisting of 1 to 10, r and u are at each occurrence independently selected from the group consisting of 0 to 10, wherein the overall number of atoms for —(C(R).sub.2).sub.p—X.sub.8—(C(R).sub.2).sub.q—(X.sub.9).sub.s—(C(R).sub.2).sub.r—(X.sub.10).sub.t(C(R).sub.2).sub.u—, is up to 20 C atoms. R.sub.0 in NR.sub.0 has a meaning as described before excluding F.

[0240] According to the invention, R is at each occurrence independently selected from the group consisting of H, F, a linear or branched alkyl group having 1 to 8 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms.

[0241] R is particularly preferably at each occurrence independently H, F, methyl or ethyl. R is very particularly preferably H.

[0242] In another preferred embodiment of the invention, o is preferably selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 within the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or within the compounds according to the invention. Preferably, o is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12. Particularly preferably, o is selected from the group consisting of 1, 2, 3, 4, 5, 6 and 7 where 1, 3, 5 and 7 or 2, 3, 4, 5 and 6 is especially preferred. Very particularly preferably, o is 5. With regards to the compounds according to the invention, the described disclaimers have to be considered for the definition of o.

[0243] In another preferred embodiment of the invention, s, t, X.sub.8, X.sub.9, X.sub.10, p, q, r and u within the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I-2-H), (I′-3), (I′-H) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or within the compounds according to the invention have the following preferred meaning:

[0244] Preferably, s is 1. Preferably, s is 0.

[0245] Preferably t is 0 or 1.

[0246] Preferably, s and t are 0.

[0247] Preferably, X.sub.8, X.sub.9 and X.sub.10 are O, S or SO.sub.2. Particularly preferably, X.sub.8, X.sub.9 and X.sub.10 are O. Particularly preferably, X.sub.8, X.sub.9 and X.sub.10 are S. Particularly preferably, X.sub.8, X.sub.9 and X.sub.10 are S02.

[0248] Preferably, p and q are each independently 1, 3, 3, 4, 5 or 6, particularly preferably 1 or 2, very particularly preferably 2 Preferably, r and u are each independently 0, 1, 2 or 3, particularly preferably 0, 1 or 2, very particularly preferably 0.

[0249] In case o is 0, —R.sub.2— is a bond.

[0250] According to the invention, suitable examples for —R.sub.2— are —(CH.sub.2)—, —(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—, —(CH.sub.2).sub.6—, —(CH.sub.2).sub.7—, —(CH.sub.2).sub.8—, —(CH.sub.2).sub.9—, —(CH.sub.2).sub.10—, —(CH.sub.2).sub.11—, —(CH.sub.2).sub.12—, —(CH.sub.2).sub.13—, —(CH.sub.2).sub.14—, —(CH.sub.2).sub.15—, —(CH.sub.2).sub.16—, —(CH.sub.2).sub.17—, —(CH.sub.2).sub.18—, —(CH.sub.2).sub.19—, —(CH.sub.2).sub.20—, —(CHCH.sub.3)—, —(CHCH.sub.3).sub.2—, —(CHCH.sub.3).sub.3—, —(CHCH.sub.3).sub.4—, —(CHCH.sub.3).sub.5—, —(CHCH.sub.3).sub.6—, —(CHCH.sub.3).sub.7—, —(CHCH.sub.3).sub.8—, —(CHCH.sub.3).sub.9—, —(CHCH.sub.3).sub.10—, —(CHCH.sub.3).sub.11—, —(CHCH.sub.3).sub.12—, —(CHCH.sub.3).sub.13—, —(CHCH.sub.3).sub.14—, —(CHCH.sub.3).sub.15—, —(CHCH.sub.3).sub.16—, —(CHCH.sub.3).sub.17—, —(CHCH.sub.3).sub.18—, —(CHCH.sub.3).sub.19—, —(CHCH.sub.3).sub.20—, —(C(CH.sub.3).sub.2)—, —(C(CH.sub.3).sub.2).sub.2—, —(C(CH.sub.3).sub.2).sub.3—, —(C(CH.sub.3).sub.2).sub.4—, —(C(CH.sub.3).sub.2).sub.5—, —(C(CH.sub.3).sub.2).sub.6—, —(C(CH.sub.3).sub.2).sub.7—, —(C(CH.sub.3).sub.2).sub.8—, —(C(CH.sub.3).sub.2).sub.9—, —(C(CH.sub.3).sub.2).sub.10—, —(C(CH.sub.3).sub.2).sub.11—, —(C(CH.sub.3).sub.2).sub.12—, —(C(CH.sub.3).sub.2).sub.13—, —(C(CH.sub.3).sub.2).sub.14—, —(C(CH.sub.3).sub.2).sub.15—, —(C(CH.sub.3).sub.2).sub.16—, —(C(CH.sub.3).sub.2).sub.17—, —(C(CH.sub.3).sub.2).sub.18—, —(C(CH.sub.3).sub.2).sub.19—, —(C(CH.sub.3).sub.2).sub.20—, —(CHC.sub.2H.sub.5)—, —(CHC.sub.2H.sub.5).sub.2—, —(CHC.sub.2H.sub.5).sub.3—, —(CHC.sub.2H.sub.5).sub.4—, —(CHC.sub.2H.sub.5).sub.5—, —(CHC.sub.2H.sub.5).sub.6—, —(CHC.sub.2H.sub.5).sub.7—, —(CHC.sub.2H.sub.5).sub.8—, —(CHC.sub.2H.sub.5).sub.9—, —(CHC.sub.2H.sub.5).sub.10—, —(CHC.sub.2H.sub.5).sub.11—, —(CHC.sub.2H.sub.5).sub.12—, —(CHC.sub.2H.sub.5).sub.13—, —(CHC.sub.2H.sub.5).sub.14—, —(CHC.sub.2H.sub.5).sub.15—, —(CHC.sub.2H.sub.5).sub.16—, —(CHC.sub.2H.sub.5).sub.17—, —(CHC.sub.2H.sub.5).sub.18—, —(CHC.sub.2H.sub.5).sub.19—, —(CHC.sub.2H.sub.5).sub.20—, —(CH.sub.2)—(CHCH.sub.3)—(CH.sub.2)—, —(CH.sub.2)—(CHCH.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2)—(CHCH.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CHCH.sub.3)—(CH.sub.2).sub.11—, —(CH.sub.2).sub.2—(CHCH.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CHCH.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.11—(CHCH.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—O—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—O—(CH.sub.2).sub.3—O—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—O—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—O—(CH.sub.2).sub.8—, —(CH.sub.2).sub.8—O—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—S—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—S—(CH.sub.2).sub.3—S—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.8—, —(CH.sub.2).sub.8—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—SO.sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—SO.sub.2—(CH.sub.2).sub.3—SO.sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.8—, —(CH.sub.2).sub.8—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(NCH.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(NCH.sub.3)—(CH.sub.2).sub.3—(NCH.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—(NCH.sub.3)—(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.8— and —(CH.sub.2).sub.8—(NCH.sub.3)—(CH.sub.2).sub.2—(NCH.sub.3)—(CH.sub.2).sub.2—; —(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2)—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.7—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.8—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.9—, —(CH.sub.2)—(CF.sub.2)—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.8—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.9—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.10—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—(CF.sub.2)—(CH.sub.2).sub.9—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.8—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—(CF.sub.2)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.5—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—(CF.sub.2)—(CH.sub.2).sub.5—, —(CFH)—(CH.sub.2)—, —(CH.sub.2)—(CFH)—, —(CH.sub.2)—(CFH)—(CH.sub.2)—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.2—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.5—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.6—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.7—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.8—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.9—, —(CH.sub.2)—(CFH)—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.7—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.8—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.9—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.10—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CFH)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—(CFH)—(CH.sub.2).sub.9—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—(CFH)—(CH.sub.2).sub.8—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—(CFH)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.5—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CFH)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CFH)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CFH)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CFH)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—(CFH)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CFH)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CFH)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CFH)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—(CFH)—(CH.sub.2).sub.5—, —(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.8—, —(CH.sub.2)—(CF.sub.2).sub.2—(CH.sub.2).sub.9—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.8—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.9—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—(CH.sub.2).sub.8—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2)—(CFH).sub.2—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.8—, —(CH.sub.2)—(CFH).sub.2—(CH.sub.2).sub.9—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.8—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.9—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CFH).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CFH).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CFH).sub.2—(CH.sub.2).sub.8—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CFH).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.4—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—(CFH).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CFH).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CFH).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—(CFH).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.5—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—(CFH).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CFH).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CFH).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—(CFH).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—(CFH).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CFH).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CFH).sub.2—(CH.sub.2).sub.4—, —(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2).sub.7—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.8—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CF.sub.2).sub.3—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CF.sub.2).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CF.sub.2).sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CF.sub.2).sub.3—(CH.sub.2).sub.4—, (CH.sub.2).sub.6—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2).sub.3—(CH.sub.2).sub.3—, —(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.7—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.8—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.9—, —(CH.sub.2)—(CF.sub.2).sub.4—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CF.sub.2).sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CF.sub.2).sub.5—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2).sub.5—(CH.sub.2)—, —(CH.sub.2)—(CF.sub.2).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.5—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2).sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CF.sub.2).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.5—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CF.sub.2).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CF.sub.2).sub.5—(CH.sub.2).sub.2—, —(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3)—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.5—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.6—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.7—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.8—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.9—, —(CH.sub.2)—(CHCF.sub.3)—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.7—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.8—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.9—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.10—(CHCF.sub.3)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CHCF.sub.3)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—(CHCF.sub.3)—(CH.sub.2).sub.9—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—(CHCF.sub.3)—(CH.sub.2).sub.8—, —(CH.sub.2).sub.4—(CHCF.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CHCF.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—(CHCF.sub.3)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—(CHCF.sub.3)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.5—(CHCF.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CHCF.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CHCF.sub.3)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CHCF.sub.3)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—(CHCF.sub.3)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CHCF.sub.3)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CHCF.sub.3)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—(CHCF.sub.3)—(CH.sub.2).sub.5—, —(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.2—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.8—, —(CH.sub.2)—(CHCF.sub.3).sub.2—(CH.sub.2).sub.9—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.8—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.9—(CHCF.sub.3).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.2—(CH.sub.2).sub.8—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.2—(CH.sub.2).sub.4—, —(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.3—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2).sub.6—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2).sub.7—, —(CH.sub.2)—(CHCF.sub.3).sub.3—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.7—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.8—(CHCF.sub.3).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.3—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.3—(CH.sub.2).sub.3—, —(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.4—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.5—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.6—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.7—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.8—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.9—, —(CH.sub.2)—(CHCF.sub.3).sub.4—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.7—(CHCF.sub.3).sub.4—(CH.sub.2)—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.4—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.4—(CH.sub.2).sub.2—, —(CHCF.sub.3).sub.5—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.5—, —(CH.sub.2)—(CHCF.sub.3).sub.5—(CH.sub.2)—, —(CH.sub.2)—(CHCF.sub.3).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2)—(CHCF.sub.3).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2)—(CHCF.sub.3).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2)—(CHCF.sub.3).sub.5—(CH.sub.2).sub.5—, —(CH.sub.2)—(CHCF.sub.3).sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.6—(CHCF.sub.3).sub.5—(CH.sub.2)—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.5—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CHCF.sub.3).sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CHCF.sub.3).sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CHCF.sub.3).sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—(CHCF.sub.3).sub.5—(CH.sub.2).sub.2—, —[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.8—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.9—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.8—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.9—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.10—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.9—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.8—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3]—(CH.sub.2).sub.5—, —[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.8—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.9—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.8—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.9—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.8—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.2—(CH.sub.2).sub.4—, —[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.8—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.3—(CH.sub.2).sub.3—, —[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.8—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.9—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.4—(CH.sub.2).sub.2—, —[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.5—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)CF.sub.3].sub.5—(CH.sub.2).sub.2—, —[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.8—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.9—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.7—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.8—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.9—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.10—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.9—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.8—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.8—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.9—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.8—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.9—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.8—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.7—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.7—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.8—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.6—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.7—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.8—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.9—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.7—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3).sub.5—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.5—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.6—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[CH(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.8—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.9—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.8—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.9—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.10—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.9—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.8—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.7—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.6—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2).sub.5—, —[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.8—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.9—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.8—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.9—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.8—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.2—(CH.sub.2).sub.4—, —[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.8—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.8—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.7—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.6—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.4—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.3—(CH.sub.2).sub.3—, —[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.6—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.7—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.8—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.9—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.10—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.7—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.3—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.4—(CH.sub.2).sub.2—, —[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.5—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.6—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2)—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.3—, —(CH.sub.2).sub.5—[C(CH.sub.3)(CH.sub.2CF.sub.3)].sub.5—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CH.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CH.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.2, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2).sub.2—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2).sub.3—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2)—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.7—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.7—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.2—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.6—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.6—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.2—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.4—, —(CH.sub.2).sub.4—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—, —(CH.sub.2).sub.3—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.5—, —(CH.sub.2).sub.5—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—O—(CF.sub.2).sub.2—(CH.sub.2).sub.3—.

[0251] Preferred examples for —R.sub.2— are —(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—, —(CH.sub.2).sub.6—, —(CH.sub.2).sub.7—, —(CH.sub.2).sub.8—, —(CH.sub.2).sub.9—, —(CH.sub.2).sub.10—, —(CH.sub.2).sub.11—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2).sub.12, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2— and —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)— according to the invention.

[0252] Compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) with substituents as described before or preferably described before having a polymerizable group as described before or preferably described before or below are preferred in case the substituent —R.sub.2— within the at least one linking element Y—R.sub.2— corresponds to —(C(R).sub.2).sub.o—, wherein R and o has a meaning as described or preferably described before.

[0253] Accordingly monomers of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) for the preparation of an ophthalmic device or precursor article for an ophthalmic device as described before with substituents as described before or preferably described before having a polymerizable group as described before or preferably described before or below are preferred in case the substituent —R.sub.2— within the at least one linking element Y—R.sub.2— corresponds to —(C(R).sub.2).sub.o—, wherein R and o has a meaning as described or preferably described before. Such ophthalmic devices and precursor articles prepared by using these monomers are especially preferred.

[0254] Particularly preferred examples for —R.sub.2— are —(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—, —(CH.sub.2).sub.6—, —(CH.sub.2).sub.7— according to the invention. Very particularly preferably, —R.sub.2— is —(CH.sub.2).sub.5— according to the invention.

[0255] Therefore, the invention is furthermore directed to an ophthalmic device or precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I-1), (I-2), (I-2-H), (I-3), (I-3-H), (I-4), (I-4-H), (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) as described before or preferably described before wherein —R.sub.2— is at each occurrence independently —(C(R).sub.2).sub.o—, wherein R and o have a meaning as described or preferably described before.

[0256] The invention therefore relates to compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) as described before or preferably described before wherein —R.sub.2— is at each occurrence independently —(C(R).sub.2).sub.o—, wherein R and o have a meaning as described or preferably described before.

[0257] The substituent Y—R.sub.2— within formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) is selected from the group consisting of O—R.sub.2—, —R.sub.2— where Y is a bond, SO.sub.2—R.sub.2— and S—R.sub.2—, wherein —R.sub.2— has a meaning as described before or preferably or particularly preferably described before.

[0258] The substituent Y—R.sub.2— is preferably selected from the group consisting of O—R.sub.2— and —R.sub.2— where Y is a bond wherein —R.sub.2— has a meaning as described before or preferably or particularly preferably described before.

[0259] The substituent Y—R.sub.2—R.sub.1 within formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) is selected from the group consisting of O—R.sub.2—R.sub.1, —R.sub.2—R.sub.1, SO.sub.2—R.sub.2—R.sub.1 and S—R.sub.2—R.sub.1, or preferably selected from the group consisting of O—R.sub.2—R.sub.1 and —R.sub.2— R.sub.1, wherein —R.sub.2— has a meaning as described before or preferably or particularly preferably described before and wherein R.sub.1 is trimethoxysilyl, dimethoxymethylsilyl or a polymerizable group according to formula (4),

##STR00022##

[0260] wherein [0261] X.sub.11 is selected from the group consisting of O, S, O—SO.sub.2, SO.sub.2—O, C(═O), OC(═O), C(═O)O, S(C═O) and (C═O)S, [0262] R.sub.10, R.sub.11, R.sub.12 are at each occurrence independently of each other selected from the group consisting of H, F, a linear or branched, non-fluorinated, partially or completely fluorinated alkyl group having 1 to 20 C atoms or aryl with 6 to 14 C atoms and c is 0 or 1.

[0263] In another preferred embodiment of the invention, c, 11, R.sub.10, R.sub.11 and R.sub.12 within the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) acting as monomers for the preparation of the ophthalmic device or precursor article of the ophthalmic device as described before or for the preparation of an oligomer, polymer or copolymer according to the invention or within the compounds according to the invention have the following preferred meaning:

[0264] Preferably, R.sub.11 and R.sub.12 are H. Preferably, c is 1.

[0265] Preferably, R.sub.10 is H, methyl, ethyl or phenyl. Particularly preferably, R.sub.10 is H or methyl.

[0266] Preferably, X.sub.11 is C(═O), OC(═O) or C(═O)O. Particularly preferably, X.sub.11 is C(═O)O.

[0267] Preferred alkenyl groups of formula (4) as polymerizable groups R.sub.1 according to the invention are therefore represented by any one selected from the group consisting of formulae (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11) and (4-12):

##STR00023##

[0268] Particularly preferred alkenyl groups of formula (4) as polymerizable groups R.sub.1 according to the invention are represented by any one selected from the group consisting of formulae (4-1), (4-2), (4-3), (4-5), (4-6), (4-11) and (4-12) as described before.

[0269] The alkenyl group represented by formula (4-1) is called methacrylate. The alkenyl group represented by formula (4-2) is called acrylate.

[0270] The preferred groups R.sub.1 are preferably combined with preferred groups of the linking element —R.sub.2— and/or the linking element Y—R.sub.2—. Combinations are excluded where two 0 atoms or one 0 atom and one S atom are directly bonded to each other as known for a skilled artisan in the field of organic chemistry.

[0271] The substituent Y—R.sub.2—R.sub.1 within formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) is therefore particularly preferably selected from the group consisting of O—R.sub.1, O—(CH.sub.2).sub.3—R.sub.1, O—(CH.sub.2).sub.4—R.sub.1, O—(CH.sub.2).sub.5—R.sub.1, O—(CH.sub.2).sub.6—R.sub.1, O—(CH.sub.2).sub.7—R.sub.1, —O—(CH.sub.2).sub.8—R.sub.1, —O—(CH.sub.2).sub.9—R.sub.1, —O—(CH.sub.2).sub.10—R.sub.1, —O—(CH.sub.2).sub.11—R.sub.1, —O—(CH.sub.2).sub.12—R.sub.1, —O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—R.sub.1, —O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—R.sub.1, O—(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, O—(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, —O—(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—R.sub.1, —O—(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—R.sub.1, —O—(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—R.sub.1, —O—(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—R.sub.1, —O—(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—R.sub.1, —O—(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, —O—(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, —O—(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—R.sub.1 and —O—(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—R.sub.1, wherein R.sub.1 is selected from the group consisting of an alkenyl of formula (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11), or (4-12);

[0272] —(CH.sub.2).sub.3—R.sub.1, —(CH.sub.2).sub.4—R.sub.1, —(CH.sub.2).sub.5—R.sub.1, —(CH.sub.2).sub.6—R.sub.1, —(CH.sub.2).sub.7—R.sub.1, —(CH.sub.2).sub.8—R.sub.1, —(CH.sub.2).sub.9—R.sub.1, —(CH.sub.2).sub.10—R.sub.1, —(CH.sub.2).sub.11—R.sub.1, —(CH.sub.2).sub.12—R.sub.1, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—R.sub.1, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—R.sub.1, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, —(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, —(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, —(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—R.sub.1, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—R.sub.1, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—R.sub.1, —(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—R.sub.1, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—R.sub.1, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—R.sub.1 and —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—R.sub.1, where Y is a bond and wherein R.sub.1 is selected from the group consisting of an alkenyl of formula (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11), or (4-12);

[0273] S—R.sub.1, S—(CH.sub.2).sub.3—R.sub.1, S—(CH.sub.2).sub.4—R.sub.1, S—(CH.sub.2).sub.5—R.sub.1, S—(CH.sub.2).sub.6—R.sub.1, S—(CH.sub.2).sub.7—R.sub.1, S—(CH.sub.2).sub.8—R.sub.1, S—(CH.sub.2).sub.9—R.sub.1, S—(CH.sub.2).sub.10—R.sub.1, S—(CH.sub.2).sub.11—R.sub.1, S—(CH.sub.2).sub.12—R.sub.1, —S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—R.sub.1, —S—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—R.sub.1, S—(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, S—(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—R.sub.1, S—(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—R.sub.1, S—(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—R.sub.1, S—(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, S—(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, S—(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—R.sub.1 and S—(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—R.sub.1, wherein R.sub.1 is selected from the group consisting of an alkenyl of formula (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11), or (4-12);

[0274] SO.sub.2—(CH.sub.2).sub.3—R.sub.1, SO.sub.2—(CH.sub.2).sub.4—R.sub.1, SO.sub.2—(CH.sub.2).sub.5—R.sub.1, SO.sub.2—(CH.sub.2).sub.6—R.sub.1, SO.sub.2—(CH.sub.2).sub.7— R.sub.1, SO.sub.2—(CH.sub.2).sub.8—R.sub.1, SO.sub.2—(CH.sub.2).sub.9—R.sub.1, SO.sub.2—(CH.sub.2).sub.10—R.sub.1, SO.sub.2—(CH.sub.2).sub.11—R.sub.1, SO.sub.2—(CH.sub.2).sub.12—R.sub.1, SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—R.sub.1, SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—R.sub.1, SO.sub.2—(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—R.sub.1, S02-(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—R.sub.1, SO.sub.2—(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—R.sub.1, SO.sub.2—(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—R.sub.1, SO.sub.2—(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2—R.sub.1 and SO.sub.2—(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)—R.sub.1, wherein R.sub.1 is selected from the group consisting of an alkenyl of formula (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11), or (4-12).

[0275] Particularly preferably, the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) comprise a polymerizable group R.sub.1 which is represented by formulae (4-1), (4-2), (4-5), (4-6), (4-11) and (4-12).

[0276] Very particularly preferably, the compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-comprise a polymerizable group R.sub.1 which is a methacryl or an acryl group represented by formula (4-1) and (4-2).

[0277] The invention therefore relates further to an ophthalmic device or a precursor article for an ophthalmic device comprising polymerized compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and/or (I″-4-H) as described before or preferably described before wherein R.sub.1 is at each occurrence independently an acryl or methacryl group.

[0278] The invention therefore relates further to compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and/or (I″-4-H) as described before or preferably described before wherein R.sub.1 is at each occurrence independently an acryl or methacryl group.

[0279] Examples for compounds/monomers of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and/or (I″-4-H) are the following compounds (A-001) to (A-180) as shown in tables 1 and 1-1.

TABLE-US-00001 TABLE 1 [00024]embedded image A-001 [00025]embedded image A-002 [00026]embedded image A-003 [00027]embedded image A-004 [00028]embedded image A-005 [00029]embedded image A-006 [00030]embedded image A-007 [00031]embedded image A-008 [00032]embedded image A-009 [00033]embedded image A-010 [00034]embedded image A-011 [00035]embedded image A-012 [00036]embedded image A-013 [00037]embedded image A-014 [00038]embedded image A-015 [00039]embedded image A-016 [00040]embedded image A-017 [00041]embedded image A-018 [00042]embedded image A-019 [00043]embedded image A-020 [00044]embedded image A-021 [00045]embedded image A-022 [00046]embedded image A-023 [00047]embedded image A-024 [00048]embedded image A-025 [00049]embedded image A-026 [00050]embedded image A-027 [00051]embedded image A-028 [00052]embedded image A-029 [00053]embedded image A-030 [00054]embedded image A-031 [00055]embedded image A-032 [00056]embedded image A-033 [00057]embedded image A-034 [00058]embedded image A-035 [00059]embedded image A-036 [00060]embedded image A-037 [00061]embedded image A-038 [00062]embedded image A-039 [00063]embedded image A-040 [00064]embedded image A-041 [00065]embedded image A-042 [00066]embedded image A-043 [00067]embedded image A-044 [00068]embedded image A-045 [00069]embedded image A-046 [00070]embedded image A-047 [00071]embedded image A-048 [00072]embedded image A-049 [00073]embedded image A-050 [00074]embedded image A-051 [00075]embedded image A-052 [00076]embedded image A-053 [00077]embedded image A-054 [00078]embedded image A-055 [00079]embedded image A-056 [00080]embedded image A-057 [00081]embedded image A-058 [00082]embedded image A-059 [00083]embedded image A-060 [00084]embedded image A-061 [00085]embedded image A-062 [00086]embedded image A-063 [00087]embedded image A-064 [00088]embedded image A-065 [00089]embedded image A-066 [00090]embedded image A-067 [00091]embedded image A-068 [00092]embedded image A-069 [00093]embedded image A-070 [00094]embedded image A-071 [00095]embedded image A-072 [00096]embedded image A-073 [00097]embedded image A-074 [00098]embedded image A-075 [00099]embedded image A-076 [00100]embedded image A-077 [00101]embedded image A-078 [00102]embedded image A-079 [00103]embedded image A-080 [00104]embedded image A-081 [00105]embedded image A-082 [00106]embedded image A-083 [00107]embedded image A-084 [00108]embedded image A-085 [00109]embedded image A-086 [00110]embedded image A-087 [00111]embedded image A-088 [00112]embedded image A-089 [00113]embedded image A-090 [00114]embedded image A-091 [00115]embedded image A-092 [00116]embedded image A-093 [00117]embedded image A-094 [00118]embedded image A-095 [00119]embedded image A-096 [00120]embedded image A-097 [00121]embedded image A-098 [00122]embedded image A-099 [00123]embedded image A-100 [00124]embedded image A-101 [00125]embedded image A-102 [00126]embedded image A-103 [00127]embedded image A-104 [00128]embedded image A-105 [00129]embedded image A-106 [00130]embedded image A-107 [00131]embedded image A-108 [00132]embedded image A-109 [00133]embedded image A-110 [00134]embedded image A-111 [00135]embedded image A-112 [00136]embedded image A-113 [00137]embedded image A-114 [00138]embedded image A-115 [00139]embedded image A-116 [00140]embedded image A-117 [00141]embedded image A-118 [00142]embedded image A-119 [00143]embedded image A-120 [00144]embedded image A-121 [00145]embedded image A-122 [00146]embedded image A-123 [00147]embedded image A-124 [00148]embedded image A-125 [00149]embedded image A-126 [00150]embedded image A-127 [00151]embedded image A-128 [00152]embedded image A-129 [00153]embedded image A-130 [00154]embedded image A-131 [00155]embedded image A-132 [00156]embedded image A-133 [00157]embedded image A-134 [00158]embedded image A-135 [00159]embedded image A-136 [00160]embedded image A-137 [00161]embedded image A-138 [00162]embedded image A-139 [00163]embedded image A-140 [00164]embedded image A-141 [00165]embedded image A-142 [00166]embedded image A-143 [00167]embedded image A-144 [00168]embedded image A-145 [00169]embedded image A-146 [00170]embedded image A-147 [00171]embedded image A-148 [00172]embedded image A-149 [00173]embedded image A-150 [00174]embedded image A-151 [00175]embedded image A-152 [00176]embedded image A-153 [00177]embedded image A-154 [00178]embedded image A-155 [00179]embedded image A-156 [00180]embedded image A-157 [00181]embedded image A-158 [00182]embedded image A-159 [00183]embedded image A-160 [00184]embedded image A-161 [00185]embedded image A-162 [00186]embedded image A-163 [00187]embedded image A-164 [00188]embedded image A-165 [00189]embedded image A-166 [00190]embedded image A-167 [00191]embedded image A-168 [00192]embedded image A-169 [00193]embedded image A-170 [00194]embedded image A-171 [00195]embedded image A-172 [00196]embedded image A-173 [00197]embedded image A-174 [00198]embedded image A-175 [00199]embedded image A-176 [00200]embedded image A-177 [00201]embedded image A-178 [00202]embedded image A-179 [00203]embedded image A-180.

[0280] Preferred examples for compounds/monomers of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and/or (I″-4-H) are the following compounds as shown in table 1-1.

TABLE-US-00002 TABLE 1-1 [00204]embedded image A-021 [00205]embedded image A-116 [00206]embedded image A-038 [00207]embedded image A-118 [00208]embedded image A-117 [00209]embedded image A-115 [00210]embedded image A-089 [00211]embedded image A-062 [00212]embedded image A-119 [00213]embedded image A-106 [00214]embedded image A-120 [00215]embedded image A-121 [00216]embedded image A-122 [00217]embedded image A-123 [00218]embedded image A-124 [00219]embedded image A-125 [00220]embedded image A-126 [00221]embedded image A-127 [00222]embedded image A-128 [00223]embedded image  A-129

[0281] The compounds of the present application may be synthesized by methods well known to the skilled person. Preferably, all syntheses are carried out under an inert atmosphere using dried solvents.

[0282] An exemplary reaction sequence is shown in Scheme 1 for the compounds of formula (I#) where A is CH.sub.2, m is 1, Y is O, —R.sub.2— is —(CH.sub.2).sub.o—, m1 is 0, R.sub.6 and R.sub.7 are H and R.sub.1 is an alkenyl of formula (4-2) and R.sub.3, R.sub.4, R.sub.5, R.sub.8, R.sub.9, R′ and n1 have a meaning as described or preferably described before.

[0283] In all schemes, Me is methyl.

##STR00224##

[0284] The first type of reaction is the formation of a stable enol equivalent.

[0285] The second type of reaction is a Suzuki reaction.

[0286] The third type of reaction is a methoxy-deprotection reaction.

[0287] The fourth type of reaction is a Williamson ether synthesis reaction.

[0288] The fifth type of reaction is an esterification reaction.

[0289] All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.

[0290] A representative synthesis according to Scheme 1 is described in Scheme 1-1.

##STR00225##

[0291] Another exemplary reaction sequence is shown in Scheme 2 for the compounds of formula (I#) where A is CH.sub.2, m is 1, Y is a bond, —R.sub.2— is —(CH.sub.2).sub.o—, m1 is 0, R.sub.6 and R.sub.7 are H and R.sub.1 is an alkenyl of formula (4-2) and R.sub.3, R.sub.4, R.sub.5, R.sub.8, R.sub.9, R′ and n1 have a meaning as described or preferably described before.

##STR00226## ##STR00227##

[0292] The first type of reaction is the formation of a stable enol equivalent.

[0293] The second type of reaction is Suzuki reaction.

[0294] The third type of reaction is a methoxy-deprotection reaction.

[0295] The fourth type of reaction is triflation reaction.

[0296] The fifth type of reaction is a cross-coupling reaction.

[0297] The sixth type of reaction is an acid-catalyzed deprotection reaction. The seventh type of reaction is an esterification reaction. All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.

[0298] A representative synthesis according to Scheme 1 is described in Scheme 2-1.

##STR00228## ##STR00229##

[0299] Another exemplary reaction sequence is shown in Scheme 3 for the compounds of formula (I#) where A is CH.sub.2, m is 2, Y is O, —R.sub.2— is —(CH.sub.2).sub.o—, m1 is 0, R.sub.6 and R.sub.7 are H and R.sub.1 is an alkenyl of formula (4-2) and R.sub.3, R.sub.4, R.sub.5, R.sub.8, R.sub.9, R′ and n1 have a meaning as described or preferably described before.

##STR00230## ##STR00231##

[0300] The first type of reaction is a Wittig reaction.

[0301] The second type of reaction is a hypervalent iodine-mediated ring-expansion reaction. The third type of reaction is the formation of a stable enol equivalent. The fourth type of reaction is a Suzuki reaction.

[0302] The fifth type of reaction is a methoxy-deprotection reaction.

[0303] The sixth type of reaction is an esterification reaction.

[0304] All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.

[0305] A representative synthesis according to Scheme 3 is described in Scheme 3-1.

##STR00232## ##STR00233##

[0306] Another exemplary reaction sequence is shown in Scheme 4 for the compounds of formula (I#) where A is CH.sub.2, m is 2, Y is a bond, —R.sub.2— is —(CH.sub.2).sub.o—, m1 is 0, R.sub.6 and R.sub.7 are H and R.sub.1 is an alkenyl of formula (4-2) and R.sub.3, R.sub.4, R.sub.5, R.sub.8, R.sub.9, R′ and n1 have a meaning as described or preferably described before.

##STR00234## ##STR00235##

[0307] The first type of reaction is a Wittig reaction.

[0308] The second type of reaction is a hypervalent iodine-mediated ring-expansion reaction. The third type of reaction is the formation of a stable enol equivalent. The fourth type of reaction is a Suzuki reaction. The fifth type of reaction is a methoxy-deprotection reaction. The sixth type of reaction is a triflation reaction. The seventh type of reaction is a cross-coupling reaction. The eight type of reaction is an acid-catalyzed deprotection reaction. The ninth type of reaction is an esterification reaction. All these types of reaction and their reaction conditions are well known to a skilled person and can be easily optimized for the specific starting materials forming the compounds of formula (I). More details can be found in the experimental section.

[0309] A representative synthesis according to Scheme 4 is described in Scheme 4-1

##STR00236## ##STR00237##

[0310] Another exemplary reaction sequence is shown in Scheme 5-1 for the compounds of formula (I#) where A is CH.sub.2, m is 2, Y is O, —R.sub.2— is —(CH.sub.2).sub.5—, m1 is 1, n is 0, R.sub.6 and R.sub.7 are H and R.sub.9 is an alkenyl of formula (4-11) or (4-12) and R.sub.3, R.sub.4, R.sub.5, R.sub.8, R.sub.9, R′ and n1 have a meaning as described or preferably described before.

##STR00238##

[0311] Another exemplary reaction sequence is shown in Scheme 6 for the compounds of formula (I#) where A is CH.sub.2, m is 2, Y is O, —R.sub.2— is —(CH.sub.2).sub.o—, m1 is 0, n is 1, R.sub.6 and R.sub.7 are H, R.sub.9 is H or R′ and R.sub.1 is a methyl-diethoxysilyl group and R.sub.3, R.sub.4, R.sub.5, R.sub.8, R′ and n1 have a meaning as described or preferably described before.

##STR00239## ##STR00240##

[0312] The first type of reaction is a Wittig reaction. The second type of reaction is a hypervalent iodine-mediated ring-expansion reaction. The third type of reaction is the formation of a stable enol equivalent. The fourth type of reaction is a Suzuki reaction. The fifth type of reaction is a methoxy-deprotection reaction. The sixth type of reaction is a Mitsunobu reaction. The seventh type is a hydrosylilation reaction.

[0313] A representative synthesis according to Scheme 6 is described in Scheme 6-1.

##STR00241##

[0314] As described before, the compounds/monomers of formula (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) as described before or preferably described before contain a polymerizable group and are predestinated as monomers for an oligomerization or a polymerization.

[0315] The invention is therefore further directed to an oligomer, polymer or copolymer comprising at least one polymerized compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) as described before or preferably described before where oligomers, polymers and copolymers of 2-(4-vinylphenyl)indene and 2-[4-(2-propen-1-yl)phenyl-1H-indene are excluded.

[0316] The term “polymer” generally means a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass (PAC, 1996, 68, 2291). The term “polymer” includes homopolymers and copolymers if not mentioned otherwise within the description. The term “oligomer” generally means a molecule of intermediate relative molecular mass, the structure of which essentially comprises a small plurality of units derived, actually or conceptually, from molecules of lower relative molecular mass (PAC, 1996, 68, 2291). In a preferred sense according to the present invention a polymer means a compound having >30 repeating units, and an oligomer means a compound with >1 and <30 repeating units.

[0317] Above and below, in formulae showing a polymer, an oligomer, a compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or a monomeric unit or a polymer formed from a compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H), an asterisk (“*”) denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group.

[0318] Suitable terminal end groups are known to the skilled artisan and depend on the polymerization method used.

[0319] The terms “repeating unit” and “monomeric unit” mean the constitutional repeating unit (CRU), which is the smallest constitutional unit the repetition of which constitutes a regular macromolecule, a regular oligomer molecule, a regular block or a regular chain (PAC, 1996, 68, 2291).

[0320] Unless stated otherwise, the molecular weight is given as the number average molecular weight M.sub.n or weight average molecular weight Mw, which is determined by gel permeation chromatography (GPC) against polystyrene standards in eluent solvents such as tetrahydrofuran, trichloromethane (TCM, chloroform), chlorobenzene or 1,2,4-trichloro-benzene. Unless stated otherwise, tetrahydrofuran is used as solvent. The degree of polymerization (n) means the number average degree of polymerization given as n=M.sub.n/M.sub.U, wherein M.sub.u is the molecular weight of the single repeating unit as described in J. M. G. Cowie, Polymers: Chemistry & Physics of Modern Materials, Blackie, Glasgow, 1991.

[0321] In the polymers including copolymers according to the present invention, the total number of repeating units n is preferably ≥30, very preferably ≤100, most preferably 200, and preferably up to 5000, very preferably up to 3000, most preferably up to 2000, including any combination of the aforementioned lower and upper limits of n.

[0322] The polymers of the present invention include homopolymers, statistical copolymers, random copolymers, alternating copolymers and block copolymers, and combinations of the aforementioned.

[0323] Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, mean “including but not limited to”, and are not intended to (and do not) exclude other components

[0324] Preferably the polymerizable group R.sub.1 forms the regioregular, alternated, regiorandom, statistical, block or random homopolymer or copolymer backbone or is part of the polymer backbone where R.sub.1 has a meaning as described or preferably described before.

[0325] Preferably, such oligomer, polymer or copolymer according to the invention comprises a constitutional unit M.sup.0 based on formulae (I), (I′) or (I″)

##STR00242##

[0326] where the polymerizable group R.sub.1 on each occurrence is polymerized and forms the regioregular, alternated, regiorandom, statistical, block or random oligomer or polymer backbone or is part of the copolymer backbone.

[0327] The invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below comprising an oligomer, polymer or copolymer comprising a constitutional unit M.sup.0 based on formulae (I), (I′) or (I″) as described before or preferably described before where R.sub.1 on each occurrence is polymerized and forms the regioregular, alternated, regiorandom, statistical, block or random oligomer or polymer backbone or is part of the copolymer backbone.

[0328] Preferably, such polymerized groups R.sub.1 are of formulae (1-p), (2-p), (3-p) or (4-p)

##STR00243##

where the asterisk “*” within formulae (1-p) to (4-p) denotes a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group, the asterisk “**” within formulae (1-p) to (4-p) denotes the linkage to the remainder of formula (I) as described before or preferably described before and R.sub.10, R.sub.11, R.sub.12, X.sub.11 and c has a meaning as described before or preferably described before.

[0329] The invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below where said polymerized group R.sub.1 is of formulae (1-p), (2-p), (3-p) or (4-p) as described before.

[0330] The invention is furthermore directed to an oligomer, polymer or copolymer as described before or preferably described below where said polymerized group R.sub.1 is of formulae (1-p), (2-p), (3-p) or (4-p) as described before.

[0331] Particularly preferably, such oligomer, polymer or copolymer according to the invention comprises a constitutional unit M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H),

##STR00244## ##STR00245## ##STR00246##

[0332] wherein —R.sub.2—, Y, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, A, m, R′, n1, X.sub.11, R.sub.10, R.sub.11, R.sub.12 and c have a meaning as described before or preferably described before or a below for the compounds of formulae (I), (I#), (I-1), (I-2), (I-2), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and (I″-4-H) and R.sub.9 is H or R′ for compounds of formulae (M.sup.0-I′), (M.sup.0-I′-1), (M.sup.0-I′-2-H), (M.sup.0-I′-3-H) or (M.sup.0-I′-4-H). Combinations are excluded where two O atoms or an O atom and a S atom are directly linked to each other as known for a skilled artisan in the field of organic chemistry.

[0333] The invention is furthermore directed to an ophthalmic device or a precursor article for an ophthalmic device as described before or preferably described below wherein the constitutional unit M.sup.0 is of formulae (M.sup.0-I′-a), (M.sup.0-I′-b), (M.sup.0-I′-c), (M.sup.0-I′-d) or (M.sup.0-I″) as described before and where the asterisk “*” denotes at each occurrence a linkage to the adjacent repeating unit in the polymer chain or oligomer chain or to a terminal end group.

[0334] Preferably, such oligomer, polymer or copolymer according to the invention comprises a constitutional unit M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-1″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H), as described before, wherein —R.sub.2— is selected from —(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—, —(CH.sub.2).sub.6—, —(CH.sub.2).sub.7—, —(CH.sub.2).sub.8—, —(CH.sub.2).sub.9—, —(CH.sub.2).sub.10—, —(CH.sub.2).sub.11—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2).sub.12, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2— and —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)— or has a meaning as preferably described before;

[0335] Y is O, S, SO.sub.2, or a bond or has a meaning as preferably described before;

[0336] R.sub.3, R.sub.4 and R.sub.5 are H, F, a straight-chain alkyl group with 1 to 4 C atoms or a straight-chain alkoxy group with 1 to 4 C atoms or has a meaning as preferably described before;

[0337] R.sub.5 is H, F, CN, SO.sub.2CF.sub.3, CF.sub.3, CF.sub.2CF.sub.3, or CH.sub.2CF.sub.3 or has a meaning as preferably described before;

[0338] R.sub.6 and R.sub.7 are H, F, a linear or branched alkyl group having 1 to 4 C atoms or a linear or branched partially or fully fluorinated alkyl group having 1 to 4 C atoms or has a meaning as preferably described before;

[0339] A is CH.sub.2 or CHR.sub.0 and R.sub.0 has a meaning as described before or preferably described before or A is preferably CH.sub.2;

[0340] m is 0, 1, 2 or 3 or has a meaning as preferably described before;

[0341] R′ is selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms or has a meaning as preferably described before;

[0342] n1 is 0, 1, 2, 3 or 4 or has a meaning as preferably described before;

[0343] X.sub.11 is selected from the group consisting of O, S, O—SO.sub.2, SO.sub.2—O, C(═O), OC(═O), C(═O)O, S(C═O) and (C═O)S, or has a meaning as preferably described before;

[0344] R.sub.11 and R.sub.12 are H;

[0345] R.sub.10 is H, methyl, ethyl or phenyl, or has a meaning as preferably described before; and

[0346] c is 1.

[0347] Preferably, such oligomer, polymer or copolymer according is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention.

[0348] Particularly preferably, such oligomer, polymer or copolymer comprises a constitutional unit M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H), as described before, wherein

[0349] —R.sub.2— is selected from —(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—, —(CH.sub.2).sub.6—, —(CH.sub.2).sub.7—, —(CH.sub.2).sub.8—, —(CH.sub.2).sub.9—, —(CH.sub.2).sub.10—, —(CH.sub.2).sub.11—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2).sub.12, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2— and —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)— or has a meaning as preferably described before;

[0350] Y is O, S, SO.sub.2, or a bond or has a meaning as preferably described before;

[0351] R.sub.3, R.sub.4 and R.sub.5 are H;

[0352] R.sub.5 is H, F or CF.sub.3 or has a meaning as preferably described before;

[0353] R.sub.6 and R.sub.7 are H;

[0354] A is CH.sub.2;

[0355] m is 0, 1, 2 or 3 or has a meaning as preferably described before;

[0356] R′ is selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms or has a meaning as preferably described before;

[0357] n.sub.1 is 0, 1, 2, 3 or 4 or has a meaning as preferably described before;

[0358] X.sub.11 is selected from the group consisting of O, S, O—SO.sub.2, SO.sub.2—O, C(═O), OC(═O), C(═O)O, S(C═O) and (C═O)S, or has a meaning as preferably described before;

[0359] R.sub.11 and R.sub.12 are H;

[0360] R.sub.10 is H, methyl, ethyl or phenyl, or has a meaning as preferably described before;

[0361] c is 1, and the position of the phenyl group is at the C atom of the isolated double bond which is adjacent to C(R.sub.6)(R.sub.7).

[0362] Particularly preferably, such oligomer, polymer or copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention.

[0363] Particularly preferably, such oligomer or polymer comprises a constitutional unit M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H), as described before, wherein

[0364] —R.sub.2— is selected from —(CH.sub.2).sub.3—, —(CH.sub.2).sub.4—, —(CH.sub.2).sub.5—, —(CH.sub.2).sub.6—, —(CH.sub.2).sub.7—, —(CH.sub.2).sub.8—, —(CH.sub.2).sub.9—, —(CH.sub.2).sub.10—, —(CH.sub.2).sub.11—, —(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—, —(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—S—(CH.sub.2).sub.2—S—(CH.sub.2).sub.2—S—(CH.sub.2)—, —(CH.sub.2)—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2)—, —(CH.sub.2)—O—(CH.sub.2).sub.2—SO.sub.2—(CH.sub.2).sub.2—O—(CH.sub.2)—, —(CH.sub.2).sub.12, —(CH.sub.2).sub.3—(CF.sub.2)—(CH.sub.2).sub.3—, —(CH.sub.2)—(CF.sub.2).sub.3—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2).sub.4—(CH.sub.2).sub.2—, —(CH.sub.2)—[CH(CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)CF.sub.3]—(CH.sub.2)—, —(CH.sub.2)—[CH(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2)—[C(CH.sub.3)(CH.sub.2CF.sub.3)]—(CH.sub.2)—, —(CH.sub.2).sub.2—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2).sub.2— and —(CH.sub.2)—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—O—(CF.sub.2)—(CH.sub.2)— or has a meaning as preferably described before;

[0365] Y is O, S, SO.sub.2, or a bond or has a meaning as preferably described before;

[0366] R.sub.3, R.sub.4 and R.sub.5 are H;

[0367] R.sub.5 is H, F or CF.sub.3 or has a meaning as preferably described before;

[0368] R.sub.6 and R.sub.7 are H;

[0369] A is CH.sub.2;

[0370] m is 0, 1, 2 or 3 or has a meaning as preferably described before;

[0371] R′ is selected from the group consisting of F, a linear or branched partially or fully fluorinated alkyl group having 1 to 10 C atoms, a linear or branched alkyl group having 1 to 10 C atoms, a linear or branched alkoxy group having 1 to 10 C atoms, a linear or branched partially or fully fluorinated alkoxy group having 1 to 10 C atoms and a linear or branched thioalkyl group having 1 to 10 C atoms or has a meaning as preferably described before;

[0372] n1 is 0, 1, 2, 3 or 4 or has a meaning as preferably described before; the position of the phenyl group is at the C atom of the isolated double bond which is adjacent to C(R.sub.6)(R.sub.7); and

##STR00247##

within formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) and (M.sup.0-I″-4-H) is derived from any one of the preferred alkenyl groups of formulae (4-1), (4-2), (4-3), (4-4), (4-5), (4-6), (4-7), (4-8), (4-9), (4-10), (4-11) and (4-12) or any preferred embodiment thereof.

[0373] Particularly preferably, such oligomer, polymer or copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention.

[0374] The copolymer may be an oligomer or polymer comprising one or more polymerized compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) as described before or preferably described before or one or more constitutional units M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I′-a), (M.sup.0-I′-b), (M.sup.0-I′-c), (M.sup.0-I′-d), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) and/or (M.sup.0-I″-4-H) as described before or preferably described before or one or more constitutional units (M.sup.0-001) to (M.sup.0-180) as described below, which may be the same or different from one another, and one or more constitutional units M.sup.2, which may be the same or different from one another. Said one or more constitutional units M.sup.2 are chemically different from the units M.sup.0. Preferably, said one or more constitutional units M.sup.2 are derived by polymerization of one or more monomers selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), methyl acrylates, n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (EGPEA), heptafluorobutyl acrylate, heptafluorobutyl methacrylate, hexafluorobutyl acrylate, hexafluorobutyl methacrylate, hexafluoroisopropyl acrylate, hexafluoroisopropyle methacrylate, petanfluoropropyl acrylate, pentafluoropropyl methacrylate, tetrafluoropropyl methacrylate, trifluoroethyl acrylate, and trifluoroethyl methacrylate.

[0375] The invention therefore relates further to an ophthalmic device or a precursor article for the ophthalmic device as described or preferably described before comprising beside of the at least one polymerized compound of formulae (I), (I′) or (I″) or the constitutional unit M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I′-a), (M.sup.0-I′-b), (M.sup.0-I′-c), (M.sup.0-I′-d), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) and/or (M.sup.0-I″-4-H) as described before or preferably described before or one or more constitutional units (M.sup.0-001) to (M.sup.0-180) as described below at least one further polymerized monomer selected from the group consisting of styrene, ethoxyethyl methacrylate (EOEMA), methyl methacrylate (MMA), methyl acrylate, n-alkyl acrylates (the n-alkyl group comprising 2-20 C-atoms), n-alkyl methacrylates (the n-alkyl group comprising 2-20 C-atoms), ethoxyethoxy ethylacrylate (EEEA), 2-hydroxyethyl methacrylate (HEMA), tetrahydrofuryl methacrylate (THFMA), glycidylmethacrylate (GMA), 16-hydroxyhexadecyl acrylate, 16-hydroxyhexadecyl methacrylate, 18-hydroxyoctadecyl acrylate, 18-hydroxyoctadecyl methacrylate, 2-phenoxyethyl acrylate (EGPEA), Bisphenol A diacrylate-1 EO/Phenol (BPADA), 2-[3′-2′H-benzotriazol-2′-yl)-4′-hydroxyphenyl]ethyl methacrylate (BTPEM) or ehtyleneglycoldimethacrylate.

[0376] Particularly preferably, the at least one further polymerized monomer is selected from methyl methacrylate, 2-hydroxyethyl methacrylate, 2-phenoxyethyl acrylate, ethoxyethoxy ethylacrylate, 8-methylnonyl methacrylate, n-butyl methacrylate, 2-ethyl hexylmethacrylate or a mixture thereof.

[0377] Particularly preferably, such copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention.

[0378] Alternatively the oligomer or polymer, preferably the polymer, according to the invention is a homopolymer, i.e. an oligomer or polymer, preferably a polymer, comprising one or more constitutional units M.sup.0 of formula (M.sup.0-I′), (M.sup.0-I′-a), (M.sup.0-I′-b), (M.sup.0-I′-c), (M.sup.0-I′-d), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H) as described before or preferably described before or (M.sup.0-001) to (M.sup.0-180) as described below and wherein all constitutional units M.sup.0 are the same.

[0379] Exemplary homopolymeric compounds based on compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and/or (I″-4-H) are the following compounds (P-001) to (P-180) as shown in table 2.

TABLE-US-00003 TABLE 2 [00248]embedded image P-001 [00249]embedded image P-002 [00250]embedded image P-003 [00251]embedded image P-004 [00252]embedded image P-005 [00253]embedded image P-006 [00254]embedded image P-007 [00255]embedded image P-008 [00256]embedded image P-009 [00257]embedded image P-010 [00258]embedded image P-011 [00259]embedded image P-012 [00260]embedded image P-013 [00261]embedded image P-014 [00262]embedded image P-015 [00263]embedded image P-016 [00264]embedded image P-017 [00265]embedded image P-018 [00266]embedded image P-019 [00267]embedded image P-020 [00268]embedded image P-021 [00269]embedded image P-022 [00270]embedded image P-023 [00271]embedded image P-024 [00272]embedded image P-025 [00273]embedded image P-026 [00274]embedded image P-027 [00275]embedded image P-028 [00276]embedded image P-029 [00277]embedded image P-030 [00278]embedded image P-031 [00279]embedded image P-032 [00280]embedded image P-033 [00281]embedded image P-034 [00282]embedded image P-035 [00283]embedded image P-036 [00284]embedded image P-037 [00285]embedded image P-038 [00286]embedded image P-039 [00287]embedded image P-040 [00288]embedded image P-041 [00289]embedded image P-042 [00290]embedded image P-043 [00291]embedded image P-044 [00292]embedded image P-045 [00293]embedded image P-046 [00294]embedded image P-047 [00295]embedded image P-048 [00296]embedded image P-049 [00297]embedded image P-050 [00298]embedded image P-051 [00299]embedded image P-052 [00300]embedded image P-053 [00301]embedded image P-054 [00302]embedded image P-055 [00303]embedded image P-056 [00304]embedded image  P-P-057 [00305]embedded image P-058 [00306]embedded image P-059 [00307]embedded image P-060 [00308]embedded image P-061 [00309]embedded image P-062 [00310]embedded image P-063 [00311]embedded image P-064 [00312]embedded image P-065 [00313]embedded image P-066 [00314]embedded image P-067 [00315]embedded image P-068 [00316]embedded image P-069 [00317]embedded image P-070 [00318]embedded image P-071 [00319]embedded image P-072 [00320]embedded image P-073 [00321]embedded image P-074 [00322]embedded image P-075 [00323]embedded image P-076 [00324]embedded image P-077 [00325]embedded image P-078 [00326]embedded image P-079 [00327]embedded image P-080 [00328]embedded image P-081 [00329]embedded image P-082 [00330]embedded image P-083 [00331]embedded image P-084 [00332]embedded image P-085 [00333]embedded image P-086 [00334]embedded image P-087 [00335]embedded image P-088 [00336]embedded image P-089 [00337]embedded image P-090 [00338]embedded image P-091 [00339]embedded image P-092 [00340]embedded image P-093 [00341]embedded image P-094 [00342]embedded image P-095 [00343]embedded image P-096 [00344]embedded image P-097 [00345]embedded image P-098 [00346]embedded image P-099 [00347]embedded image P-100 [00348]embedded image P-101 [00349]embedded image P-102 [00350]embedded image P-103 [00351]embedded image P-104 [00352]embedded image P-105 [00353]embedded image P-106 [00354]embedded image P-107 [00355]embedded image P-108 [00356]embedded image P-109 [00357]embedded image P-110 [00358]embedded image P-111 [00359]embedded image P-112 [00360]embedded image P-113 [00361]embedded image P-114 [00362]embedded image P-115 [00363]embedded image P-116 [00364]embedded image P-117 [00365]embedded image P-118 [00366]embedded image P-119 [00367]embedded image P-120 [00368]embedded image P-121 [00369]embedded image P-122 [00370]embedded image P-123 [00371]embedded image P-124 [00372]embedded image P-125 [00373]embedded image P-126 [00374]embedded image P-127 [00375]embedded image P-128 [00376]embedded image P-129 [00377]embedded image P-130 [00378]embedded image P-131 [00379]embedded image P-132 [00380]embedded image P-133 [00381]embedded image P-134 [00382]embedded image P-135 [00383]embedded image P-136 [00384]embedded image P-137 [00385]embedded image P-138 [00386]embedded image P-139 [00387]embedded image P-140 [00388]embedded image P-141 [00389]embedded image P-142 [00390]embedded image P-143 [00391]embedded image P-144 [00392]embedded image P-145 [00393]embedded image P-146 [00394]embedded image P-147 [00395]embedded image P-148 [00396]embedded image P-149 [00397]embedded image P-150 [00398]embedded image P-151 [00399]embedded image P-152 [00400]embedded image P-153 [00401]embedded image P-154 [00402]embedded image P-155 [00403]embedded image P-156 [00404]embedded image P-157 [00405]embedded image P-158 [00406]embedded image P-159 [00407]embedded image P-160 [00408]embedded image P-161 [00409]embedded image P-162 [00410]embedded image P-163 [00411]embedded image P-164 [00412]embedded image P-165 [00413]embedded image P-166 [00414]embedded image P-167 [00415]embedded image P-168 [00416]embedded image P-169 [00417]embedded image P-170 [00418]embedded image P-171 [00419]embedded image P-172 [00420]embedded image P-173 [00421]embedded image P-174 [00422]embedded image P-175 [00423]embedded image P-176 [00424]embedded image P-177 [00425]embedded image P-178 [00426]embedded image P-179 [00427]embedded image  P-180

[0380] The letter n gives the degree of polymerization as explained before.

[0381] Exemplary constitutional units M.sup.0 based on compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and/or (I″-4-H) or constitutional unit M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H) are the following compounds (M.sup.0-001) to (M.sup.0-180) as shown in table 2-1.

TABLE-US-00004 TABLE 2-1 [00428]embedded image M.sup.0-001 [00429]embedded image M.sup.0-002 [00430]embedded image M.sup.0-003 [00431]embedded image M.sup.0-004 [00432]embedded image M.sup.0-005 [00433]embedded image M.sup.0-006 [00434]embedded image M.sup.0-007 [00435]embedded image M.sup.0-008 [00436]embedded image M.sup.0-009 [00437]embedded image M.sup.0-010 [00438]embedded image M.sup.0-011 [00439]embedded image M.sup.0-012 [00440]embedded image M.sup.0-013 [00441]embedded image M.sup.0-014 [00442]embedded image M.sup.0-015 [00443]embedded image M.sup.0-016 [00444]embedded image M.sup.0-017 [00445]embedded image M.sup.0-018 [00446]embedded image M.sup.0-019 [00447]embedded image M.sup.0-020 [00448]embedded image M.sup.0-021 [00449]embedded image M.sup.0-022 [00450]embedded image M.sup.0-023 [00451]embedded image M.sup.0-024 [00452]embedded image M.sup.0-025 [00453]embedded image M.sup.0-026 [00454]embedded image M.sup.0-027 [00455]embedded image M.sup.0-028 [00456]embedded image M.sup.0-029 [00457]embedded image M.sup.0-030 [00458]embedded image M.sup.0-031 [00459]embedded image M.sup.0-032 [00460]embedded image M.sup.0-033 [00461]embedded image M.sup.0-034 [00462]embedded image M.sup.0-035 [00463]embedded image M.sup.0-036 [00464]embedded image M.sup.0-037 [00465]embedded image M.sup.0-038 [00466]embedded image M.sup.0-039 [00467]embedded image M.sup.0-040 [00468]embedded image M.sup.0-041 [00469]embedded image M.sup.0-042 [00470]embedded image M.sup.0-043 [00471]embedded image M.sup.0-044 [00472]embedded image M.sup.0-045 [00473]embedded image M.sup.0-046 [00474]embedded image M.sup.0-047 [00475]embedded image M.sup.0-048 [00476]embedded image M.sup.0-049 [00477]embedded image M.sup.0-050 [00478]embedded image M.sup.0-051 [00479]embedded image M.sup.0-052 [00480]embedded image M.sup.0-053 [00481]embedded image M.sup.0-054 [00482]embedded image M.sup.0-055 [00483]embedded image M.sup.0-056 [00484]embedded image M.sup.0-057 [00485]embedded image M.sup.0-058 [00486]embedded image M.sup.0-059 [00487]embedded image M.sup.0-060 [00488]embedded image M.sup.0-061 [00489]embedded image M.sup.0-062 [00490]embedded image M.sup.0-063 [00491]embedded image M.sup.0-064 [00492]embedded image M.sup.0-065 [00493]embedded image M.sup.0-066 [00494]embedded image M.sup.0-067 [00495]embedded image M.sup.0-068 [00496]embedded image M.sup.0-069 [00497]embedded image M.sup.0-070 [00498]embedded image M.sup.0-071 [00499]embedded image M.sup.0-072 [00500]embedded image M.sup.0-073 [00501]embedded image M.sup.0-074 [00502]embedded image M.sup.0-075 [00503]embedded image M.sup.0-076 [00504]embedded image M.sup.0-077 [00505]embedded image M.sup.0-078 [00506]embedded image M.sup.0-079 [00507]embedded image M.sup.0-080 [00508]embedded image M.sup.0-081 [00509]embedded image M.sup.0-082 [00510]embedded image M.sup.0-083 [00511]embedded image M.sup.0-084 [00512]embedded image M.sup.0-085 [00513]embedded image M.sup.0-086 [00514]embedded image M.sup.0-087 [00515]embedded image M.sup.0-088 [00516]embedded image M.sup.0-089 [00517]embedded image M.sup.0-090 [00518]embedded image M.sup.0-091 [00519]embedded image M.sup.0-092 [00520]embedded image M.sup.0-093 [00521]embedded image M.sup.0-094 [00522]embedded image M.sup.0-095 [00523]embedded image M.sup.0-096 [00524]embedded image M.sup.0-097 [00525]embedded image M.sup.0-098 [00526]embedded image M.sup.0-099 [00527]embedded image M.sup.0-100 [00528]embedded image M.sup.0-101 [00529]embedded image M.sup.0-102 [00530]embedded image M.sup.0-103 [00531]embedded image M.sup.0-104 [00532]embedded image M.sup.0-105 [00533]embedded image M.sup.0-106 [00534]embedded image M.sup.0-107 [00535]embedded image M.sup.0-108 [00536]embedded image M.sup.0-109 [00537]embedded image M.sup.0-110 [00538]embedded image M.sup.0-111 [00539]embedded image M.sup.0-112 [00540]embedded image M.sup.0-113 [00541]embedded image M.sup.0-114 [00542]embedded image M.sup.0-115 [00543]embedded image M.sup.0-116 [00544]embedded image  M.sup.0-117. [00545]embedded image M.sup.0-118 [00546]embedded image M.sup.0-119 [00547]embedded image M.sup.0-120 [00548]embedded image M.sup.0-121 [00549]embedded image M.sup.0-122 [00550]embedded image M.sup.0-123 [00551]embedded image M.sup.0-124 [00552]embedded image M.sup.0-125 [00553]embedded image M.sup.0-126 [00554]embedded image M.sup.0-127 [00555]embedded image M.sup.0-128 [00556]embedded image M.sup.0-129 [00557]embedded image M.sup.0-130 [00558]embedded image M.sup.0-131 [00559]embedded image M.sup.0-132 [00560]embedded image M.sup.0-133 [00561]embedded image M.sup.0-134 [00562]embedded image M.sup.0-135 [00563]embedded image M.sup.0-136 [00564]embedded image M.sup.0-137 [00565]embedded image M.sup.0-138 [00566]embedded image M.sup.0-139 [00567]embedded image M.sup.0-140 [00568]embedded image M.sup.0-141 [00569]embedded image M.sup.0-142 [00570]embedded image M.sup.0-143 [00571]embedded image M.sup.0-144 [00572]embedded image M.sup.0-145 [00573]embedded image M.sup.0-146 [00574]embedded image M.sup.0-147 [00575]embedded image M.sup.0-148 [00576]embedded image M.sup.0-149 [00577]embedded image M.sup.0-150 [00578]embedded image M.sup.0-151 [00579]embedded image M.sup.0-152 [00580]embedded image M.sup.0-153 [00581]embedded image M.sup.0-154 [00582]embedded image M.sup.0-155 [00583]embedded image M.sup.0-156 [00584]embedded image M.sup.0-157 [00585]embedded image M.sup.0-158 [00586]embedded image M.sup.0-159 [00587]embedded image M.sup.0-160 [00588]embedded image M.sup.0-161 [00589]embedded image M.sup.0-162 [00590]embedded image M.sup.0-163 [00591]embedded image M.sup.0-164 [00592]embedded image M.sup.0-165 [00593]embedded image M.sup.0-166 [00594]embedded image M.sup.0-167 [00595]embedded image M.sup.0-168 [00596]embedded image M.sup.0-169 [00597]embedded image M.sup.0-170 [00598]embedded image M.sup.0-171 [00599]embedded image M.sup.0-172 [00600]embedded image M.sup.0-173 [00601]embedded image M.sup.0-174 [00602]embedded image M.sup.0-175 [00603]embedded image M.sup.0-176 [00604]embedded image M.sup.0-177 [00605]embedded image M.sup.0-178 [00606]embedded image M.sup.0-179 [00607]embedded image  M.sup.0-180. [00608]text missing or illegible when filed

[0382] Preferred examples for monomeric units M.sup.0 derived from compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) and/or (I″-4-H) or for constitutional units M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H) are the following monomeric units as shown in table 2-2.

TABLE-US-00005 TABLE 2-2 [00609]embedded image M.sup.0-021 [00610]embedded image M.sup.0-116 [00611]embedded image M.sup.0-038 [00612]embedded image M.sup.0-118 [00613]embedded image M.sup.0-117 [00614]embedded image M.sup.0-115 [00615]embedded image M.sup.0-089 [00616]embedded image M.sup.0-062 [00617]embedded image M.sup.0-119 [00618]embedded image M.sup.0-106 [00619]embedded image M.sup.0-120 [00620]embedded image M.sup.0-121 [00621]embedded image M.sup.0-122 [00622]embedded image M.sup.0-123 [00623]embedded image M.sup.0-124 [00624]embedded image M.sup.0-125 [00625]embedded image M.sup.0-126 [00626]embedded image M.sup.0-127 [00627]embedded image M.sup.0-128 [00628]embedded image  M.sup.0-129.

[0383] Preferably a copolymer according to the invention as described before or preferably described before comprises the one or more constitutional units M.sup.0 as described before with substituents as described before or preferably described before in a molar ratio m1 and the one or more constitutional units M.sup.2 in a molar ratio m2, wherein the ratio m1:m2 is at least 0.01 and at most 100.

[0384] Particularly preferably, such copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention.

[0385] The oligomers, polymers or copolymers, preferably polymers or polymers, according to the invention as described before or preferably described may be cross-linked. Particularly preferably, such polymer or copolymer is comprised in the ophthalmic device or precursor article for an ophthalmic device according to the invention.

[0386] The oligomers or polymers of the present invention may be made by any suitable method. It is, however, preferred that the present oligomers, polymers and copolymers are made by radical polymerization, wherein the polymerization reaction is started by means of a suitable radical polymerization initiator. For the purposes of the present invention the type of radical polymerization initiator is not particularly limited and may be any suitable radical generating compound. Such compounds are well known to the skilled person. Suitable polymerization initiators may be selected from thermal initiators or photoinitiators, i.e. compounds that generate radicals by exposure to heat or irradiation with light of a suitable wavelength. Examples of suitable thermal polymerization initiators may be selected from the groups of compounds comprising one or more peroxide groups, i.e. compounds comprising a group —O—O—, and/or compounds comprising one or more azo groups, i.e. compounds comprising a group —N═N—.

[0387] Suitable polymerization initiators comprising one or more peroxide groups may, for example, be selected from the groups consisting of t-butyl(peroxy-2-ethyl-hexanoate), di-(tert-butylcyclohexyl)peroxydicarbonate and benzoylperoxide.

[0388] Suitable polymerization initiators comprising one or more azo groups may, for example, be selected from the group consisting of 1,1′-azobis(cyclohexancarbonitrile) and 2,2′azobis(cyclohexanecarbonitrile) (AIBN).

[0389] Suitable examples of a photoinitiator are dimethylaminobenzoate/camphorquinone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (TPO) or phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide (BAPO).

[0390] If a photoinitiator is used as polymerization initiator, it is preferred that the wavelength required to decompose said photoinitiator is different from the wavelength needed to irradiate the compound of the present application so as to change its optical properties.

[0391] Preferably, the radical initiators are used in an amount of at least 0.0001 eq and of at most 0.1 eq of the main monomer. Such radical initiators could be thermal initiators, e.g. azobisisobutyronitrile (AIBN) or photochemical initiators like dimethylaminobenzoate/camphorquinone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (TPO) or phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide (BAPO).

[0392] The present invention is also directed to a composition for polymerization. Depending upon the intended use such composition as described or preferably described before may comprise further different components. Such further components may, for example, be selected from the group consisting of UV absorbers, antioxidants and cross-linkers. Cross-linkers may also be referred to as crosslinking agents.

[0393] The present invention is also directed to a composition for polymerization comprising at least one compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180) as described or preferably described before and/or an oligomer or polymer as described before or preferably described before but having at least one reactive group left for polymerization excluding 2-(vinylphenyl)indene, 2-[4-(2-propen-1-yl)phenyl-1H-indene and any oligomer, polymer or copolymer derived from 2-(vinylphenyl)indene and 2-[4-(2-propen-1-yl)phenyl-1H-indene and/or a crosslinking agent and/or a UV absorber and/or a radical initiator and optionally further monomers different from compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180).

[0394] The present invention is also directed to a preferred composition for polymerization comprising at least one compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180) as described or preferably described before excluding 2-(vinylphenyl)indene, 2-[4-(2-propen-1-yl)phenyl-1H-indene and/or a crosslinking agent and/or a UV absorber and/or a radical initiator and optionally further monomers different from compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180).

[0395] A composition comprising at least one compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180) as described or preferably described before and an oligomer or polymer according to the invention as described before is primarily used for the synthesis of block copolymers with the condition that the oligomer or polymer has at least one reactive group left which may react with the monomers.

[0396] The compositions may include or comprise, essentially consist of or consist of the said requisite or optional constituents. All compounds or components which can be used in the compositions are either known and commercially available or can by synthesized by known processes.

[0397] The UV absorber that may be used in the present composition is not particularly limited and can easily be selected from those generally known to the skilled person. Generally suitable UV absorbers are characterized by being unsaturated compounds, preferably compounds comprising one or more selected from group consisting of olefinic groups, aryl groups and heteroaryl groups; these groups may be present in any combination.

[0398] Suitable UV-absorber for use in the present composition may, for example, be selected from those comprising a group selected from benzotriazole, benzophenone and triazine. Suitable UV-absorbers are, for example, disclosed in U.S. Pat. Nos. 5,290,892; 5,331,073 and 5,693,095.

[0399] Suitable UV-absorber are 2-(3-(t-butyl)-4-hydroxy-5-(5-methoxy-2-benzotriazolyl)phenoxy)ethyl methacrylate, 3-(3-(t-butyl)-4-hydroxy-5-(5-methoxy-2-benzotriazolyl)phenoxy)propyl methacrylate, 3-(3-t-Butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl)propyl methacrylate3-(3-(tert-Butyl)-4-hydroxy-5-(5-methoxy-2H-benzo[d][1,2,3]triazol-2-yl)phenoxy)propylmethacrylat, 2-(2-Hydroxy-5-vinylphenyl)-2H-benzotriazol, Allyl-2-hydroxybenzophenon, 2-Allyl-6-(2H-benzotriazol-2-yl)-p-cresol, 4-Methacryloxy-2-hydroxybenzophenon, 2-(2′-Hydroxy-3′-methallyl-5′-methylphenyl)benzotriazol, 2-Hydroxy-4-methacryloyloxybenzophenon, 4-Acryloylethoxy-2-hydroxybenzophenon, 2-[3-(2H-Benzotriazol-2-yl)-4-hydroxyphenyl]ethylmethacrylat, 2-(2′-Hydroxy-5′-methacrylamidophenyl)-5-methoxybenzotriazol, 2-(2′-Hydroxy-5′-methacrylamidophenyl)-5-chlorobenzotriazol, 2-(2′-Hydroxy-5′-methacryloxypropylphenyl)benzotriazol, 2-(2′-Hydroxy-5′-methacryloylpropyl-3′-tert-butyl-phenyl)-5-methoxy-2H-benzotriazol, 2-(3-(tert-Butyl)-4-hydroxy-5-(5-methoxy-2H-benzo[d][1,2,3]triazol-2-yl)phenoxy)ethylmethacrylat, 2-[3′-tert-Butyl-2′-hydroxy-5′-(3″-methacryloyloxypropyl)phenyl]-5-chlorbenzotriazol, 2-{2′-Hydroxy-3′-tert-butyl-5′-[3′-methacryloyloxypropoxy]phenyl}-5-methoxy-2H-benzotriazol, 2-[3′tert-Butyl-5′-(3″-dimethylvinylsilylpropoxy)-2′-hydroxyphenyl]-5-methoxybenzotriazol, 2-(tert-Butyl)-6-(5-chloro-2H-benzo[d][1,2,3]triazol-2-yl)-4-vinylphenol, 2-(2H-1,2,3-benzotriazol-2-yl)-4-methyl-6-(2-methylprop-2-enyl)phenol, 2-(3-acetyl-2-aminophenoxy)ethyl methacrylat, 2-(4-benzoyl-3-hydroxyphenoxy)ethyl acrylat or a combination of this compounds.

[0400] Suitable cross-linker may be used to impart elastomeric properties to the present composition and the ophthalmic devices or precursor articles produced therewith. Typically any suitable di- or tri-functional monomer may be used as crosslinker. Such monomers are generally well known to the skilled person and may be selected from poly(ethylene glycol) diacrylate, poly(ethylene glycol) dimethacrylate, ethyleneglycoldimethacrylate (EGDMA), ethyleneglycoldiacrylate, 1,3-propanedioldiacrylat, 1,6-Hexanedioldiacrylate, 1,8-Octanedioldiacrylate, 1,15-Pentadecandioldiacrylate, 1,16-Hexadecanedioldiacrylate, 1,18-Octadecanedioldiacrylate, 1,3-Propanedioldimethacrylate, 1,6-Hexanedioldimethacrylate, 1,8-Octanedioldimethacrylate, 1,15-Pentadecanedioldimethacrylate, 1,16-Hexadecanedioldimethacrylate, 1,18-Octadecanedioldimethacrylate.

[0401] Preferred cross-linker may be selected from the following group of compounds

##STR00629##

[0402] Ethylene glycol dimethacrylate (EGDMA) is particularly preferred.

[0403] Suitable antioxidants are phenyl acrylate derivatives bearing a hindered phenol moiety. A preferred antioxidant is

##STR00630##

[0404] The compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180) according to the invention as described or preferably described before and their oligomers, polymers or copolymers as described before or preferably described before comprising one or more constitutional units M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H), or one or more constitutional units (M.sup.0-001) to (M.sup.0-127) as described before or preferably described before are particularly well suited for use in optically active devices as described before.

[0405] The compounds of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180) according to the invention as described or preferably described before and their oligomers, polymers or copolymers as described before or preferably described before comprising one or more constitutional units M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H), or one or more constitutional units (M.sup.0-001) to (M.sup.0-180) as described before or preferably described before are particularly sensitive to two-photon or multiphoton absorption. Hence the ophthalmic device and the precursor article for the ophthalmic device are sensitive to two-photon or multiphoton absorption.

[0406] Hence the present invention is also directed to precursor articles wherein said precursor article is a blank which may be transformed into optically active ophthalmic devices comprising at least one oligomer, polymer or copolymer as described before or preferably described before comprising one or more constitutional units M.sup.0 of formulae (M.sup.0-I′), (M.sup.0-I″), (M.sup.0-I′-1), (M.sup.0-I″-1), (M.sup.0-I′-2-H), (M.sup.0-I″-2-H), (M.sup.0-I′-3-H), (M.sup.0-I″-3-H), (M.sup.0-I′-4-H) or (M.sup.0-I″-4-H), or one or more constitutional units (M.sup.0-001) to (M.sup.0-180) as described before or preferably described before.

[0407] Preferred ophthalmic devices are optically active ophthalmic devices. Examples of such ophthalmic devices or eye-implants include lenses, keratoprostheses, and corneal inlays or rings. More preferably, said ophthalmic device or eye-implant is a lens article. Most preferably, such ophthalmic device is a lens. The type of lens is not restricted and may comprise a contact lens or an intraocular lens. Most preferably, such ophthalmic device is an intraocular lens article, which may, for example, be a posterior chamber intraocular lens or an anterior chamber intraocular lens.

[0408] A blank of this invention may be produced as a step in the manufacturing process used to create a lens, preferably an intraocular lens. For example, without limitation, a manufacturing process may include the steps of polymer synthesis, polymer sheet casting, blank cutting, optic lathe cutting, optic milling, haptic milling or attachment, polishing, solvent extraction, sterilization and packaging while the term polymer is used as described before or preferably described before.

[0409] The present ophthalmic devices or precursor articles for an ophthalmic device according to the invention as described before or preferably described before may be formed by a process comprising the steps of [0410] providing a composition comprising at least one compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-180) as described herein or preferably described herein and/or an oligomer or polymer as described herein or preferably described herein but having at least one reactive group left for polymerization and optionally further monomers different from compounds of formulae (I), (I′) or (I″) and/or crosslinking agents and/or UV absorbers and/or radical initiators; and [0411] subsequently forming the ophthalmic device or precursor article of said composition.

[0412] The present ophthalmic devices or precursor articles according to the invention as described before or preferably described before may be formed by a process comprising the steps of [0413] providing a composition comprising at least one compound of formulae (I), (I#), (I-1), (I-2), (I-2H), (I-3), (I-3-H), (I-4), (I-4-H), (I′), (I′-a), (I′-b), (I′-c), (I′-d), (I′-1), (I′-2), (I′-2-H), (I′-3), (I′-3-H), (I′-4), (I′-4-H) (I″), (I″-1), (I″-2), (I″-2-H), (I″-3), (I″-3-H), (I″-4) or (I″-4-H) or compounds (A-001) to (A-127) as described herein or preferably described herein and optionally further monomers different from compounds of formulae (I), (I′) or (I″) and/or crosslinking agents and/or UV absorbers and/or radical initiators; and [0414] subsequently forming the ophthalmic device or precursor article of said composition.

[0415] Intraocular lenses in accordance with the present invention are believed to show particularly advantageous properties in that they are flexible enough so as to be rolled or folded and consequently requiring a much smaller incision for them to be inserted into the eye. It is believed that this will allow for improved healing of the eye, particularly in respect to the time for the eye to heal.

[0416] The type of intraocular lens is not limited in any way. It may, for example, be a pseudo-phakic intraocular lens or a phakic intraocular lens. The former type replaces the eye's natural, crystalline lens, usually to replace a cataractous lens that has been removed. The latter type is used to supplement an existing lens and functions as a permanent corrective lens, which is implanted in the anterior or posterior chamber to correct refractive errors of the eye. It may, for example, comprise one or more optic and one or more haptic components, wherein the one or more optic components serve as lens and the one or more haptic components are attached to the one or more optic components and hold the one or more optic components in place in the eye. The present intraocular lens may be of a one-piece design or of multi-piece design, depending on whether the one or more optic components and the one or more haptic components are formed from a single piece of material (one-piece design) or are made separately and then combined (multi-piece design). The present intraocular lens is also designed in such a way that it allows to be, for example, rolled up or folded small enough so that it fits through an incision in the eye, said incision being as small as possible, for example, at most 3 mm in length.

[0417] Additionally, intraocular lenses in accordance with the present invention allow for the non-invasive adjustment of the optical properties, particularly the refractive power, after implantation of the lens into the eye, thus reducing the need for post-surgery vision aids or reducing or totally avoiding follow-up surgery.

[0418] In order to change the optical properties and particularly the refractive power of the intraocular lens it is exposed to irradiation having a wavelength of at least 200 nm and of at most 1500 nm.

[0419] Hence, the present invention is also directed to a process of changing the optical properties of an ophthalmic device or a precursor article for an ophthalmic device as defined or preferably defined herein, said process comprising the steps of [0420] providing an ophthalmic device or a precursor article for an ophthalmic device as defined herein; and [0421] subsequently exposing said ophthalmic device or precursor article to irradiation having a wavelength of at least 200 nm and at most 1500 nm.

[0422] Preferably, said irradiation has a wavelength of at least 250 nm or 300 nm, more preferably of at least 350 nm, even more preferably of at least 400 nm, still even more preferably of at least 450 nm, and most preferably of at least 500 nm. Preferably, said irradiation has a wavelength of at most 1400 nm or 1300 nm or 1200 nm or 1100 nm or 1000 nm, more preferably of at most 950 nm or 900 nm, even more preferably of at most 850 nm, still even more preferably of at most 800 nm and most preferably of at most 750 nm.

[0423] Alternatively, you may describe the change of refractive power as a modification of the index of refraction of said ophthalmic device as described before or preferably described before. Alternatively, you may describe the change of refractive power as a modification of the index of refraction of said intraocular lens article as described before or preferably described before. Irradiation within the focal volume results in refractive optical structures characterized by a change in refractive index relative to the index of refraction of the bulk of said ophthalmic device or alternatively the non-irradiated portion of said ophthalmic device. Irradiation within the focal volume results in refractive optical structures characterized by a change in refractive index relative to the index of refraction of the bulk of said intraocular lens article or alternatively the non-irradiated portion of said intraocular lens article. The change in refractive index can in other words be used to form patterned desired refractive structures in the optical ophthalmic device as described or preferably described before, preferably in the intraocular lens article as described or preferably described before.

[0424] It is preferred to provide refractive structures that exhibit a change in refractive index, and exhibit little or no scattering loss in such a way that ablation or removal of the optical ophthalmic device, preferably the intraocular lens article is not observed in the irradiated region.

[0425] In such processes, the irradiated regions of the ophthalmic device as described before or preferably described before can take the form of two- or three-dimensional, area or volume filled refractive structures that can provide spherical, aspherical, toroidal, or cylindrical correction. In fact, any optical structure can be formed to yield power correction in both physical directions. Moreover, the optical structures can be stacked vertically or written in separate planes in the ophthalmic device as described before or preferably described before to act as a single lens element.

EXAMPLES

[0426] The following examples are intended to show the advantages of the present compounds in a non-limiting way.

[0427] Unless indicated otherwise, all syntheses are carried out under an inert atmosphere using dried (i.e. water-free) solvents. Solvents and reagents are purchased from commercial suppliers.

[0428] DCM is used to denote dichloromethane. DMF is used to denote dimethylformamide. EE is used to denote ethyl acetate. THE is used to denote tetrahydrofuran. RT means room temperature.

[0429] Copolymer-properties can be investigated on blanks, prepared by bulk polymerization of the monomers. Co-monomers, cross-linkers and initiators therefore can be purchased from commercial sources. All chemicals are of highest purity available and can be used as received.

[0430] Synthesis of Precursor Materials:

Example 1

[0431] ##STR00631##

[0432] To a solution of diisopropylamine (4.25 m1; 30.28 mmol; 1.10 eq.) in THE (30 ml) n-butyllithium (2.5M in hexane) (12.11 m1; 30.28 mmol; 1.10 eq.) is added dropwise at −78° C. The mixture is stirred for 10 min at this temperature and 30 min at 0° C. 5-methoxy-1,2,3,4-tetrahydronaphthalen-2-one (5.00 g; 27.52 mmol; 1.00 eq.), dissolved in THE (30 ml) is added to the LDA solution at −78° C. and stirred for 2 h. Then N-phenyl-bis-(trifluoromethanesulfonimide) (11.80 g; 33.03 mmol; 1.20 eq.) is added and stirred overnight while the cooling bath warmed to RT. The solvent is removed, and the crude product is cleaned by column chromatography (2% EtOAc/heptane). The synthesis yield 8.52 g of trifluoromethanesulfonic acid 5-methoxy-3,4-dihydro-naphthalen-2-yl ester (27.6 mmol, quant.).

[0433] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.16 (t, J=7.9 Hz, 1H), 6.81 (dd, J=8.3, 1.0 Hz, 1H), 6.71 (dd, J=7.6, 0.9 Hz, 1H), 6.44 (t, J=1.3 Hz, 1H), 3.83 (s, 3H), 3.05 (t, J=8.6 Hz, 2H), 2.66 (td, J=8.7, 1.4 Hz, 2H).

[0434] Analogously, other derivatives are prepared in the same manner:

TABLE-US-00006 Yield No. Reactant Product [%] 1a [00632]embedded image [00633]embedded image 95 1b [00634]embedded image [00635]embedded image 92 1c [00636]embedded image [00637]embedded image 98

##STR00638##

[0435] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.00 (d, J=7.9 Hz, 1H), 6.71 (d, J=8.0 Hz, 2H), 6.43 (d, J=1.4 Hz, 1H), 3.80 (s, 3H), 3.03 (t, J=8.4 Hz, 2H), 2.67 (td, J=8.4, 1.4 Hz, 2H).

Example 2.1

[0436] ##STR00639##

[0437] To a solution of trifluoromethanesulfonic acid 5-methoxy-3,4-dihydro-naphthalen-2-yl ester (10.0 g; 32.4 mmol, 1.00 eq.) and Iron(III) acetylacetonate (572 mg, 1.62 mmol, 0.05 eq.) in 1-methyl-2-pyrrolidinone (NMP) (29.7 mL) and tetrahydrofuran (650 ml) phenylmagnesium bromide is added fastly at −30° C. The mixture is stirred for 45 min and quenched with sat. NH.sub.4Cl-solution. After dilution with water, the aqueous layer is extracted four times with diethylether. The organic layers are dried over Na.sub.2SO.sub.4 and the solvent is evaporated. The crude product is cleaned by column chromatography (0-5% EtOAc/heptane). The synthesis yield 5.00 g of 8-methoxy-3-phenyl-1,2-dihydronaphthalene (21.2 mmol, 65% of theory).

[0438] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.60-7.56 (m, 2H), 7.40 (t, J=7.7 Hz, 2H), 7.33-7.28 (m, 1H), 7.18 (t, J=7.9 Hz, 1H), 6.86 (d, J=1.5 Hz, 1H), 6.84-6.79 (m, 2H), 3.89 (s, 3H), 2.99 (dd, J=9.2, 7.4 Hz, 2H), 2.77 (td, J=8.4, 1.3 Hz, 2H).

[0439] Analogously, other derivatives are prepared with phenylmagnesium bromide in the same manner:

TABLE-US-00007 Yield No. Reactant Product [%] 2a [00640]embedded image [00641]embedded image 80 2b [00642]embedded image [00643]embedded image 61 2c [00644]embedded image [00645]embedded image 65

##STR00646##

[0440] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.48-7.43 (m, 2H), 7.29 (dd, J=8.4, 7.1 Hz, 2H), 7.18 (tt, J=6.8, 1.2 Hz, 1H), 7.00 (d, J=8.0 Hz, 1H), 6.69-6.64 (m, 2H), 3.75 (s, 3H), 2.86 (dd, J=9.1, 7.0 Hz, 2H), 2.69-2.63 (m, 2H).

Example 2.2

[0441] ##STR00647##

[0442] 4-Biphenylboronic acid (1.00 g, 5.05 mmol, 1.00 eq.), Pd(dppf)Cl.sub.2 (0.092 g, 0.126 mmol, 0.025 eq.) and 4-methoxy-6,7-dihydro-5H-benzo[7]annulen-8-yl trifluoromethane-sulfonate (1.56 g, 1.00 eq.) are dissolved in 1,4-dioxane (80 mL). Then 3 M NaOH-solution (20 mL) is added the mixture is stirred under reflux for 2 h. The reaction is quenched with sat. NH.sub.4Cl-solution and diluted with EtOAc. The phases are separated, and the aqueous phase is extracted with EtOAc. The organic layers are dried over MgSO.sub.4 and the crude product is cleaned by column chromatography (5-10% EtOAc/cyclohexane). The synthesis yield 1.45 g 4-(5-methoxy-3,4-dihydronaphthalen-2-yl)-1,1′-biphenyl (88% yield of theory).

[0443] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.68-7.58 (m, 6H), 7.45 (dd, J=8.5, 7.0 Hz, 2H), 7.39-7.32 (m, 1H), 7.17 (t, J=7.9 Hz, 1H), 6.90 (d, J=1.5 Hz, 1H), 6.86-6.72 (m, 2H), 3.87 (s, 3H), 2.98 (dd, J=9.1, 7.5 Hz, 2H), 2.78 (td, J=8.4, 1.3 Hz, 2H).

Example 3

[0444] ##STR00648##

[0445] A solution of boron tribromide (1.79 mL, 18.6 mmol, 1.10 eq.) in DCM (75 mL) is added to 8-methoxy-3-phenyl-1,2-dihydronaphthalene (4.00 g, 16.9 mmol, 1.00 eq.) in DCM (70 mL) at 0° C. The cooling bath is removed and stirred for 5 h. The reaction is quenched with sat. NaHCO.sub.3-solution and extracted with DCM three times. The organic layers are dried over MgSO.sub.4 and the solvent is removed. The synthesis yield 3.80 g 6-phenyl-7,8-dihydronaphthalen-1-ol (17.10 mmol, quant.).

[0446] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.58-7.54 (m, 2H), 7.39 (dd, J=8.5, 7.0 Hz, 2H), 7.32-7.28 (m, 1H), 7.07 (t, J=7.8 Hz, 1H), 6.84 (s, 1H), 6.79 (dd, J=7.6, 1.0 Hz, 1H), 6.68 (dd, J=8.1, 1.0 Hz, 1H), 4.65 (s, 1H), 2.94 (dd, J=9.0, 7.3 Hz, 2H), 2.85-2.72 (m, 2H).

[0447] Analogously, other derivatives are prepared in the same manner:

TABLE-US-00008 Yield No. Reactant Product [%] 3a [00649]embedded image [00650]embedded image 86 3b [00651]embedded image [00652]embedded image 85 3c [00653]embedded image [00654]embedded image 96 3d [00655]embedded image [00656]embedded image 70

##STR00657##

[0448] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.52 (dd, J=8.3, 1.3 Hz, 2H), 7.36 (t, J=8.4, 7.0 Hz, 2H), 7.27-7.24 (m, 1H), 7.02 (d, J=7.9 Hz, 1H), 6.80 (s, 1H), 6.67-6.63 (m, 2H), 4.66 (s, 1H), 2.90 (dd, J=9.1, 7.1 Hz, 2H), 2.73 (td, J=8.2, 1.2 Hz, 2H).

##STR00658##

[0449] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.67-7.60 (m, 6H), 7.46 (dd, J=8.3, 7.1 Hz, 2H), 7.40-7.32 (m, 1H), 7.08 (t, J=7.8 Hz, 1), 6.90 (d, J=1.4 Hz, 1H), 6.80 (d, J=7.5 Hz, 1H), 6.69 (dd, J=8.1, 1.0 Hz, 1H), 2.96 (dd, J=9.1, 7.3 Hz, 2H), 2.86-2.76 (m, 2H).

Example 4

[0450] ##STR00659##

[0451] 6-Phenyl-7,8-dihydronaphthalen-1-ol is dissolved in DCM (30 mL) and triethylamine (7.18 mL, 51.3 mmol, 3.00 eq.) is added followed by the addition of trifluoromethanesulfonic anhydride (3.67 mL, 22.2 mmol, 1.30 eq., dissolved in 5.50 m1 DCM) at 0° C. The solution is stirred overnight while warming to room temperature. The reaction is washed with water two times and the aqueous layers are extracted two times with DCM. The organic layers are dried over MgSO.sub.4 and the solvent is evaporated. The crude product is cleaned by column chromatography (0-10% EtOAc/heptane). The synthesis yield 4.30 g 6-phenyl-7,8-dihydronaphthalen-1-yl trifluoromethanesulfonate (12.1 mmol, 71% of theory).

[0452] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.55 (dd, J=8.4, 1.3 Hz, 2H), 7.41 (t, J=7.6 Hz, 2H), 7.36-7.31 (m, 1H), 7.27-7.23 (m, 1H), 7.16 (d, J=7.5 Hz, 1H), 7.10 (d, J=8.2 Hz, 1H), 6.87 (s, 1H), 3.09-3.02 (m, 2H), 2.80 (ddd, J=9.3, 7.2, 1.4 Hz, 2H).

[0453] Analogously, other derivatives are prepared in the same manner:

TABLE-US-00009 Yield No. Reactant Product [%] 4a [00660]embedded image [00661]embedded image 88 4b [00662]embedded image [00663]embedded image 77 4c [00664]embedded image [00665]embedded image 78

Example 5a

[0454] ##STR00666##

[0455] 5-Bromopentan-1-ol (5.47 g; 29.47 mmol; 1.00 eq.) is dissolved in dichloromethane (75.28 m1; 1178.85 mmol; 40.00 eq.) and para-toluenesulfonic-monohydrate (7.40 mg; 0.04 mmol; 0.001 eq.) is added at 0° C. 3,4-Dihydro-2H-pyran, 97% (3.33 m1; 35.37 mmol; 1.20 eq.) is added over a period of 1 h and warmed overnight to r.t. The organic phase is washed with sat. NaHCO.sub.3-Lsg. and the phases are separated. The organic phase is dried over MgSO.sub.4 and the solvent is removed. The crude product is purified via column chromatography (0-5% EtOAC/heptane) and yield 6.4 g 2-((5-bromopentyl)oxy)tetrahydro-2H-pyran (25.48 mmol; 87% of theory).

[0456] .sup.1H NMR (500 MHz, Chloroform-d) δ 4.57 (dd, J=4.5, 2.8 Hz, 1H), 3.86 (ddd, J=11.1, 7.6, 3.3 Hz, 1H), 3.75 (dt, J=9.7, 6.6 Hz, 1H), 3.54-3.47 (m, 1H), 3.45-3.36 (m, 3H), 1.90 (dt, J=14.3, 7.0 Hz, 2H), 1.83 (qd, J=7.9, 3.5 Hz, 1H), 1.75-1.68 (m, 1H), 1.66-1.60 (m, 2H), 1.54 (dddd, J=19.2, 14.5, 7.6, 3.2 Hz, 6H).

[0457] The other THP-ether derivatives 2-(3-bromopropoxy)tetrahydro-2H-pyran and 2-((6-bromohexyl)oxy)tetrahydro-2H-pyran are prepared in the same manner using 3-bromopropan-1-ol or 6-bromohexan-1-ol using the above-mentioned reaction procedure.

Example 5b

[0458] ##STR00667##

[0459] To a solution of 9-[5-(oxan-2-yloxy)pentyl]-9-borabicyclo[3.3.1]nonane (0.3M in THF, 33.9 mL, 8.47 mmol, 1.50 eq.) and Pd(dppf)Cl.sub.2 (207 mg, 0.28 mmol, 0.05 eq.) in THF (80 mL) is added 6-phenyl-7,8-dihydronaphthalen-1-yl trifluoromethanesulfonate (2.00 g, 5.64 mmol, 1.00 eq.) and 3 M NaOH-solution (17.0 mL, 50.8 mmol, 9.00 eq.) and stirred for 6 hat reflux. The reaction is quenched with sat. NH.sub.4Cl-solution and the phases are separated. The aqueous layer is extracted with 2-Methyl-THF two times. The organic layers are dried over MgSO.sub.4 and the solvent is removed. The crude product is cleaned by column chromatography (0-10% EtOAc/heptane). The synthesis yield 1.08 g 2-{[5-(6-phenyl-7,8-dihydronaphthalen-1-yl)pentyl]oxy}oxane (2.87 mmol, 51% of theory).

[0460] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.57-7.53 (m, 2H), 7.38 (t, J=7.7 Hz, 2H), 7.30-7.27 (m, 1H), 7.11 (t, J=7.5 Hz, 1H), 7.01 (ddd, J=11.5, 7.5, 1.3 Hz, 2H), 6.85 (s, 1H), 4.58 (dd, J=4.5, 2.8 Hz, 1H), 3.86 (ddd, J=11.0, 7.6, 3.2 Hz, 1H), 3.76 (dt, J=9.7, 6.9 Hz, 1H), 3.53-3.47 (m, 1H), 3.40 (dt, J=9.5, 6.6 Hz, 1H), 2.93 (dd, J=9.1, 7.0 Hz, 2H), 2.74 (t, J=7.7 Hz, 2H), 2.70-2.63 (m, 2H), 1.83 (ddt, J=11.5, 8.4, 4.6 Hz, 1H), 1.76-1.44 (m, 11H).

[0461] Analogously, other derivatives are prepared in the same manner: R.sub.1 means reactant, R.sub.2 means reactant 2, [P] means product.

TABLE-US-00010 No. Yield [%] 5ba R1 [00668]embedded image R2 [00669]embedded image [P] [00670]embedded image 74 5bb R1 [00671]embedded image R2 [00672]embedded image [P] [00673]embedded image 69 5bc R1 [00674]embedded image R2 [00675]embedded image [P] [00676]embedded image 58 5bd R1 [00677]embedded image R2 [00678]embedded image [P] [00679]embedded image 54 5be R1 [00680]embedded image R2 [00681]embedded image [P] [00682]embedded image 69 5bf R1 [00683]embedded image R2 [00684]embedded image [P] [00685]embedded image 57 5bg R1 [00686]embedded image R2 [00687]embedded image [P] [00688]embedded image 73 5bh R1 [00689]embedded image R2 [00690]embedded image [P] [00691]embedded image 76 5bi R1 [00692]embedded image R2 [00693]embedded image [P] [00694]embedded image 79 5bj R1 [00695]embedded image R2 [00696]embedded image [P] [00697]embedded image 74 5bk R1 [00698]embedded image R2 [00699]embedded image [P] [00700]embedded image 66

Example 6

[0462] ##STR00701##

[0463] 2-{[5-(6-phenyl-7,8-dihydronaphthalen-1-yl)pentyl]oxy}oxane (980 mg, 2.60 mmol, 1.00 eq.) is dissolved in DCM (15 mL) and MeOH (15 mL). Then conc. HCl (0.325 mL, 3.90 mmol, 1.50 eq.) is added and stirred for 45 min. The reaction is quenched with sat. NaHCO.sub.3-solution and diluted with DCM. The phases are separated, and the aqueous phase is extracted with DCM three times. The organic layers are dried over MgSO.sub.4 and the solvent is removed. The crude product is cleaned by column chromatography (20-40% EtOAc/heptane). The synthesis yield 730 mg 5-(6-phenyl-7,8-dihydronaphthalen-1-yl)pentan-1-ol (2.50 mmol, 96% of theory).

[0464] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.58-7.52 (m, 2H), 7.38 (dd, J=8.4, 7.0 Hz, 2H), 7.31-7.26 (m, 1H), 7.12 (t, J=7.5 Hz, 1H), 7.05-7.00 (m, 2H), 6.86 (d, J=1.4 Hz, 1H), 3.67 (t, J=6.6 Hz, 2H), 2.94 (dd, J=9.1, 7.0 Hz, 2H), 2.78-2.72 (m, 2H), 2.69-2.62 (m, 2H), 1.70-1.56 (m, 4H), 1.51-1.42 (m, 2H), 1.26 (s, 1H).

[0465] Analogously other derivatives are prepared in the same manner:

TABLE-US-00011 Yield No. Reactant Product [%] 6a [00702]embedded image [00703]embedded image 92 6b [00704]embedded image [00705]embedded image 94 6c [00706]embedded image [00707]embedded image 99 6d [00708]embedded image [00709]embedded image 96 6e [00710]embedded image [00711]embedded image 95 6f [00712]embedded image [00713]embedded image 91 6g [00714]embedded image [00715]embedded image 93 6h [00716]embedded image [00717]embedded image 90 6i [00718]embedded image [00719]embedded image 94 6j [00720]embedded image [00721]embedded image 97 6k [00722]embedded image [00723]embedded image 98

Preparation of Compounds According to the Invention

Example 7

[0466] ##STR00724##

[0467] 5-(6-phenyl-7,8-dihydronaphthalen-1-yl)pentan-1-ol (640 mg, 2.19 mmol, 1.00 eq.), 4-(Dimethylamino)-pyridine (13.4 mg, 0.11 mmol, 0.05 eq.) are dissolved in THE (25 mL) and triethylamine (1.21 mL, 8.75 mmol, 4.00 eq.) is added. Acryloyl chloride (0.240 mL, 2.85 mmol, 1.30 eq.) is added at 0° C. and stirred at room temperature for 5 h. The reaction is quenched with 2-propanol (0.25 mL). The suspension is filtered, and the solvent of the filtrate is removed. The crude product is cleaned by column chromatography (20-40% EtOAc/heptane). The synthesis yield 644 mg 5-(6-phenyl-7,8-dihydronaphthalen-1-yl)pentyl prop-2-enoate (1.86 mmol, 85% of theory).

[0468] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.58-7.53 (m, 2H), 7.38 (t, J=7.7 Hz, 2H), 7.28 (t, J=7.4 Hz, 1H), 7.12 (t, J=7.5 Hz, 1H), 7.02 (ddd, J=6.8, 5.4, 1.3 Hz, 2H), 6.86 (s, 1H), 6.40 (dd, J=17.3, 1.5 Hz, 1H), 6.13 (dd, J=17.3, 10.4 Hz, 1H), 5.82 (dd, J=10.4, 1.5 Hz, 1H), 4.18 (t, J=6.7 Hz, 2H), 2.93 (dd, J=9.1, 7.0 Hz, 2H), 2.79-2.72 (m, 2H), 2.71-2.63 (m, 2H), 1.77-1.70 (m, 2H), 1.67-1.59 (m, 2H), 1.52-1.44 (m, 2H).

[0469] Analogously, other derivatives are prepared in the same manner with acryloyl chloride:

TABLE-US-00012 Yield No. Reactant Product [%] 7a [00725]embedded image [00726]embedded image 94 7b [00727]embedded image [00728]embedded image 95 7c [00729]embedded image [00730]embedded image 92 7d [00731]embedded image [00732]embedded image 91 7e [00733]embedded image [00734]embedded image 88 7f [00735]embedded image [00736]embedded image 90 7g [00737]embedded image [00738]embedded image 89 7h [00739]embedded image [00740]embedded image 81 7i [00741]embedded image [00742]embedded image 87 7j [00743]embedded image [00744]embedded image 89 7k [00745]embedded image [00746]embedded image 90

Example 8

[0470] ##STR00747##

[0471] 6-phenyl-7,8-dihydronaphthalen-1-ol (775 mg, 3.49 mmol, 1.00 eq.) is dissolved in THE (40 mL) and triethylamine (1.95 mL, 14.0 mmol, 4.00 eq.) and acryloyl chloride (0.341 mL, 4.01 mmol, 1.15 eq.) is added at 0° C. After stirring at r.t. for 3 h the suspension is filtered. The solvent of the filtrate is evaporated, and the crude product is cleaned by column chromatography (10-30% 2-Methyl-THE/heptane). The synthesis yield 600 mg 6-phenyl-7,8-dihydronaphthalen-1-yl prop-2-enoate (2.17 mmol, 62% of theory).

[0472] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.55-7.52 (m, 2H), 7.38 (t, J=7.7 Hz, 2H), 7.32-7.28 (m, 1H), 7.21 (t, J=7.8 Hz, 1H), 7.06 (dd, J=7.5, 1.1 Hz, 1H), 6.94 (dd, J=8.1, 1.1 Hz, 1H), 6.87 (d, J=1.5 Hz, 1H), 6.65 (dd, J=17.3, 1.2 Hz, 1H), 6.38 (dd, J=17.3, 10.5 Hz, 1H), 6.05 (dd, J=10.5, 1.2 Hz, 1H), 2.82 (dd, J=8.7, 6.4 Hz, 2H), 2.73 (ddt, J=8.8, 7.5, 1.9 Hz, 2H).

[0473] Analogously, other derivatives are prepared in the same manner with acryloyl chloride:

TABLE-US-00013 Yield No. Reactant Product [%] 8a [00748]embedded image [00749]embedded image 71 8b [00750]embedded image [00751]embedded image 84 8c [00752]embedded image [00753]embedded image 77

[0474] Preparation of Precursor Materials:

Example 9

[0475] ##STR00754##

[0476] 6-phenyl-7,8-dihydronaphthalen-1-ol (866 mg, 3.90 mmol, 1.00 eq.) is refluxed with potassium carbonate (2.18 g, 15.6 mmol, 4.00 eq.) and 2-[(5-bromopentyl)oxy]oxane (1.03 g, 4.09 mmol, 1.05 mmol) in acetone (15 mL) for 2 d. The suspension is filtered, and the solvent of the filtrate is evaporated. The residue is dissolved in DCM (25 mL) and MeOH (25 mL) and conc. HCl (0.49 mL) is added. After stirring for 1 h the reaction is quenched with sat. NaHCO.sub.3-solution and the phases are separated. The aqueous phase is extracted two times with DCM. The organic layers are dried over MgSO.sub.4. The crude product is cleaned by column chromatography (12-30% 2-MTHF/Cyclohexane). The synthesis yield 1.06 g 5-[(6-phenyl-7,8-dihydronaphthalen-1-yl)oxy]pentan-1-ol (3.44 mmol, 88%).

[0477] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.57-7.53 (m, 2H), 7.38 (t, J=7.7 Hz, 2H), 7.28 (t, J=7.4 Hz, 1H), 7.13 (t, J=7.9 Hz, 1H), 6.83 (s, 1H), 6.77 (dd, J=14.7, 7.8 Hz, 2H), 4.01 (t, J=6.3 Hz, 2H), 3.70 (td, J=6.3, 5.2 Hz, 2H), 3.00-2.93 (m, 2H), 2.74 (td, J=8.3, 7.8, 1.4 Hz, 2H), 1.89-1.82 (m, 2H), 1.71-1.63 (m, 2H), 1.63-1.56 (m, 2H), 1.43 (s, 1H).

[0478] Analogously, other derivatives are prepared in the same manner: R.sub.1 means reactant 1, R.sub.2 means reactant 2 and [P] means product.

TABLE-US-00014 No. Yield [%] 9a R1 [00755]embedded image R2 [00756]embedded image [P] [00757]embedded image 79 9b R1 [00758]embedded image R2 [00759]embedded image [P] [00760]embedded image 83 9c R1 [00761]embedded image R2 [00762]embedded image [P] [00763]embedded image 84 9d R1 [00764]embedded image R2 [00765]embedded image [P] [00766]embedded image 90 9e R1 [00767]embedded image R2 [00768]embedded image [P] [00769]embedded image 78 9f R1 [00770]embedded image R2 [00771]embedded image [P] [00772]embedded image 83 9g R1 [00773]embedded image R2 [00774]embedded image [P] [00775]embedded image 84 9h R1 [00776]embedded image R2 [00777]embedded image [P] [00778]embedded image 81 9i R1 [00779]embedded image R2 [00780]embedded image [P] [00781]embedded image 78 9j R1 [00782]embedded image R2 [00783]embedded image [P] [00784]embedded image 84 9k R1 [00785]embedded image R2 [00786]embedded image [P] [00787]embedded image 75 9l R1 [00788]embedded image R2 [00789]embedded image [P] [00790]embedded image 52

##STR00791##

[0479] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.69-7.58 (m, 6H), 7.45 (dd, J=8.4, 7.0 Hz, 2H), 7.39-7.31 (m, 1H), 7.14 (t, J=7.9 Hz, 1H), 6.90 (d, J=1.4 Hz, 1H), 6.81 (d, J=7.5 Hz, 1H), 6.77 (dd, J=8.2, 1.0 Hz, 1H), 4.02 (t, J=6.3 Hz, 2H), 3.71 (q, J=6.2 Hz, 2H), 2.99 (dd, J=9.1, 7.5 Hz, 2H), 2.77 (td, J=8.3, 1.3 Hz, 2H), 1.92-1.84 (m, 2H), 1.73-1.65 (m, 2H), 1.64-1.58 (m, 2H), 1.27 (q, J=4.0, 2.8 Hz, 1H).

##STR00792##

[0480] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.54-7.51 (m, 2H), 7.36 (t, J=7.7 Hz, 2H), 7.27-7.24 (m, 1H), 7.05 (d, J=8.2 Hz, 1H), 6.81 (s, 1H), 6.73-6.70 (m, 2H), 3.99 (t, J=6.4 Hz, 2H), 3.73-3.65 (m, 2H), 2.92 (dd, J=9.1, 7.0 Hz, 2H), 2.74-2.71 (m, 2H), 1.83 (p, J=6.7 Hz, 2H), 1.66 (dq, J=8.7, 6.2 Hz, 2H), 1.60-1.53 (d, J=5.7 Hz, 2H), 1.29 (t, J=5.4 Hz, 1H).

Example 10

[0481] ##STR00793##

[0482] 5-[(6-phenyl-7,8-dihydronaphthalen-1-yl)oxy]pentan-1-ol (1.06 g mg, 3.44 mmol, 1.00 eq.) is dissolved in THE (40 mL) and triethylamine (1.91 mL, 13.8 mmol, 4.00 eq.) and acryloyl chloride (0.371 mL, 4.45 mmol, 1.30 eq.) is added at 0° C. After stirring at r.t. for 3 h the suspension is filtered. The solvent of the filtrate is evaporated, and the crude product is cleaned by column chromatography (1-10% 2-Methyl-THF/cyclohexane). The synthesis yield 996 mg 5-[(6-phenyl-7,8-dihydronaphthalen-1-yl)oxy]pentyl prop-2-enoate (2.75 mmol, 80% of theory).

[0483] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.57-7.52 (m, 2H), 7.38 (t, J=7.7 Hz, 2H), 7.28 (t, J=7.4 Hz, 1H), 7.15-7.10 (m, 1H), 6.82 (d, J=1.5 Hz, 1H), 6.79 (d, J=7.5 Hz, 1H), 6.75 (dd, J=8.2, 1.0 Hz, 1H), 6.41 (dd, J=17.4, 1.5 Hz, 1H), 6.13 (dd, J=17.4, 10.4 Hz, 1H), 5.82 (dd, J=10.4, 1.5 Hz, 1H), 4.21 (t, J=6.6 Hz, 2H), 4.01 (t, J=6.3 Hz, 2H), 2.99-2.91 (m, 2H), 2.76-2.69 (m, 2H), 1.91-1.83 (m, 2H), 1.82-1.74 (m, 2H), 1.65-1.57 (m, 2H).

[0484] Analogously, other derivatives are prepared in the same manner:

TABLE-US-00015 Yield No. Reactant Product [%] 10a [00794]embedded image [00795]embedded image 81 10b [00796]embedded image [00797]embedded image 89 10c [00798]embedded image [00799]embedded image 83 10d [00800]embedded image [00801]embedded image 86 10e [00802]embedded image [00803]embedded image 94 10f [00804]embedded image [00805]embedded image 89 10g [00806]embedded image [00807]embedded image 90 10h [00808]embedded image [00809]embedded image 86 10i [00810]embedded image [00811]embedded image 87 10j [00812]embedded image [00813]embedded image 82 10k [00814]embedded image [00815]embedded image 88 10l [00816]embedded image [00817]embedded image 62 10m [00818]embedded image [00819]embedded image 42

##STR00820##

[0485] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.70-7.55 (m, 6H), 7.45 (t, J=7.7 Hz, 2H), 7.38-7.32 (m, 1H), 7.14 (t, J=7.9 Hz, 1H), 6.90 (d, J=1.5 Hz, 1H), 6.81 (d, J=7.5 Hz, 1H), 6.76 (dd, J=8.2, 1.0 Hz, 1H), 6.42 (dd, J=17.4, 1.4 Hz, 1H), 6.14 (dd, J=17.3, 10.4 Hz, 1H), 5.83 (dd, J=10.4, 1.5 Hz, 1H), 4.22 (t, J=6.6 Hz, 2H), 4.02 (t, J=6.3 Hz, 2H), 2.98 (dd, J=9.1, 7.5 Hz, 2H), 2.84-2.72 (m, 2H), 1.92-1.84 (m, 2H), 1.83-1.75 (m, 2H), 1.67-1.58 (m, 2H).

##STR00821##

[0486] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.54-7.51 (m, 2H), 7.36 (dd, J=8.5, 7.0 Hz, 2H), 7.27-7.24 (m, 1H), 7.05 (d, J=8.2 Hz, 1H), 6.82 (s, J=1.6 Hz, 1H), 6.74-6.69 (m, 2H), 6.44-6.38 (m, 1H), 6.13 (ddd, J=17.3, 10.4, 3.2 Hz, 1H), 5.83 (dd, J=10.4, 1.4 Hz, 1H), 4.20 (t, J=6.6 Hz, 2H), 3.98 (t, J=6.3 Hz, 2H), 2.92 (dd, J=9.1, 7.0 Hz, 2H), 2.73 (ddd, J=9.4, 7.1, 1.3 Hz, 2H), 1.83 (dq, J=8.1, 6.5 Hz, 2H), 1.76 (dt, J=15.0, 6.8 Hz, 2H), 1.63-1.55 (m, 2H).

Example 11

[0487] ##STR00822##

[0488] 5-Methoxy-1-tetralone (6.63 g, 37.6 mmol, 1.00 eq.) and methyltriphenylphosphonium iodide is suspended in THE (35 mL). Potassium tert-butanolate (35.3 g, 0.489 mol, 13.00 eq., previously dissolved in THE (35 mL)) is added slowly. After addition, the mixture is stirred for 2 h. The reaction is quenched with sat. NH.sub.4Cl-solution and diluted with methyl tert-butylether. The layers are separated, and the aqueous phase is extracted with methyl tert-butylether. The organic layers are dried over MgSO.sub.4 and the crude product is cleaned by column chromatography (0-5% EtOAc/cyclohexane). The synthesis yield 5.90 g 5-methoxy-1-methylidene-1,2,3,4-tetrahydronaphthalene (33.9 mmol, 90% of theory).

[0489] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.30-7.23 (m, 1H), 7.14 (td, J=7.9, 0.8 Hz, 1H), 6.75 (dd, J=8.0, 1.0 Hz, 1H), 5.47 (d, J=1.2 Hz, 1H), 4.96 (d, J=1.5 Hz, 1H), 3.83 (s, 3H), 2.75 (t, J=6.4 Hz, 2H), 2.52-2.47 (m, 2H), 1.92-1.84 (m, 2H).

[0490] Analogously, other derivatives are prepared in the same manner:

TABLE-US-00016 Yield No. Reactant Product [%] 11a [00823]embedded image [00824]embedded image 68 11b [00825]embedded image [00826]embedded image 87 11c [00827]embedded image [00828]embedded image 86 11d [00829]embedded image [00830]embedded image 97

##STR00831##

[0491] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.59 (d, J=8.7 Hz, 1H), 6.73 (dd, J=8.7, 2.8 Hz, 1H), 6.67 (dd, J=2.7, 1H), 5.36 (d, J=1.4 Hz, 1H), 4.81 (d, J=1.5 Hz, 1H), 3.73 (s, 3H), 2.76 (t, J=6.2 Hz, 2H), 2.46-2.43 (m, 2H), 1.75 (p, J=6.2 Hz, 2H).

##STR00832##

[0492] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.07 (d, J=9.1 Hz, 1H), 6.70 (d, J=6.2 Hz, 2H), 5.03 (s, 1H), 4.89 (d, J=2.3 Hz, 1H), 3.72 (s, 3H), 2.68-2.65 (m, 2H), 2.31 (t, J=6.0 Hz, 2H), 1.74 (p, J=6.1 Hz, 2H), 1.66 (p, J=5.9 Hz, 2H).

Example 12

[0493] ##STR00833##

[0494] Iodobenzene (4.34 mL, 38.9 mmol, 1.15 eq.), 3-chlorperoxybenzoic acid (8.73 g, 38.9 mmol, 1.15 eq.) and para-toluenesulfonic acid (7.56 g, 38.9 mmol, 1.15 eq.) are dissolved in DCM (250 mL). Then 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (40 mL) is added and the reaction mixture is stirred for 45 min. After the addition of water (16 mL), 5-methoxy-1-methylidene-1,2,3,4-tetrahydronaphthalene (5.90 g, 33.9 mmol, 1.00 eq.) is added at 0° C. After the reaction is complete, sat. NH.sub.4Cl-solution is added. The layers are separated, and the aqueous layer is extracted with 2-methyl tetrahydrofuran two times. The organic layers are dried over MgSO.sub.4 and the crude product is cleaned by column chromatography (10-25% EtOAc/cyclohexane). The synthesis yield 4.86 g 1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-one (25.5 mmol, 75% of theory).

[0495] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.12 (dd, J=8.3, 7.5 Hz, 1H), 6.80 (dd, J=8.3, 1.0 Hz, 1H), 6.74 (dd, J=7.5, 1.0 Hz, 1H), 3.80 (s, 3H), 3.69 (s, 2H), 3.01-2.95 (m, 2H), 2.51 (t, J=6.9 Hz, 2H), 1.98-1.89 (m, 2H).

[0496] Analogously, other derivatives are prepared in the same manner:

TABLE-US-00017 No. Reactant Product Yield [%] 12a [00834]embedded image [00835]embedded image 85 12b [00836]embedded image [00837]embedded image 79 12c [00838]embedded image [00839]embedded image 66 12d [00840]embedded image [00841]embedded image 89

##STR00842##

[0497] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.07 (d, J=8.2 Hz, 1H), 6.79 (d, J=2.7 Hz, 1H), 6.72 (dd, J=8.3, 2.8 Hz, 1H), 3.72 (s, 3H), 3.65 (s, 2H), 2.93-2.88 (m, 2H), 2.51-2.48 (m, 2H), 1.88-1.81 (m, 2H).

##STR00843##

[0498] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.03 (d, J=8.4 Hz, 1H), 6.79 (d, J=2.8 Hz, 1H), 6.73 (dd, J=8.3, 2.7 Hz, 1H), 3.73 (s, 3H), 3.69 (s, 2H), 2.77-2.75 (m, 2H), 2.22-2.20 (m, 2H), 1.75 (ddd, J=8.7, 7.4, 4.5 Hz, 2H), 1.61-1.56 (m, 2H).

Example 13

[0499] ##STR00844##

[0500] To a solution of diisopropylamine (3.94 mL, 28.1 mmol, 1.10 eq.) in THE (30 mL) is added n-butyllithium (2.5 M in hexanes, 11.2 mL, 28.1 mmol, 1.10 eq.) at −78° C. dropwise. The mixture is stirred at this temperature for 10 min and 30 min at 0° C. 1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-one (4.86 g, 25.6 mmol, 1.00 eq.) is dissolved in THE (25 mL) and added to the LDA solution at −78° C. and stirred for 2 h. N-Phenyl-bis-(trifluormethanesulfonimide) (11.0 g, 30.6 mmol, 1.20 eq.) is added and stirred overnight while warming to room temperature. The solvent is evaporated und cleaned by column chromatography (2% EtOAc/cyclohexane). The synthesis yield 7.57 g 4-methoxy-6,7-dihydro-5H-benzo[7]annulen-8-yl trifluoro-methanesulfonate (23.5 mmol, 92% of theory).

[0501] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.15 (t, J=8.0 Hz, 1H), 6.83 (d, J=8.3 Hz, 1H), 6.79 (d, J=7.6 Hz, 1H), 6.56 (s, 1H), 3.82 (s, 3H), 2.99-2.92 (m, 2H), 2.75 (t, J=6.7 Hz, 1H), 1.99-1.89 (m, 2H).

[0502] Analogously, other derivatives are prepared in the same manner:

TABLE-US-00018 Yield No. Reactant Product [%] 13a [00845]embedded image [00846]embedded image 92 13b [00847]embedded image [00848]embedded image 81 13c [00849]embedded image [00850]embedded image 92 13d [00851]embedded image [00852]embedded image 93 13e [00853]embedded image [00854]embedded image 94

##STR00855##

[0503] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.28 (d, J=8.1 Hz, 1H), 6.83-6.77 (m, 2H), 6.73-6.68 (m, 1H), 3.76 (s, 3H), 2.83-2.78 (m, 2H), 2.75 (dt, J=6.5, 3.3 Hz, 2H), 1.87 (dt, J=10.5, 6.3 Hz, 2H).

##STR00856##

[0504] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.20 (d, J=8.5 Hz, 1H), 6.83 (dd, J=8.5, 2.7 Hz, 1H), 6.80 (d, J=2.6 Hz, 1H), 6.65 (s, 1H), 3.76 (s, 3H), 2.74 (dd, J=7.4, 5.3 Hz, 2H), 2.56-2.53 (m, 2H), 1.67 (h, J=5.7, 5.2 Hz, 2H), 1.50 (dq, J=12.0, 5.9 Hz, 2H).

Example 14

[0505] ##STR00857##

[0506] Benzeneboronic acid (3.51 g, 28.2 mmol, 1.20 eq.), Pd(dppf)Cl.sub.2 (0.859 g, 1.17 mmol, 0.05 eq.) and 4-methoxy-6,7-dihydro-5H-benzo[7]annulen-8-yl trifluoromethane-sulfonate (7.57 g, 1.00 eq.) are dissolved in 1,4-dioxane (350 mL). Then 3 M NaOH-solution (70 mL) is added the mixture is stirred under reflux for 2 h. The reaction is quenched with sat. NH.sub.4Cl-solution and diluted with EtOAc. The phases are separated, and the aqueous phase is extracted with EtOAc. The organic layers are dried over MgSO.sub.4 and the crude product is cleaned by column chromatography (5-10% EtOAc/cyclohexane). The synthesis yield 5.16 g 4-methoxy-8-phenyl-6,7-dihydro-5H-benzo[7]annulene (20.6 mmol, 88% of theory).

[0507] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.54-7.49 (m, 2H), 7.36 (t, J=7.7 Hz, 2H), 7.31-7.26 (m, 1H), 7.16 (t, J=7.9 Hz, 1H), 6.85 (d, J=7.7 Hz, 1H), 6.82 (s, 1H), 6.78 (dd, J=8.3, 1.0 Hz, 1H), 3.85 (s, 3H), 2.88-2.83 (m, 2H), 2.57 (t, J=6.9 Hz, 2H), 2.25-2.18 (m, 2H).

[0508] Analogously, other derivatives are prepared with benzeneboronic acid in the same manner:

TABLE-US-00019 Yield No. [%] 14a [00858]embedded image [00859]embedded image 79 14b [00860]embedded image [00861]embedded image 90 14c [00862]embedded image [00863]embedded image 86 14d [00864]embedded image [00865]embedded image 73

##STR00866##

[0509] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.50 (d, J=7.9 Hz, 2H), 7.36 (dd, J=8.4, 6.9 Hz, 2H), 7.28-7.26 (t, J=7.5 Hz, 1H), 7.16 (d, J=8.1 Hz, 1H), 6.76-6.73 (m, 3H), 3.83 (s, 3H), 2.82-2.80 (m, 2H), 2.68-2.65 (m, 2H), 2.23-2.18 (m, 2H).

##STR00867##

[0510] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.55-7.52 (m, 1H), 7.38-7.27 (m, 4H), 7.12 (d, J=8.4 Hz, 1H), 6.82 (s, 1H), 6.79 (d, J=2.7 Hz, 1H), 6.75 (dd, J=8.4, 2.7 Hz, 1H), 3.83 (s, 3H), 2.73-2.70 (m, 2H), 2.42-2.40 (m, 2H), 1.79-1.72 (m, 2H), 1.59 (q, J=5.9 Hz, 1H).

[0511] Analogously, additional derivatives are prepared with different boronic acids in the same manner:

TABLE-US-00020 No. Yield [%] 14e R1 [00868]embedded image R2 [00869]embedded image [P] [00870]embedded image 93 14f R1 [00871]embedded image R2 [00872]embedded image [P] [00873]embedded image 92 14g R1 [00874]embedded image R2 [00875]embedded image [P] [00876]embedded image 81 14h R1 [00877]embedded image R2 [00878]embedded image [P] [00879]embedded image 96 14i R1 [00880]embedded image R2 [00881]embedded image [P] [00882]embedded image 85 14j R1 [00883]embedded image R2 [00884]embedded image [P] [00885]embedded image 87

##STR00886##

[0512] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.45 (d, J=8.7 Hz, 2H), 7.23-7.09 (m, 4H), 6.91 (d, J=8.7 Hz, 2H), 6.75 (s, 1H), 3.84 (s, 3H), 2.88-2.72 (m, 2H), 2.62 (t, J=6.8 Hz, 2H), 2.27-2.12 (m, 2H).

##STR00887##

[0513] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (dd, J=8.6, 5.5 Hz, 2H), 7.14 (d, J=8.2 Hz, 1H), 7.03 (t, J=8.7 Hz, 2H), 6.74 (dd, J=11.0, 2.7 Hz, 2H), 6.68 (s, 1H), 3.82 (s, 3H), 2.82-2.78 (m, 2H), 2.63 (t, J=6.7 Hz, 2H), 2.18 (p, J=6.5 Hz, 2H).

##STR00888##

[0514] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.34 (td, J=8.7, 6.5 Hz, 1H), 7.13 (d, J=9.1 Hz, 1H), 6.90-6.81 (m, 2H), 6.76 (dd, J=6.3, 2.7 Hz, 2H), 6.56 (s, 1H), 3.84 (s, 3H), 2.88-2.83 (m, 2H), 2.57 (t, J=6.7 Hz, 2H), 2.20 (p, J=6.6 Hz, 2H).

##STR00889##

[0515] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.37-7.26 (m, 2H), 7.23-7.18 (m, 3H), 7.17-7.13 (m, 1H), 6.99 (td, J=7.4, 1.1 Hz, 1H), 6.94 (dd, J=8.1, 1.0 Hz, 1H), 6.58 (s, 1H), 3.87 (s, 3H), 2.93-2.82 (m, 2H), 2.57 (td, J=6.8, 1.0 Hz, 2H), 2.30-2.16 (m, 2H).

##STR00890##

[0516] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.45 (d, J=8.5 Hz, 2H), 7.33-7.24 (m, 2H), 7.23-7.19 (m, 2H), 7.19-7.13 (m, 2H), 6.80 (s, 1H), 2.86-2.71 (m, 2H), 2.67-2.56 (m, 2H), 2.52 (s, 3H), 2.27-2.15 (m, 2H).

Example 15-1

[0517] ##STR00891##

[0518] To 4-methoxy-8-phenyl-6,7-dihydro-5H-benzo[7]annulene (5.16 g, 20.6 mmol, 1.00 eq.) in DCM (180 mL) is added BBr.sub.3 (2.18 mL, 22.7 mmol, 1.00 eq.) and stirred for 6 h. The mixture is quenched with sat. NaHCO.sub.3-solution and extracted with DCM three times. The organic layers are dried over MgSO.sub.4 and the crude product is cleaned by column chromatography (5-15% EtOAc/cyclohexane). The synthesis yield 4.50 g 8-phenyl-6,7-dihydro-5H-benzo[7]annulen-4-ol (19.0 mmol, 92% of theory).

[0519] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.54-7.48 (m, 2H), 7.40-7.34 (m, 2H), 7.31-7.26 (m, 1H), 7.06 (t, J=7.8 Hz, 1H), 6.84 (d, J=7.5 Hz, 1H), 6.81 (s, 1H), 6.68 (dd, J=8.1, 1.1 Hz, 1H), 4.73 (d, J=1.4 Hz, 1H), 2.85-2.79 (m, 2H), 2.59 (t, J=6.9 Hz, 2H), 2.28-2.21 (m, 2H).

Analogously, other derivatives are prepared in the same manner:

TABLE-US-00021 Yield No. [%] 15a [00892]embedded image [00893]embedded image 87 15b [00894]embedded image [00895]embedded image 89 15c [00896]embedded image [00897]embedded image 93 15d [00898]embedded image [00899]embedded image 87 15e [00900]embedded image [00901]embedded image 99 15f [00902]embedded image [00903]embedded image quant 15g [00904]embedded image [00905]embedded image 91 15h [00906]embedded image [00907]embedded image 85 15i [00908]embedded image [00909]embedded image 75

##STR00910##

[0520] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.50-7.46 (m, 2H), 7.35 (dd, J=8.4, 7.0 Hz, 2H), 7.29-7.25 (m, 1H), 7.11-7.09 (m, 1H), 6.73 (s, 1H), 6.68-6.66 (m, 2H), 4.66 (s, 1H), 2.79-2.76 (m, 2H), 2.67-2.64 (m, 2H), 2.19 (tt, J=6.6, 5.3 Hz, 2H).

##STR00911##

[0521] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.57-7.52 (m, 2H), 7.37 (t, J=7.6 Hz, 2H), 7.33-7.28 (m, 1H), 7.08 (d, J=8.2 Hz, 1H), 6.81 (s, 1H), 6.74 (d, J=2.7 Hz, 1H), 6.68 (dd, J=8.2, 2.6 Hz, 1H), 4.88 (s, 1H), 2.71-2.68 (m, 2H), 2.43-2.41 (m, 2H), 1.75 (p, J=6.0 Hz, 2H), 1.59 (p, J=5.9 Hz, 2H).

##STR00912##

[0522] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.41 (d, J=8.6 Hz, 2H), 7.23-7.06 (m, 4H), 6.83 (d, J=8.6 Hz, 2H), 6.74 (s, 1H), 4.82 (t, J=7.2 Hz, 1H), 2.88-2.70 (m, 2H), 2.67-2.52 (m, 2H), 2.27-2.15 (m, 2H).

##STR00913##

[0523] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.31 (td, J=8.6, 6.5 Hz, 1H), 7.08-7.03 (m, 1H), 6.88-6.78 (m, 2H), 6.66 (d, J=6.7 Hz, 2H), 6.52 (s, 1H), 4.66 (s, 1H), 2.82-2.78 (m, 2H), 2.54 (t, J=6.7 Hz, 2H), 2.17 (p, J=6.5 Hz, 2H).

[0524] .sup.19F NMR (470 MHz, Chloroform-d) δ −110.9 (q, J=9.1 Hz), −112.6.

Example 15-2

[0525] ##STR00914##

[0526] 8-[4-(methylsulfanyl)phenyl]-6,7-dihydro-5H-benzo[7]annulene (44.48 mmol; 1.0 eq.; 11.85 g) is dissolved in 1-methylpyrrolidin-2-one (889.63 mmol; 20.0 eq.; 85.62 ml) and tert.-butylmercaptane sodium salt (133.44 mmol; 3.0 eq.; 16.63 g) is added at r.t. The reaction mixture is heated to 180° C. overnight. The reaction mixture is then added to 1 L of water and extracted three times with EtOAc. Combined organics are washed with H.sub.2O and brine before they are dried over Na.sub.2SO.sub.4 and filtered over a pad of silica which is rinsed with EtOAc. The crude product is purified by column chromatography on silica gel (cyclohexane/EtOAc 0-3%). The synthesis yield 9.96 g 4-{6,7-dihydro-5H-benzo[7]annulen-8-yl}benzene-1-thiol (39.46 mmol, 89% of theory).

[0527] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.41 (d, J=8.4 Hz, 2H), 7.29 (d, J=8.4 Hz, 2H), 7.25-7.14 (m, 4H), 6.80 (s, 1H), 3.49 (s, 1H), 2.89-2.71 (m, 2H), 2.70-2.59 (m, 2H), 2.36-2.16 (m, 2H).

Example 16-1

[0528] ##STR00915##

[0529] 6-phenyl-7,8-dihydronaphthalen-1-ol (866 mg, 3.90 mmol, 1.00 eq.) is refluxed with potassium carbonate (2.18 g, 15.6 mmol, 4.00 eq.) and 2-[(5-bromopentyl)oxy]oxane (1.03 g, 4.09 mmol, 1.05 mmol) in acetone (15 mL) for 2 d. The suspension is filtered and the solvent of the filtrate is evaporated. The residue is dissolved in DCM (25 mL) and MeOH (25 mL) and conc. HCl (0.49 mL) is added. After stirring for 1 h the reaction is quenched with sat. NaHCO.sub.3-solution and the phases are separated. The aqueous phase is extracted two times with DCM. The organic layers are dried over MgSO.sub.4. The crude product is cleaned by column chromatography (12-30% 2-methyl tetrahydrofuran/cyclohexane). The synthesis yield 1.06 g 5-[(6-phenyl-7,8-dihydronaphthalen-1-yl)oxy]pentan-1-ol (3.44 mmol, 88% of theory).

[0530] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.54-7.49 (m, 2H), 7.37 (t, J=7.7 Hz, 2H), 7.28 (t, J=7.4 Hz, 1H), 7.13 (t, J=7.9 Hz, 1H), 6.84 (d, J=7.6 Hz, 1H), 6.82 (s, 1H), 6.76 (dd, J=8.2, 1.0 Hz, 1H), 4.00 (t, J=6.3 Hz, 2H), 3.73-3.68 (m, 2H), 2.89-2.84 (m, 2H), 2.57 (t, J=6.9 Hz, 2H), 2.25-2.18 (m, 2H), 1.90-1.82 (m, 2H), 1.72-1.62 (m, 2H).

[0531] Analogously, other derivatives are prepared in the same manner: R.sub.1 means reactant and [P] means product.

TABLE-US-00022 Yield No. [%] 16a R1 [00916]embedded image R2 [00917]embedded image [P] [00918]embedded image 80 16b R1 [00919]embedded image R2 [00920]embedded image [P] [00921]embedded image 83 16c R1 [00922]embedded image R2 [00923]embedded image [P] [00924]embedded image 77 16d R1 [00925]embedded image R2 [00926]embedded image [P] [00927]embedded image 75 16e R1 [00928]embedded image R2 [00929]embedded image [P] [00930]embedded image 80 16f R1 [00931]embedded image R2 [00932]embedded image [P] [00933]embedded image 84 16g R1 [00934]embedded image R2 [00935]embedded image [P] [00936]embedded image 82 16h R1 [00937]embedded image R2 [00938]embedded image [P] [00939]embedded image 79 16i R1 [00940]embedded image R2 [00941]embedded image [P] [00942]embedded image 76 16j R1 [00943]embedded image R2 [00944]embedded image [P] [00945]embedded image 78 16k R1 [00946]embedded image R2 [00947]embedded image [P] [00948]embedded image 85 16l R1 [00949]embedded image R2 [00950]embedded image [P] [00951]embedded image 89 16m R1 [00952]embedded image R2 [00953]embedded image [P] [00954]embedded image 77 16n R1 [00955]embedded image R2 [00956]embedded image [P] [00957]embedded image 66 16o R1 [00958]embedded image R2 [00959]embedded image [P] [00960]embedded image 77 16p R1 [00961]embedded image R2 [00962]embedded image [P] [00963]embedded image 78 16q R1 [00964]embedded image R2 [00965]embedded image [00966]embedded image 98

##STR00967##

[0532] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.51-7.49 (m, 2H), 7.36 (t, J=7.7 Hz, 2H), 7.28 (d, J=7.6 Hz, 1H), 7.16-7.13 (m, 1H), 6.74 (dd, J=6.9, 2.1 Hz, 3H), 4.00 (t, J=6.4 Hz, 2H), 3.71 (q, J=6.2 Hz, 2H), 2.82-2.79 (m, 2H), 2.67 (t, J=6.7 Hz, 2H), 2.20 (qd, J=6.6, 3.6 Hz, 2H), 1.84 (p, J=6.7 Hz, 2H), 1.70-1.65 (m, 2H), 1.61-1.55 (m, 2H).

##STR00968##

[0533] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.57-7.55 (m, 2H), 7.37 (dd, J=8.4, 6.9 Hz, 2H), 7.32-7.27 (m, 1H), 7.11 (d, J=8.5 Hz, 1H), 6.82 (d, J=2.2 Hz, 2H), 6.75 (dd, J=8.4, 2.7 Hz, 1H), 4.38 (t, J=5.1 Hz, 1H), 3.96 (t, J=6.5 Hz, 2H), 3.42 (q, J=5.8 Hz, 2H), 2.63 (dd, J=7.1, 4.1 Hz, 2H), 2.37-2.31 (m, 2H), 1.70 (dt, J=13.4, 7.0 Hz, 4H), 1.46 (dddd, J=18.9, 15.3, 7.4, 2.3 Hz, 6H).

##STR00969##

[0534] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J=8.7 Hz, 2H), 7.23-7.09 (m, 4H), 6.89 (d, J=8.7 Hz, 2H), 6.75 (s, 1H), 4.00 (t, J=6.4 Hz, 2H), 3.70 (q, J=6.0 Hz, 2H), 2.90-2.67 (m, 2H), 2.62 (t, J=6.8 Hz, 2H), 2.21 (p, J=6.7 Hz, 2H), 1.95-1.77 (m, 2H), 1.74-1.62 (m, 2H), 1.62-1.51 (m, 2H), 1.26 (t, J=5.2 Hz, 1H).

##STR00970##

[0535] .sup.1H NMR (500 MHz, DMSO-d6) δ 7.55 (dd, J=8.8, 5.5 Hz, 2H), 7.21-7.15 (m, 3H), 6.77-6.73 (m, 2H), 6.72 (s, 1H), 4.37 (t, J=5.2 Hz, 1H), 3.96 (t, J=6.5 Hz, 2H), 3.43-3.39 (m, 2H), 2.77-2.73 (m, 2H), 2.63-2.59 (m, 2H), 2.10-2.03 (m, 2H), 1.71 (p, J=6.7 Hz, 2H), 1.50-1.42 (m, 4H).

##STR00971##

[0536] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.31 (td, J=8.6, 6.5 Hz, 1H), 7.10-7.07 (m, 1H), 6.83 (dddd, J=19.5, 11.2, 8.6, 2.6 Hz, 2H), 6.72 (d, J=6.9 Hz, 2H), 6.53 (s, 1H), 3.99 (t, J=6.4 Hz, 2H), 3.69 (td, J=6.5, 2.6 Hz, 2H), 2.84-2.80 (m, 2H), 2.55 (t, J=6.7 Hz, 2H), 2.17 (p, J=6.5 Hz, 2H), 1.83 (p, J=6.7 Hz, 2H), 1.66 (dt, J=15.2, 6.6 Hz, 2H), 1.60-1.52 (m, 2H), 1.28 (s, J=4.4 Hz, 1H).

##STR00972##

[0537] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.43 (d, J=8.3 Hz, 2H), 7.31 (d, J=8.3 Hz, 2H), 7.24-7.11 (m, 4H), 6.80 (s, 1H), 3.66 (q, J=6.1 Hz, 2H), 2.95 (t, J=7.3 Hz, 2H), 2.87-2.74 (m, 2H), 2.62 (t, J=6.8 Hz, 2H), 2.21 (p, J=6.7 Hz, 2H), 1.71 (p, J=7.4 Hz, 2H), 1.66-1.42 (m, 4H), 1.23 (t, J=5.3 Hz, 1H).

Example 16-2-1

[0538] ##STR00973##

[0539] 5-(4-(6,7-dihydro-5H-benzo[7]annulen-8-yl)phenoxy)pentan-1-ol (0.70 g, 2.17 mmol, 1.00 eq) is dissolved in CH.sub.2Cl.sub.2 (9.70 mL) before Et.sub.3N (0.61 mL, 4.34 mmol, 2.00 eq) is added dropwise at r.t. The resulting reaction mixture is cooled to O ° C. before mesyl chloride (0.18 mL, 2.39 mmol, 1.10 eq) is added dropwise. After 1.5 h at 0° C. TLC shows complete conversion. The reaction mixture is added to water and extracted with CH.sub.2Cl.sub.2 (3×10 mL). Combined organic extracts are washed with brine (15 mL), dried over Na.sub.2SO.sub.4 and filtered over a pad of silica which is rinsed with CH.sub.2Cl.sub.2. After removal of the solvent under reduced pressure compound 5-(4-(6,7-dihydro-5H-benzo[7]annulen-8-yl)phenoxy)pentyl methanesulfonate (0.84 g, 2.10 mmol, 97%) is isolated as pale yellow oil and can be used for the next step without further purification.

[0540] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J=8.8 Hz, 2H), 7.22-7.07 (m, 4H), 6.88 (d, J=8.8 Hz, 2H), 6.75 (s, 1H), 4.27 (t, J=6.5 Hz, 2H), 4.00 (t, J=6.2 Hz, 2H), 3.01 (s, 3H), 2.85-2.76 (m, 2H), 2.68-2.56 (m, 2H), 2.21 (m, 2H), 1.95-1.78 (m, 4H), 1.63 (m, 2H).

Example 16-2-2

[0541] ##STR00974##

[0542] 5-(4-(6,7-dihydro-5H-benzo[7]annulen-8-yl)phenoxy)pentyl methanesulfonate (0.84 g, 2.10 mmol, 1.00 eq) is dissolved in MeCN (8.22 mL) before potassium thioacetate (0.26 g, 2.31 mmol, 1.10 eq) is added portion wise at r.t. The resulting reaction mixture is heated to 50° C. for 16 h. The reaction mixture is added to water and extracted with EtOAc (3×10 mL). Combined organic extracts are washed with brine (15 mL), dried over Na.sub.2SO.sub.4 and filtered over a pad of silica which is rinsed with EtOAc. After removal of the solvent under reduced pressure the crude product is purified via column chromatography using Cyhex/EtOAc (10% to 15% EtOAc) to give compound S-(5-(4-(6,7-dihydro-5H-benzo[7]annulen-8-yl)phenoxy)pentyl) ethanethioate (0.61 g, 1.60 mmol, 76%) as pale yellow oil which crystallizes during storage in the fridge.

[0543] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.43 (d, J=8.8 Hz, 2H), 7.23-7.10 (m, 4H), 6.88 (d, J=8.8 Hz, 2H), 6.74 (s, 1H), 3.98 (t, J=6.4 Hz, 2H), 2.91 (t, J=7.2 Hz, 2H), 2.83-2.76 (m, 2H), 2.61 (t, J=6.8 Hz, 2H), 2.33 (s, 3H), 2.21 (m, 2H), 1.81 (m, 2H), 1.73-1.60 (m, 2H), 1.62-1.52 (m, 2H).

Example 16-2-3

[0544] ##STR00975##

[0545] S-(5-(4-(6,7-dihydro-5H-benzo[7]annulen-8-yl)phenoxy)pentyl) ethanethioate (0.61 g, 1.60 mmol, 1.00 eq) is dissolved in THE (9.74 mL) and cooled to O ° C. before LiAlH.sub.4 (70.5 mg, 1.76 mmol, 1.10 eq) is added carefully. The resulting reaction mixture is heated to 65° C. for 1 h. The reaction mixture is cooled to 0° C. before 1 m HCl (5 mL) is added. After gas evolution stopped, the organic layer is extracted with EtOAc (3×10 mL). Combined organic extracts are washed with brine (15 mL), dried over Na.sub.2SO.sub.4 and filtered over a pad of silica which is rinsed with EtOAc. After removal of the solvent compound 5-(4-(6,7-dihydro-5H-benzo[7]annulen-8-yl)phenoxy)pentane-1-thiol (0.54 g, 1.60 mmol, 99%) is isolated as colorless oil which crystallizes during storage in the fridge and can be used for the next step without further purification.

[0546] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J=8.7 Hz, 2H), 7.21-7.10 (m, 4H), 6.89 (d, J=8.7 Hz, 2H), 6.75 (s, 1H), 3.99 (t, J=6.4 Hz, 2H), 2.90-2.68 (m, 2H), 2.68-2.46 (m, 4H), 2.21 (p, J=6.7 Hz, 2H), 1.81 (m, 2H), 1.71 (p, J=7.2 Hz, 2H), 1.59 (m, 2H), 1.36 (t, J=7.8 Hz, 1H).

Preparation of Compounds According to the Invention

Example 17

[0547] ##STR00976##

[0548] 5-({8-phenyl-6,7-dihydro-5H-benzo[7]annulen-4-yl}oxy)pentan-1-ol (1.87 g, 5.80 mmol, 1.00 eq.) is dissolved in THE (70 mL) and triethylamine (3.22 mL, 23.2 mmol, 4.00 eq.) and acryloyl chloride (0.628 mL, 7.54 mmol, 1.30 eq.) is added at 0° C. After stirring at r.t. for 3 h the suspension is filtered. The solvent of the filtrate is evaporated and the crude product is cleaned by column chromatography (1-10% 2-methyl tetrahydrofuran/cyclohexane). The synthesis yield 1.94 g 5-({8-phenyl-6,7-dihydro-5H-benzo[7]annulen-4-yl}oxy)pentyl prop-2-enoate (5.14 mmol, 89% of theory).

[0549] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.53-7.49 (m, 2H), 7.37 (t, J=7.7 Hz, 2H), 7.28 (t, J=7.4 Hz, 1H), 7.13 (t, J=7.9 Hz, 1H), 6.84 (d, J=7.6 Hz, 1H), 6.82 (s, 1H), 6.75 (dd, J=8.2, 1.0 Hz, 1H), 6.41 (dd, J=17.4, 1.5 Hz, 1H), 6.13 (dd, J=17.3, 10.4 Hz, 1H), 5.82 (dd, J=10.4, 1.5 Hz, 1H), 4.21 (t, J=6.6 Hz, 2H), 4.00 (t, J=6.2 Hz, 2H), 2.89-2.83 (m, 2H), 2.56 (t, J=6.9 Hz, 2H), 2.25-2.17 (m, 2H), 1.90-1.83 (m, 2H), 1.82-1.74 (m, 2H), 1.66-1.56 (m, 2H).

[0550] Analogously, other derivatives are prepared in the same manner with acryloyl chloride. R1 means reactant, [P] means product:

TABLE-US-00023 Yield No. [%] 17a R1 [00977]embedded image [P] [00978]embedded image 82 17b R1 [00979]embedded image [P] [00980]embedded image 84 17c R1 [00981]embedded image [P] [00982]embedded image 79 17d R1 [00983]embedded image [P] [00984]embedded image 87 17e R1 [00985]embedded image [P] [00986]embedded image 86 17f R1 [00987]embedded image [P] [00988]embedded image 77 17g R1 [00989]embedded image [P] [00990]embedded image 83 17h R1 [00991]embedded image [P] [00992]embedded image 85 17i R1 [00993]embedded image [P] [00994]embedded image 88 17j R1 [00995]embedded image [P] [00996]embedded image 79 17k R1 [00997]embedded image [P] [00998]embedded image 81 17l R1 [00999]embedded image [P] [01000]embedded image 85 17m R1 [01001]embedded image [P] [01002]embedded image 43 17n R1 [01003]embedded image [P] [01004]embedded image <10   17o R1 [01005]embedded image [P] [01006]embedded image 52

##STR01007##

[0551] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.51-7.48 (m, 2H), 7.35 (t, J=7.6 Hz, 2H), 7.28-7.25 (m, 1H), 7.15-7.12 (m, 1H), 6.75-6.71 (m, 3H), 6.41 (dd, J=17.2, 1.4 Hz, 1H), 6.13 (dd, J=17.4, 10.4 Hz, 1H), 5.83 (dd, J=10.5, 1.4 Hz, 1H), 4.20 (t, J=6.6 Hz, 2H), 3.99 (t, J=6.3 Hz, 2H), 2.82-2.77 (m, 2H), 2.66 (t, J=6.7 Hz, 2H), 2.19 (p, J=6.5 Hz, 2H), 1.87-1.80 (m, 2H), 1.77 (dt, J=14.4, 6.8 Hz, 2H), 1.62-1.54 (m, 2H).

##STR01008##

[0552] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.54 (dd, J=7.6, 1.6 Hz, 2H), 7.36 (t, J=7.6 Hz, 2H), 7.31-7.27 (m, 1H), 7.10 (d, J=8.4 Hz, 1H), 6.82 (s, 1H), 6.78 (d, J=2.7 Hz, 1H), 6.74 (dd, J=8.4, 2.6 Hz, 1H), 6.41 (dd, J=17.3, 1.5 Hz, 1H), 6.13 (dd, J=17.4, 10.4 Hz, 1H), 5.83 (dd, J=10.5, 1.4 Hz, 1H), 4.20 (t, J=6.7 Hz, 2H), 3.99 (t, J=6.3 Hz, 2H), 2.72-2.68 (m, 2H), 2.44-2.39 (m, 2H), 1.87-1.82 (m, 2H), 1.76 (dt, J=10.9, 5.9 Hz, 4H), 1.62-1.56 (m, 4H).

##STR01009##

[0553] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J=8.7 Hz, 2H), 7.23-7.09 (m, 4H), 6.89 (d, J=8.7 Hz, 2H), 6.75 (s, 1H), 6.41 (dd, J=17.3, 1.5 Hz, 1H), 6.13 (dd, J=17.3, 10.4 Hz, 1H), 5.83 (dd, J=10.4, 1.5 Hz, 1H), 4.20 (t, J=6.6 Hz, 2H), 4.00 (t, J=6.4 Hz, 2H), 2.88-2.74 (m, 2H), 2.62 (t, J=6.8 Hz, 2H), 2.30-2.08 (m, 2H), 1.90-1.81 (m, 2H), 1.77 (m, 2H), 1.67-1.48 (m, 3H).

##STR01010##

[0554] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J=8.8 Hz, 2H), 7.23-7.09 (m, 4H), 6.89 (d, J=8.8 Hz, 2H), 6.75 (s, 1H), 6.47-6.21 (m, 2H), 5.68 (dd, J=10.0, 1.4 Hz, 1H), 3.99 (t, J=6.4 Hz, 2H), 3.01 (t, J=7.3 Hz, 2H), 2.88-2.76 (m, 2H), 2.62 (t, J=6.8 Hz, 2H), 2.21 (p, J=6.7 Hz, 2H), 1.90-1.75 (m, 2H), 1.75-1.65 (m, 2H), 1.65-1.55 (m, 2H).

##STR01011##

[0555] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J=8.7 Hz, 2H), 7.24-7.07 (m, 4H), 6.88 (d, J=8.7 Hz, 2H), 6.75 (s, 1H), 6.54 (dd, J=16.7, 9.9 Hz, 1H), 6.42 (d, J=16.7 Hz, 1H), 6.12 (d, J=9.8 Hz, 1H), 4.17 (t, J=6.4 Hz, 2H), 4.00 (t, J=6.2 Hz, 2H), 2.96-2.73 (m, 2H), 2.62 (t, J=6.8 Hz, 2H), 2.21 (p, J=6.7 Hz, 2H), 1.83 (h, J=6.6 Hz, 4H), 1.70-1.56 (m, 2H).

Example 18

[0556] ##STR01012##

[0557] 5-({8-phenyl-6,7-dihydro-5H-benzo[7]annulen-4-yl}oxy)pentan-1-ol (1.87 g, 5.80 mmol, 1.00 eq.) is dissolved in DCM (30 mL) and triethylamine (3.22 mL, 23.2 mmol, 4.00 eq.). 4.(Dimethylamino)pyridine (140 mg, 1.16 mmol, 0.20 eq.) and methacrylic anhydride (1.19 mL, 7.54 mmol, 1.30 eq.) are added at 0° C. After stirring at r.t. for 3 h the suspension is filtered. The solvent of the filtrate is evaporated and the crude product is cleaned by column chromatography (1-10% 2-methyl tetrahydrofuran/cyclohexane). The synthesis yield 2.02 g 5-({8-phenyl-6,7-dihydro-5H-benzo[7]annulen-4-yl}oxy)pentyl 2-methylprop-2-enoate (5.16 mmol, 89% of theory).

[0558] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.53-7.49 (m, 2H), 7.37 (t, J=7.7 Hz, 2H), 7.30-7.26 (m, 1H), 7.13 (t, J=7.9 Hz, 1H), 6.84 (d, J=7.6 Hz, 1H), 6.81 (s, 1H), 6.75 (dd, J=8.1, 1.1 Hz, 1H), 6.13-6.06 (m, 1H), 5.58-5.51 (m, 1H), 4.20 (t, J=6.6 Hz, 2H), 4.00 (t, J=6.2 Hz, 2H), 2.89-2.83 (m, 2H), 2.56 (t, J=6.9 Hz, 2H), 2.25-2.17 (m, 2H), 1.95 (t, J=1.3 Hz, 3H), 1.90-1.83 (m, 2H), 1.82-1.74 (m, 2H), 1.66-1.58 (m, 2H).

[0559] Analogously, other derivatives are prepared with methacrylic anhydride in the same manner: R.sub.1 means reactant and [P] means product.

TABLE-US-00024 Yield No. [%] 18a R1 [01013]embedded image [P] [01014]embedded image 79 18b R1 [01015]embedded image [P] [01016]embedded image 85 18c R1 [01017]embedded image [P] [01018]embedded image 80 18d R1 [01019]embedded image [P] [01020]embedded image 83 18e R1 [01021]embedded image [P] [01022]embedded image 88 18f R1 [01023]embedded image [P] [01024]embedded image 86 18g R1 [01025]embedded image [P] [01026]embedded image 80 18h R1 [01027]embedded image [P] [01028]embedded image 81 18i R1 [01029]embedded image [01030]embedded image 77 18j R1 [01031]embedded image [01032]embedded image 76 18k R1 [01033]embedded image [P] [01034]embedded image 74 18l R1 [01035]embedded image [P] [01036]embedded image 88 18m R1 [01037]embedded image [P] [01038]embedded image 83 18n R1 [01039]embedded image [P] [01040]embedded image 52 18o R1 [01041]embedded image [P] [01042]embedded image 96 18p R1 [01043]embedded image [P] [01044]embedded image 70 18q R1 [01045]embedded image [P] [01046]embedded image 83 18r R1 [01047]embedded image [P] [01048]embedded image 28 18s R1 [01049]embedded image [P] [01050]embedded image 95 18t R1 [01051]embedded image [P] [01052]embedded image 81

##STR01053##

[0560] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.52-7.49 (m, 2H), 7.36 (t, J=7.7 Hz, 2H), 7.29-7.26 (m, 1H), 7.16-7.13 (m, 1H), 6.75-6.73 (m, 3H), 6.12 (t, J=1.3 Hz, 1H), 5.57 (t, J=1.7 Hz, 1H), 4.20 (t, J=6.6 Hz, 2H), 4.00 (t, J=6.4 Hz, 2H), 2.82-2.79 (m, 2H), 2.67 (t, J=6.7 Hz, 2H), 2.23-2.18 (m, 2H), 1.97 (s, 3H), 1.88-1.82 (m, 2H), 1.81-1.75 (m, 2H), 1.63-1.58 (m, 2H).

##STR01054##

[0561] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.55-7.52 (m, 2H), 7.36 (dd, J=8.3, 6.8 Hz, 2H), 7.31-7.27 (m, 1H), 7.10 (d, J=8.4 Hz, 1H), 6.82 (s, 1H), 6.78 (d, J=2.6 Hz, 1H), 6.74 (dd, J=8.4, 2.7 Hz, 1H), 6.11 (t, J=1.4 Hz, 1H), 5.56 (p, J=1.6 Hz, 1H), 4.19 (t, J=6.6 Hz, 2H), 4.00 (t, J=6.4 Hz, 2H), 2.72-2.69 (m, 2H), 2.44-2.39 (m, 2H), 1.96 (t, J=1.3 Hz, 3H), 1.88-1.82 (m, 2H), 1.80-1.72 (m, 2H), 1.63-1.55 (m, 4H).

##STR01055##

[0562] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J=8.7 Hz, 2H), 7.25-7.08 (m, 4H), 6.89 (d, J=8.7 Hz, 2H), 6.75 (s, 1H), 6.11 (s, 1H), 5.56 (t, J=1.7 Hz, 1H), 4.19 (t, J=6.6 Hz, 2H), 4.00 (t, J=6.3 Hz, 2H), 2.84-2.75 (m, 2H), 2.61 (t, J=6.8 Hz, 2H), 2.21 (p, J=6.7 Hz, 2H), 1.95 (t, J=1.2 Hz, 3H), 1.91-1.81 (m, 2H), 1.77 (m, 2H), 1.65-1.55 (m, 2H).

##STR01056##

[0563] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.43 (d, J=8.8 Hz, 2H), 7.23-7.08 (m, 4H), 6.89 (d, J=8.8 Hz, 2H), 6.74 (s, 1H), 6.08 (d, J=1.3 Hz, 1H), 5.57 (d, J=1.6 Hz, 1H), 3.99 (t, J=6.4 Hz, 2H), 2.96 (t, J=7.3 Hz, 2H), 2.85-2.75 (m, 2H), 2.61 (t, J=6.8 Hz, 2H), 2.32-2.12 (m, 2H), 1.98 (dd, J=1.6, 1.0 Hz, 3H), 1.83 (p, J=6.6 Hz, 2H), 1.73-1.64 (m, 2H), 1.64-1.55 (m, 2H).

##STR01057##

[0564] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.44 (dd, J=8.7, 5.4 Hz, 2H), 7.12 (d, J=8.2 HZ, 1H), 7.03 (t, J=8.7 Hz, 2H), 6.72 (d, J=7.4 Hz, 2H), 6.67 (s, 1H), 6.11 (t, J=1.4 Hz, 1H), 5.56 (p, J=1.6 Hz, 1H), 4.19 (t, J=6.6 Hz, 2H), 3.99 (t, J=6.3 Hz, 2H), 2.81-2.77 (m, 2H), 2.65-2.61 (m, 2H), 2.18 (p, J=6.5 Hz, 2H), 1.95 (s, 3H), 1.87-1.81 (m, 2H), 1.80-1.74 (m, 2H), 1.62-1.58 (m, 2H).

##STR01058##

[0565] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.61-7.55 (m, 4H), 7.14 (d, J=8.0 Hz, 1H), 6.78 (s, 1H), 6.73 (d, J=7.6 Hz, 2H), 6.11 (s, 1H), 5.56 (t, J=1.8 Hz, 1H), 4.19 (t, J=6.6 Hz, 2H), 3.99 (t, J=6.4 Hz, 2H), 2.84-2.78 (m, 2H), 2.66 (t, J=6.7 Hz, 2H), 2.20 (p, J=6.5 Hz, 2H), 1.95 (s, 3H), 1.84 (p, J=6.7 Hz, 2H), 1.77 (p, J=6.8 Hz, 2H).

[0566] .sup.19F NMR (470 MHz, Chloroform-d) δ −62.4.

##STR01059##

[0567] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.31 (td, J=8.7, 6.6 Hz, 1H), 7.10-7.07 (m, 1H), 6.88-6.78 (m, 2H), 6.72 (d, J=6.8 Hz, 2H), 6.53 (s, 1H), 6.11 (s, 1H), 5.56 (t, J=1.6 Hz, 1H), 4.19 (t, J=6.6 Hz, 2H), 3.99 (t, J=6.3 Hz, 2H), 2.84-2.80 (m, 2H), 2.55 (t, J=6.6 Hz, 2H), 2.17 (p, J=6.5 Hz, 2H), 1.95 (s, 3H), 1.87-1.81 (m, 2H), 1.77 (dt, J=14.4, 6.8 Hz, 2H), 1.62-1.54 (m, 2H).

[0568] .sup.19F NMR (470 MHz, Chloroform-d) δ −110.8 (q, J=8.9 Hz), −112.7.

##STR01060##

[0569] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.56-7.54 (m, 2H), 7.38 (dd, J=8.5, 7.1 Hz, 1H), 7.29-7.27 (m, 1H), 7.07 (d, J=8.2 Hz, 1H), 6.83 (d, J=1.3 Hz, 1H), 6.75-6.71 (m, 2H), 6.13 (s, 1H), 5.58 (t, J=1.7 Hz, 1H), 4.21 (t, J=6.5 Hz, 2H), 4.01 (t, J=6.4 Hz, 2H), 2.94 (dd, J=9.1, 7.1 Hz, 2H), 2.76-2.73 (m, 2H), 1.98 (dt, J=4.7, 1.3 Hz, 5H), 1.88-1.84 (m, 2H), 1.81-1.77 (m, 2H), 1.63-1.59 (m, 2H).

##STR01061##

[0570] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.43 (d, J=8.4 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 7.24-7.10 (m, 4H), 6.80 (s, 1H), 6.10 (s, 1H), 5.55 (t, J=1.6 Hz, 1H), 4.15 (t, J=6.6 Hz, 2H), 2.95 (t, J=7.3 Hz, 2H), 2.87-2.75 (m, 2H), 2.62 (t, J=6.7 Hz, 2H), 2.21 (dq, J=10.1, 6.7 Hz, 2H), 1.95 (t, J=1.3 Hz, 3H), 1.75-1.68 (m, 4H), 1.57-1.51 (m, 2H).

##STR01062##

[0571] .sup.1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J=8.5 Hz, 2H), 7.67 (d, J=8.5 Hz, 2H), 7.25-7.15 (m, 4H), 6.89 (s, 1H), 6.07 (s, 1H), 5.55 (t, J=1.6 Hz, 1H), 4.12 (dd, J=7.1, 5.6 Hz, 2H), 3.18-3.01 (m, 2H), 2.88-2.78 (m, 2H), 2.66 (t, J=6.7 Hz, 2H), 2.24 (p, J=6.6 Hz, 2H), 1.93 (t, J=1.2 Hz, 3H), 1.86-1.74 (m, 2H), 1.68 (dt, J=14.8, 6.7 Hz, 2H), 1.50 (td, J=8.1, 5.7 Hz, 2H).

Example 19

[0572] Characterization of inventive compounds through melting points: Melting points are measured with a TA Instruments Q2000 differential scanning calorimeter during heating in the first heating run with 20 K/min from −100° C. to 200° C. in a hermetic aluminium pans.

TABLE-US-00025 Compound m.p. [° C.] [01063]embedded image 100 [01064]embedded image  46 [01065]embedded image Not observed [01066]embedded image Not observed [01067]embedded image Not observed [01068]embedded image Not observed [01069]embedded image  62 [01070]embedded image  59 [01071]embedded image  49 [01072]embedded image  58 [01073]embedded image  43 [01074]embedded image  69 [01075]embedded image Not observed [01076]embedded image Not observed [01077]embedded image  64 [01078]embedded image Not observed [01079]embedded image  33 [01080]embedded image Not observed

Examples of Application

Example 20—General Polymerization Procedure to Produce Bulk Copolymer

[0573] For production of bulk copolymer blanks, the monomers are melted under vacuum.

[0574] These monomers in a composition as indicated in table 3 below are well mixed under stirring using gentle heat and degassed by three freeze-pump-thaw cycles. Appropriate amounts (0.02-0.12 equiv.) of a radical initiator are added (e. g. 1,1′-(3,3,5-trimethylcyclohexylidene)bis[2-(1,1-dimethylethyl)peroxide [Luperox® 231] or 2-[(E)-2-(I-cyano-1-methylethyl)diazen-1-yl]-2-methylpropanenitrile).

[0575] Two glass plates are coated with a polyethylene sheet and a 0.5 mm thick cell is created between the polyethylene sheets using a silicone rubber gasket. The coated faces of the glass sheets are clipped together using spring clips with a syringe needle being placed between the gasket and the polyethylene sheets. The cavity is then filled with the above formulation through the needle using a gastight syringe. Once the cavity is filled the syringe needle is removed, a final clip is used to seal the mould and the assembly is placed in an oven. The polymerization temperature is between 60° C. and 180° C. and the individual polymerization conditions are choosen for the respective initiators, which can be extracted for the skilled person from the formulation mixture. The moulds are allowed to cool to room temperature before the film is removed from the mould.

TABLE-US-00026 TABLE 3 Compositions - Amount of compounds is given in mol-%: mol % mol % mol % mol % mol % mol % Example Monomer monomer n-BuAc EGDMA HEMA UV-Abs. EtMAc 1 A-021 23.1 74.6 2.3 0 0 0 2 A-115 89.2 0 8.9 0 0 0 3 A-116 89.2 0 8.9 0 0 0 4 A-116 24.6 69.5 4.9 0 0 0 5 A-115 23.9 70.3 4.8 0 0 0 6 A-115 48.7 0 2.4 18.0 0 25.9 7 A-115 33.3 9.8 1.7 15.4 0.8 35.1 8 A-117 33.9 43.3 1.7 16.3 0.8 0 9 A-117 34.3 43.9 3.4 16.5 0.8 0 10 A-117 27.2 51.0 0.9 14.9 0.8 0 11 A-038 29.0 68.8 5.3 0 1.2 0 12 A-062 39.0 37.4.sup.a 3.8.sup.b 18.1 0.9 0 13 A-062 38.0 38.4.sup.c 3.8.sup.b 17.8 0.9 0 14 A-089 38.9 37.4.sup.a 3.8.sup.b 18.1 0.9 0 15 A-062 9.0 67.6.sup.a 3.8.sup.b 17.9 0.9 0 16 A-089 20.3 58.2.sup.a 3.5.sup.b 16.5 0.8 0 17 A-062 20.4 58.1.sup.a 3.5.sup.b 16.5 0.8 0 18 A-119 92.0 0 6.6 0 0 0 19 A-106 91.0 0 8.7.sup.d 0 0 0 20 A-120 91.1 0 7.9.sup.d 0 0 0 21 A-120 35.8 59.2.sup.e 4.0.sup.f 0 0 0 22 A-121 35.0 60.0.sup.e 4.1.sup.f 0 0 0 23 A-122 34.6 60.4.sup.e 4.1.sup.f 0 0 0 24 A-123 34.9 60.0.sup.e 4.1.sup.f 0 0 0 25 A-126 33.7 61.2.sup.e 5.9.sup.f 0 0 0 26 A-128 89.8 0 9.0 0 0 0 27 A-129 89.1 0 9.7 0 0 0 Table 3: n-BuAc = n-butylacrylate; EGDMA = Ethylene glycol dimethacrylate; HEMA = Hydroxyethylmethacrylate; EtMAc = Ethylmethacrylate. .sup.a2,2,3,4,4,4-hexafluorobutyl acrylate is used instead of n-butylacrylate. .sup.bPolyethyleneglycol dimethacrylate (M.sub.n 750) is used instead of EGDMA. .sup.c8-methylnonyl methacrylate is used instead of EGDMA. .sup.doxybis(ethane-2,1-diyl) bis(2-methylacrylate) is used instead of EGDMA. .sup.eiso-decyl methacrylate is used instead of n-butylacrylate. .sup.fPolyethyleneglycol diacrylate (M.sub.n 250) is used instead of EGDMA. The compositions shown in table 3 are formulated in the same way as described in Example 20 mixing all compounds together while stirring. A heating bath for the stirring is used, where necessary.

[0576] Refractive index change is induced by irradiation at 340-365 nm. The refractive indices (n) of the polymer films and blanks at 590 nm are measured on Schmidt+Haensch AR12 before and after irradiation. The following table shows the refractive indice after irradiation as well as the change in refractive index (max. Δn).

[0577] The phase transition temperatures are determined with a TA Instruments Q2000 differential scanning calorimeter during heating in the second heating run with 20 K/min from −100° C. to 200° C. in a hermetic aluminium pans.

TABLE-US-00027 TABLE 4 Results after irradiation and refractive index change Absorption T.sub.g n.sub.D, maximum Example [° C.] 35° C. Δn [nm] 1 — 1.554 0.009 — 2 7.85 1.601 0.024 — 3 −3.34 1.603 0.016 — 4 −15.55 1.547 0.004 — 5 −9.24 1.540 0.001 — 6 — 1.576 0.026 — 7 — 1.564 0.020 — 8 15.03 1.562 0.026 287 9 — 1.564 0.029 — 10 1.552 0.018 — 11 30.14 1.587 0.042 — 12 3.37 1.543 0.026 — 13 −4.32 1.549 0.015 — 14 17.39 1.520 0.021 — 15 3.23 1.477 0.011 — 16 10.40 1.484 0.019 — 17 3.82 1.502 0.014 — 18 33.13 1.601 0.007 281 19 39.58 1.591 0.018 282 20 43.12 1.613 0.006 285 21 7.88 1.549 0.015 308 22 5.59 1.543 0.013 — 23 −30.02 — — — 24 1.87 1.565 0.015 — 25 −0.05 1.528 0.007 319 26 30.12 1.636 0.021 — 27 46.33 1.608 0.008 —

[0578] The results of the copolymer examples 2, 3, 6-17, 19, 21, 22, 24, 26 show a significant refractive index change after irradiation. Also the glass transition temperature of most of the respective polymers show values below room temperature documenting the advantages of the compounds.